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Abbreviations 
AcOH   Acetic Acid 
ADDA   3-amino-10-phenyl-2,6,8-trimethyl-9-metoxy-4,6-decadienoic acid 
ADI   Acceptable Daily Intake 
Aib   Amino isobutyric acid 
cAMP   cyclic Adenosyl Monophosphate 
AP-M   Aminopeptidases-M 
Boc   tert-butoxycarbonyl- 
bw   body weight  
CAN   Cerium Ammonium Nitrate 
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DIPEA   Diisopropylethylamine 
DGI   Direct G-protein Interaction 
DMAP   N,N-dimethylaminopyridine 
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Panoramica generale 
Panoramica Generale delle Tematiche Trattate nel Lavoro di Tesi 
Introduzione 
La ricerca di farmaci nuovi e stabili spinge sempre più i chimici di sintesi alla ricerca di 
molecole in grado di mimare la struttura e l’attività delle molecole naturali biologicamente 
attive, migliorandone le caratteristiche di stabilità nel mezzo biologico. Nell’ambito, quindi, 
delle scienze biologiche, chimiche e farmacologiche, si fa sempre più forte l’interesse verso 
la peptidomimetica. I peptidomimetici, infatti, sono molecole ispirate a peptidi naturali, ma in 
grado di offrire numerosi vantaggi, se paragonati ai farmaci peptidici classici; oltre a 
presentare un’accresciuta efficienza e selettività, i peptidomimetici possono avere minori 
effetti collaterali, presentare una migliorata somministrazione orale e una prolungata attività 
farmacologica, non essendo soggetti alla degradazione enzimatica.  
Un approccio peptidomimetico che è emerso negli ultimi anni con particolare veemenza, 
consiste nell’uso di amminoacidi non-proteinogenici nella costruzione di foldameri, 
specialmente peptidici. L’uso di tali amminoacidi è giustificato dal fatto che i peptidi che li 
contengono formano strutture secondarie stabili, presentano nuove attività biologiche e 
possono essere usati per il design di strutture molecolari e catalizzatori.  
Inoltre amminoacidi non-proteinogenici o non-ribosomiali possono avere pronunciati 
effetti sulla conformazione degli scheletri peptidici. 
Per esempio, amminoacidi α,α-disostituiti, come l’Aib e la α-etilalanina, conferiscono 
rigidità allo scheletro peptidico attraverso la formazione di α-eliche e β-turn. Queste strutture 
organizzate sono responsabili dell’attività biologica dei ‘peptaboil’, un gruppo di peptidi 
antibiotici isolati da funghi e caratterizzati da una larga percentuale di residui Aib. Nei doppi 
strati lipidici delle membrane biologiche, i ‘peptaboil’ danno origine a canali ionici voltaggio-
dipendente che sono simili a quelli ritrovati nelle sinapsi neuronali e, ad alte concentrazioni, 
possono causare la lisi cellulare. I residui α,α-disostituiti sono inoltre trovati in peptidi di 
natura differente, come nella clamidocina, un tetrapeptide ciclico inibitore della proliferazione 
cellulare, nella quale essi hanno simili effetti conformazionali. 
I β-amminoacidi sono ritrovati in animali, microrganismi, organismi marini, sia in forma 
libera che come derivati, e posseggono un’ampia varietà di proprietà farmacologiche. Essi 
vengono rinvenuti in peptidi naturali ad attività antibiotica e antimicotica, e vengono inoltre 
utilizzati per costruire β-peptidi per uso terapeutico. Piccole catene di β-peptidi, ad esempio, 
hanno mostrato attività inibitrice verso una proteina di membrana coinvolta nei processi di 
assorbimento di colesterolo e lipidi, mentre altre posseggono attività antimicrobica e 
antiemolitica. β-Peptidi con un’alta concentrazione di cariche positive attraversano le 
membrane biologiche di batteri e mammiferi e possono essere considerati un nuovo gruppo 
di ‘cell penetrating peptides’. Inoltre essi posseggono un’elevata stabilità contro le peptidasi e 
le proteasi, sia in vitro che in vivo. Infine, essi possono adottare strutture secondarie stabili 
come α-eliche, β-turn e sheet. 
L’importanza farmacologica dei peptidi non-ribosomali giustifica la considerevole 
attenzione rivolta alla loro preparazione; quest’ultima richiede efficienti sintesi degli 
amminoacidi costituenti. Sebbene non sia sempre tenuto nella dovuta attenzione, il coupling 
di questi residui inusuali è spesso difficoltoso, a causa della ridotta reattività dei residui 
amminoacidici nella formazione dei legami peptidici. 
Linee Generali 
Tenendo presente tutto quanto sopra, come parte del nostro studio di amminoacidi non-
naturali, abbiamo deciso di mettere a punto nuovi e semplici metodi di sintesi stereoselettiva 
di amminoacidi non-proteinogenici; inoltre abbiamo preso in considerazione lo studio delle 
loro possibili applicazioni nel campo delle tecnologie alimentari e farmaceutiche. 
In particolare, gli obiettivi raggiunti sono: 
• Sintesi stereoselettiva di β2,3-amminoacidi (2,3-disostituiti) attraverso l'introduzione 
sulla posizione C-2 di β3-amminoacidi di: 
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1. Gruppi polari (OH, NH2, CH2OH) 
2. Gruppi non polari (CH3, CH2Ph) 
3. Deuterio, con completa diteurazione della posizione C-2. 
• Sintesi di nuovi mimici dell’ aspartame: 
1. Sintesi in soluzione di diversi dipeptidi contenenti β-amminoacidi 2,3-
disostituiti 
2. Studi conformazionali, attraverso dicroismo circolare (CD) e dinamica 
molecolare, di questi dipeptidi 
• Sintesi di amminoacidi ‘lipidici’: 
1. Introduzione di lunghe catene idrofobiche sulla posizione C-2 di β-alanina 
2. Sintesi di peptidi contenenti questo tipo di β-amminoacidi 2,2-disostituiti  
• Sintesi di α-amminoacidi α,α-disostituiti: 
1. Sintesi di peptidi contenenti α-amminoacidi α,α-disostituiti: nuovi ‘cell 
penetrating peptides (CPPs)’ 
Resultati e discussione 
Nella prima fase dei nostri studi, abbiamo messo a punto un’introduzione stereocontrollata 
sulla posizione C-2 di β3-amminoacidi di gruppi polari (OH, NH2, CH2OH) e non polari (CH3, 
CH2Ph). 
Recentemente, abbiamo riportato la preparazione di 2-idrossi-β3-amminoacidi 
enantiomericamente puri attraverso l’ossidrilazione di enolati chirali di β3-amminoacidi. 
Benzil N,N-diprotetti β3-ammino metil esteri, preparati dai loro corrispondenti  
α-amminoacidi, sono stati trattati con potassio esametildisilazanuro (KHMDS), e il risultante 
enolato è stato fatto reagire con un elettrofilo per ottenere i derivati 2-sostitutiti.
R"2N OMe R"2N
R'''
R'
CO2Me
R"2N CO2Me
H2N
R'
CO2Me
H2N
R'
CO2Me R''= MPM, Bn
R'= -Ph, -Bn, -CH2OH
R' R' O-K+
R"'= NH2, OH, CH2OH
        CH3, CH2Ph
       Rese: 65-95%
   r.d.: (90:10) - (98:2 )
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Protezione
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Schema 1 
L’induzione asimmetrica è esercitata dal centro stereogenico dell’amminoacido di partenza, il 
contributo del quale è amplificato dalla presenza di gruppi protettori ingombranti sulla 
funzione amminica. Le rese e i rapporti diastereoisomerici sono molto elevati in tutti i casi da 
noi presi in considerazione. 
Nella seconda parte del lavoro di tesi, i β2,3-amminoacidi sono stati usati per la sintesi di 
una serie di dipeptidi del gusto. La scoperta del dolcificante aspartame [H-(L)-Asp-(L)-Phe-
OMe] ha infatti ispirato la sintesi di un largo numero di analoghi peptidici con l’obiettivo di 
trovare nuovi composti, non solo con un migliorato profilo dolcificante, ma specialmente più 
stabili alla degradazione proteolitica. 
Infatti è noto che l’aspartame è idrolizzato dalle esterasi dell’intestino ad acido aspartico, 
metanolo e fenilalanina. Quindi, come fonte di fenilalanina, l’aspartame risulta pericoloso per 
persone affette da fenilchetonuria. 
In accordo con i modelli proposti per le interazioni dolcificante-recettore, la disponibilità di 
analoghi conformazionalmente rigidi è molto importante per stabilire le caratteristiche 
molecolari richieste per esplicare un gusto dolce o amaro. L’incorporazione di amminoacidi 
conformazionalmente costretti costituisce uno strumento essenziale per esplorare questo 
aspetto. Molti analoghi conformazionalmente costretti dell’aspartame sono stati sintetizzati e 
studiati: in ognuno di questi, il residuo di L-Phe è stato sostituito da diversi residui 
amminoacidici, inclusi β-amminoacidi. In questo modo, inoltre, si è eliminata la produzione di 
fenilalanina, generata dall’idrolisi dell’aspartame. E’ riportato che β-amminoacidi  
2,3-disostituiti sono conformazionalmente più rigidi dei semplici β2 e/o β3-amminoacidi. Come 
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estensione del nostro studio sulla sintesi di β2,3-amminoacidi, abbiamo quindi preso in 
considerazione il loro uso nella sintesi di nuovi peptidi analoghi dell’aspartame, in cui il  
β2,3-amminoacido è utilizzato per la sostituzione del residuo di L-Phe. 
Si sono quindi preparati diversi peptidi, come mostrato nello schema 2. 
BocHN
O
O
OtBu
OH H2N
O
R
Ph
OMe
H2N N
H
O
R
O
O
HO
Ph
OMe
BocHN
N
H
O
R
O
O
Ph
OMe
tBuO
+
R= OH, NH2
     CH3, CH2Ph
I2, Im, PPh3
CH2Cl2
70-80%
80-95%
 
Schema 2 
La ricerca volta alla delucidazione dei dettagli delle relazioni struttura-attività dell’aspartame 
e dei suoi analoghi ha condotto all’ampia accettazione della teoria di Goodman per la 
predizione del gusto dolce. Per poter comparare le strutture dei nostri peptidi con le ben note 
strutture di altri peptidi ad attività dolcificante, abbiamo combinato alla sintesi, studi di 
dinamica molecolare e di dicroismo circolare. 
I profili CD dei nostri peptidi sono sovrapponibili a quelli dell’aspartame. Le uniche 
differenze possono essere interpretate alla luce di un diverso numero di conformeri a bassa 
energia, i cui contributi CD si annullano reciprocamente. I nostri peptidi risultano quindi più 
flessibili rispetto all’aspartame, sebbeno le loro caratteristiche strutturali siano più vicine a 
quelle dell’aspartame di altri peptidi noti in letteratura. 
Dai dati di dinamica molecolare risulta che i peptidi presentano diverse conformazioni 
che corrispondono a minimi di energia; tra queste in ogni caso c’è anche la conformazione a  
“L-shape”, necessaria per l’interazione della molecole con il recettore del gusto. 
Una terza parte del progetto di dottorato è stata, infine, focalizzata allo studio della sintesi 
e della reattività di α- e β-amminoacidi α,α-disostituiti. 
La sintesi di peptidi contenenti residui α,α-disostitutiti ingombranti, come l’Aib, è infatti 
complicata da numerosi problemi. Ciclizzazioni a dichetopiperazine, attribuite all’effetto dei 
gruppi alchilici geminali, possono avvenire facilmente con certi peptidi contenenti Aib e 
residui analoghi, in seguito alla deprotezione del sito N-terminale. 
La congestione sterica dei residui α,α-disostituiti impedisce inoltre la formazione dei 
legami peptidici e, come atteso, i coupling sono particolarmente difficili quando entrambi i 
gruppi amminico e carbossilico sono ingombrati.  
D'altra parte i β-amminoacidi α,α-disostituiti dovrebbero poter essere accoppiati mediante 
i metodi di sintesi convenzionali (EDC/HOBt), senza incorrere in particolari complicazioni, 
come quelle che invece si sperimentano con α-amminoacidi α,α-disostituiti stericamente 
ingombrati. 
Quindi abbiamo deciso di introdurre, sulla posizione C-2 di β-amminoacidi, lunghe catene 
idrofobiche, in quanto è riportato che peptidi ‘coniugati’ con α-amminoacidi lipidici mostrano 
una migliorata permeabilità verso le membrane cellulari e un’accresciuta stabilità biologica. 
Per la preparazione di β-amminoacidi α,α-disostituiti sono noti molti metodi; noi abbiamo 
scelto quello sviluppato nel nostro laboratorio: alchilazione dell’estere metilico dell’acido  
3-amminopropanoico N-benzil protetto 3 via doppia deprotonazione. 
Per la preparazione del β-tetrapeptide α,α-disostituito 1 abbiamo quindi usato come 
building block la β-alanina 2,2-disostitutita protetta 4, ottenuta per doppia alchilazione 
dell’estere tert-butilico dell’acido 3-(dibenzylamino)propanoico 3, e successiva idrolisi del 
gruppo estereo. 
Come in parte atteso, il coupling condotto in maniera convenzionale non ha funzionato 
sul nostro β2,2-amminoacido; l’attivazione della funzione carbossilica è stata realizzata con 
ossalil cloruro per generare un acil cloruro più reattivo, come è riportato nello Shema 3. 
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Schema 3 
Infine, come parte di un progetto sviluppato in collaborazione con il Prof. Seebach, presso lo 
Swiss Federal Institute of Technology (ETH) in Zurigo, abbiamo preparato un derivato  
α,α-dialchilato della glicina, recante catene laterali che verranno poi convertite in analoghe 
catene laterali dell’arginina (Schema 4). Tali amminoacidi costituiscono i building block per la 
sintesi di peptidi  ad alta presenza di cariche positive; questo tipo di peptidi è in grado di 
legare e attraversare le membrane biologiche, costituendo così una potenziale nuova classe 
di ‘cell penetrating peptides (CPPs)’. Per tale motivo, il primo passo è stato lo sviluppo di una 
procedura per la preparazione dell’isocianato 11: la doppia alchilazione dell’etil isocianato 10 
ha fornito il prodotto di dialchilazione con due gruppi ω-azido-propilici, in eccellenti rese 
(Schema 4). Le opportune modificazioni dei gruppi funzionali hanno poi condotto all’ammino 
etil estere 12 e all’acido N-Cbz protetto 13, che sono stati poi accoppiati con HATU/NMM 
(Schema 4). Come da attendersi per quanto accennato in precedenza sulla reattività di 
residui amminoacidici a,a-disostitutiti, questa reazione di coupling è molto lenta (7 giorni) e 
procede con solo il 38% di resa. 
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Summary 
Summary 
The peptidomimetic research continues to inspire medicinal chemists for seeking either 
potential drugs or pharmacological tools. 
A peptidomimetic approach that has emerged in recent years, with significant potential, 
consists of the use of non-proteinogenic amino acids in the construction of foldamers, 
especially peptides. The use of non-proteinogenic amino acids is accounted for by the 
capability of non-natural amino acid containing peptides to form unique secondary structures, 
to show novel biological activities, and to be used as rulers for the design of molecular 
devices and catalysts. 
 
Having all this in mind, as a part of our interest in the chemistry of non-natural amino acids, 
we planned to devise new and simple methods for stereoselective synthesis, readily 
applicable also on large scale, of non-proteinogenic amino acids; moreover, we decided to 
study their possible exploitation in food technologies and pharmaceutical applications. 
 
In particular, the goals we have reached so far are: 
• Stereoselective synthesis of β2,3-amino acids (2,3-disubstituted) by introduction at the 
C-2 position of β3-amino acids of: 
1. Polar groups (OH, NH2, CH2OH) 
2. Non polar groups (CH3, CH2Ph) 
3. Deuterium, with total dideuteration of C-2 position. 
• Synthesis of new mimics of aspartame: 
3. Solution-phase synthesis of different dipeptides containing  
β2,3-disubstituted β-amino acids 
4. Conformational studies, carried out by circular dicroism (CD) and molecular 
dynamics, of such dipeptides 
• Synthesis of ‘lipidic’ amino acids: 
1. Introduction of long hydrophobic chains at C-2 position of β-alanine 
2. Synthesis of peptides containing this kind of 2,2-disubstituted β-alanine 
• Synthesis of α,α-disubstituted α-amino acids 
1. Synthesis of peptides containing  α,α-disubstituted α-amino acids: new cell 
penetrating peptides (CPPs)
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Chapter 1 
Proteins and Peptides 
Proteins constitute a class of biomacromolecules which virtually affect every feature 
that characterizes a living organism. 
All organisms make use of many chemical reactions to supply themselves 
continually with energy, but these reactions, by themselves, could not occur fast 
enough under physiological conditions to sustain life. The rate of these reactions in 
organisms is increased, of many orders of magnitude, by the presence of enzymes, 
which are proteins. Expression of the encoded genetic information of nucleic acids, 
essential for life and mostly specific for the structure of a protein, depends almost 
entirely on proteins. Proteins store and transport a variety of particles ranging from 
macromolecules to electrons. They are the crucial components of muscles and other 
systems for converting chemical energy into mechanical energy. They also are 
necessary for sight, hearing, and the other senses. Many others are simply structural, 
providing the filamentous architecture within cells and the materials that are used in 
hair, nails, tendons and bones of animals. 
In spite of these diverse biological functions, proteins represent a relatively 
homogeneous class of molecules. All are the same type of linear polymer, built on 
various combinations of 20 amino acids. They differ only for the sequence in which 
the amino acids are assembled into polymeric chains. The secret of their functional 
diversity lies partly in the chemical diversity of the amino acids but even more in the 
diversity of the three-dimensional structures that these building blocks can form, 
simply by being linked in different sequences. The awesome functional properties of 
proteins can be understood only in terms of relationship to their three-dimensional 
structures. 
A series of incisive studies in the late 1950s and early 1960s revealed that the 
amino acid sequences of proteins are genetically determined. Amino acid sequences 
are important for several reasons. First, knowledge of the sequence of a protein is 
very helpful, indeed usually essential, in elucidating its mechanism of action, and 
proteins with novel properties can be generated by varying the sequence of known 
structures. Secondly, analyses of relations between amino acid sequences and 
three-dimensional structures of proteins are uncovering the rules that govern the 
folding of polypeptide chains. Amino acid sequence is the link between the genetic 
message in DNA and the three-dimensional structure that performs a protein’s 
biological function. Third, alterations in amino acid sequences can produce abnormal 
function and disease. Fatal diseases, such as sickle-cell anaemia and cystic fibrosis, 
can result from a change in a single amino acid in a single protein. Fourth, the 
sequence reveals much about the evolutionary history of a protein. Consequently, 
molecular events in evolution can be traced from amino acid sequences. 
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Peptidomimetics 
The peptidomimetic research continues to inspire medicinal chemists for seeking 
either potential drugs or pharmacological tools.1 In biological, chemical, and 
pharmaceutical areas, in fact, they offer interesting advantages over physiologically 
active peptides, which as active substances are crucial for living organisms. Beside 
increasing efficiency and selectivity of natural peptides, peptidomimetics may 
decrease side effects, improving oral bioavailability and prolonging the 
pharmacological activity by hindering enzymatic degradation within the organism.2
Natural peptides and proteins are of key importance in many chronic and 
infectious disorders. Prion diseases, for instance, are a result of conformational 
changes of a protein, while the development of Alzheimer's disease is associated 
with deposition of β-amyloid peptides in insoluble form. Autoimmune diseases are 
characterized by recognition dysfunction, self-peptides being attacked by immune 
system as foreign molecules.  
At the same time, peptides as therapeutic agents are of very limited use. Peptides 
are highly flexible molecules, easily degraded by proteases and usually too polar to 
pass membranes that separate them from their targets in the cells.  
Considerable efforts have been made in designing compounds with improved 
bioavailability and capability to mimic peptide functions, resulting in a heterogeneous 
class of compounds known as peptidomimetics.  
From a structural point of view peptidomimetics can be prepared by approaches 
ranging from the slight modification of the initial structure of a peptide to the 
generation of a pure non-peptide. 
The very first steps in peptidomimetic design were based on simple N– or  
C–terminus modifications, single amino acid replacement or exchange of natural with 
unnatural side chains as well as of L- with D-amino acids. 
Extension of the 
peptide chain
Replacement of the 
amide bond
XNH CH CO
R
CO-NH
O
NH
CH2
NH-CO
CH(OH)-CH2
CH=CH
CH2-CH2
P=O(OH)-CH2
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hydroxyethylene
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NH CH
R
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O N CS
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CH2 SOn(CO) BH-
depsi aza thio
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ketomethylene bora  [5] n=1,2  [6]
P=O(OH)
B(OH)
[7]
[8]
Exchange of individual units
 
Table 1.1  The most frequent modifications of the peptide backbones (modified from Wiley-VCH 
Angewante Chemie, Int. Ed., ref. 2) 
Modification of the peptide backbone generally involves the exchange of units in the 
peptide chain with sterically or electronically equivalent units, as well as the 
introduction of additional functions. The most general modifications2 are synoptically 
shown in Table 1.1. 
Cyclization reactions are very useful in the synthesis of peptidomimetic. The 
conformation of a peptide can be stabilized or blocked by the introduction of bridges 
of various lengths between different parts of the molecule. The bridging can either 
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occur within a single amino acid residue, or involve several amino acid residues. 
Bridges can be introduced at various sites and involve various backbone regions. 
The bridge can be a link between two side chains, between two backbone units, or 
between a side chain and backbone unit. In addition the peptide bond can be 
completely or exclusively incorporated into a ring. 
There are also interesting examples of cyclic peptides and peptidomimetics 
having a sugar moiety. Sugar amino acids offer many possibilities in the preparation 
of peptidomimetics with predictable conformational characteristics.  
Few examples of the tremendous amount of available peptidomimetic compounds 
with structural motifs ranging from peptide chains to completely non-peptidic 
components are shown2 in Figure 1.1. 
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Figure 1.1  Structural motifs of some peptidomimetics. 
Finally, peptides can be constructed with completely non-natural amino acids, such 
as β-amino acids,3 γ-amino acids,3 and α,α-disubstituted amino acids.4 The use of 
non-proteinogenic amino acids has aroused much attention among organic as well 
as peptide and medicinal chemists, because non-natural amino acid containing 
peptides form unique secondary structures,3 show novel biological activities,5 and 
can be used as rulers for the design of molecular devices and catalysts.6
Peptidomimetic Drug Design 
de novo Design 
A goal, that has not been achieved yet, is the de novo design of peptidomimetics.2 
Presently, natural substrates or model structures identified by screenings (plant or 
animal extracts, substances isolated from microorganisms, compound libraries) are 
required as the starting point to develop new bioactive compounds. In contrast, de 
novo design implies development without such a starting point. Thus, the structure of 
a peptidomimetic drug would be developed, for example, based only on the known 
amino acid sequence of the natural peptide or the natural interaction partner. Then 
the final goal of de novo design would be of immense practical value in medicinal 
chemistry; it is enough to consider that the research in drug development is still 
based on empirical findings: thousands of compounds must be synthesized and 
tested before one of them is deemed marketable by FDA. The other compounds are 
discarded during stringent pharmacological, toxicological and clinical tests. Certainly 
with the help of de novo development this rejection rate could be drastically reduced.  
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A step in the direction of de novo design has been taken by various computer 
programs which have the task of calculating new active structures based only on the 
active site of the enzyme.  
Rational Drug Design 
Rational drug design is the oldest alternative to medicinal chemistry drug 
development procedures. Thanks to the recent technological progresses, it became 
an integral part of the drug development process. Highly refined methods of 
conformational analysis (e.g. NMR, X-ray structural analysis) and the new computer 
programs have made an important contribution to the current state of the  
art. Coupled with rapid through-put screening technology, this approach is becoming 
the predominant method used in drug discovery programs. In addition, synthetic 
chemistry has also made great progress; without the modern methods developed by 
organic chemists the construction of complex, stereochemically defined molecules 
with particular functional groups and hydrophobic elements attached to a non-
peptidic scaffold would hardly have been possible.  
A peptidomimetic approach that has emerged in recent years with significant 
potential, is the incorporation of non-natural amino acids into proteins. In this way it is 
possible to give the protein structure specific properties, that increase its stability to 
proteolytic degradation and its activity as drug. 
Some of the techniques used to develop new peptidomimetics are briefly 
described below.7
Bioconjugation 
Bioconjugation8 is the simplest and longest standing method for the introduction of 
non-natural amino acids into proteins. The approach relies on the existing 
functionality of a protein, and through the use of appropriate chemical reagents, 
some chosen amino acid side chains can be modified. All side chains displaying 
reactive functionality can be modified, and, depending on the functionality in question 
and the choice of modifying reagents, highly selective, quantitative modifications can 
take place. 
The most widely used bioconjugation strategy exploits the latent nucleophilicity of 
the thiol side chain of cysteine. Through the use of appropriate electrophiles thiol 
groups can be rapidly, selectively and quantitatively modified. Cysteine modifications 
fall into two major categories: alkylation and mixed disulfide formation. Within these 
categories further subdivisions can be made according to the choice of modifying 
reagent employed. 
Non-Ribosomal Peptide Synthesis  
In eukaryotes, the synthesis of cellular peptides and proteins is conducted by the 
ribosomal machinery, in which the genetic information encoded in mRNA is 
translated into specific peptide sequences by a protein/RNA complex that moves 
progressively along each mRNA strand. In prokaryotes, a number of biologically 
important peptides are synthesised by a different mechanism, in which the entire 
sequence of a peptide is dictated by the structure of the enzyme that synthesizes it. 
This process, non-ribosomal peptide synthesis,9 is directed by large  
modular enzymes termed non-ribosomal peptide synthases (NRPS). NRPSs are 
responsible for the synthesis of a diverse set of peptides, including several 
antimicrobial agents, and peptide fragments that are subsequently incorporated into 
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other secondary metabolites, such as the tripeptide δ-(L-α-aminoadipoyl)-L-cysteinyl-
D-valine (Figure 1.2),10 a precursor in the synthesis of penicillins and cephalosporins. 
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Figure 1.2  δ-(L-α-Aminoadipoyl)-L-cysteinyl-D-valine. 
A unique feature of NRPSs is the diversity of the peptides that can be synthesised. 
Whereas ribosomal peptide synthesis produces linear peptides composed of all  
L-amino acids, containing only minor post-translational modifications, the non-
ribosomal peptide synthesis produces an array of chemically diverse peptides that 
frequently contain drastic modifications, including cyclic structures, D-amino acid 
presence, N-methylation, unusual heteroaromatic groups, and series of N- and  
C-terminal modifications. The synthesis of each of these peptides is catalysed by a 
unique non-ribosomal peptide synthase. Each module of the synthase contains the 
requisite components for the activation and reaction of a single amino acid. Diversity 
is achieved by the recruitment of different components in each module according to 
the amino acid to be incorporated. 
tRNA Engineering Method 
Over the course of the last twenty-five years the research of several groups has been 
focused on finding a way to use the natural coded protein synthesis machinery to 
produce proteins that contain non-natural amino acids.  
During the protein synthesis, the coded message of DNA is transcribed by RNA-
polymerase in messenger RNA molecules (mRNA). Every mRNA is made up of 
‘codons’. Each codon codes for one of the twenty natural amino acids; it is made up 
of three nucleic-bases that are recognised by complementary three bases 
constituting an ‘anti-codon’ within a transfer RNA molecule (tRNA).  
Amino acid
mRNA
tRNA
GUA
CAU
 
3'
5'
5'
3'
Figure 1.3  The codon reading event of coded protein synthesis. 
The recognition is made through Watson–Crick base-pairing. Each tRNA molecule is 
chemically linked to a specific amino acid that corresponds to the specific anti-codon 
present in that tRNA molecule as shown in Figure 1.3. 
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Thus, it would be possible to attach a non-natural amino acid to the tRNA to insert 
that non-natural amino acid in place of the originally expected one. However, in so 
doing a naturally occurring amino acid would be replaced by a non-natural amino 
acid in all instances, and the number of possible amino acids within a protein would 
still be limited to twenty. The idea is, thus, to attach non-natural amino acids to the 
anti-codon that possesses the complementary sequence to the stop-codon. The 
genetic code, indeed, also contains three codons that are used to send ‘‘stop’’ 
signals to the protein synthesis machinery and thus terminate translation when 
required. By using a tRNA molecule that possesses an anti-codon that is 
complementary to one of the stop codon signals it is possible to ‘‘suppress’’ the stop 
signal and in addition, insert an amino acid that is attached to the suppressor tRNA in 
place of the stop signal. There have been two main obstacles on this pathway: first, 
charging by chemical or enzymatic methods the tRNA molecules with non-natural 
amino acids can be challenging. Second, the existing tRNA aminoacylation system 
must not charge the suppressor tRNA with any other amino acid. This is critical in 
order to maintain the fidelity in terms of the amino acid composition of translated 
proteins. So the use of coded protein synthesis for the production of proteins 
containing non-natural amino acids opens up an immense number of possibilities.3  
Peptide Ligation 
The chemical ligation11 is one of the most useful and important approach for the 
synthesis of proteins; it consists in the coupling of unprotected peptide fragments in 
acqueous solution trough the intervention of selective covalent bond-forming reaction. 
A number of selective reagents suitable for the covalent modification of proteins have 
been known for many years, but general methodologies for the ligation of peptide 
fragments through the formation of natural backbone amides have only recently 
become widely available. These methods have enormous potential for the 
preparation of macromolecules containing novel peptide or protein domains, and 
have proven particularly useful for the synthesis of proteins that are traditionally 
difficult to obtain by in vivo molecular biology-based approaches, such as membrane 
proteins.  
The most widely applied ligation method is the reaction of an N-terminal cysteine 
of a peptide or protein with a C-terminal thioester of another peptide (Scheme 
1.1).11,12
 
Scheme 1.1  Native chemical ligation: thioester-based method. 
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Following a reversible intramolecular transthioesterification to form a thioester bridge 
between the two peptides, intramolecular attack of the α-amino group of the  
C-terminal peptide furnishes the desired peptide bond. This approach, often termed 
‘native chemical ligation’, requires that one of the peptides to be fused has a cysteine 
at the N-terminus, and produces a ligated product containing at least one cysteine. 
N-terminal cysteines are readily prepared by a number of conventional in vitro and  
in vivo methods. The major challenge with this approach is the synthesis of a peptide 
or protein with a C-terminal thioester.  
Peptides Constructed from non-Proteinogenic Amino Acids 
A peptidomimetic approach, which has emerged in recent years with significant 
potential, is the use of non-proteinogenic amino acids in the construction of 
foldamers, especially peptides. 
As mentioned before, the use of non-proteinogenic amino acids has became 
important because non-natural amino acid containing peptides present peculiar 
characteristics.3,5,6 Non-proteinogenic or non-ribosomal amino acids can have 
pronounced effects on the conformation of the peptide backbone.  
For example, N-alkyl amino acids (or imino acids) exhibit reduced preferences for the 
trans conformation normally assumed by secondary amides, and this effect can lead 
to biologically relevant β-turn structures, similar to those often induced by proline 
residues.13 N-Methyl peptides can form less intermolecular hydrogen bonds and this 
can significantly affect peptide secondary and tertiary structures, and as a result 
these peptides are useful for activity-structure relationship studies.  
N-Substituted peptides may also exhibit enhanced hydrophobicity and improved 
stability to proteolytic enzymes, which can increase bioavailability and therapeutic 
potential.14 Bioactive natural peptides containing N-methyl residues are widespread 
and commonly occur in bacterial antibiotics, fungal metabolites such astentoxin and 
cyclosporine,15 marine natural products such as dolastatins, jaspamides, and many 
others, and the cyanobacterial microcystins and nodularin, among others (see also 
Chapter 2 and NRPS).  
α,α-Disubstituted amino acids, such as Aib and α-ethylalanine,16 rigidify the 
peptide backbone through the formation of helixes and β-turns.17 These organized 
structures are responsible for the interesting biological activity of the peptaibols,18 a 
group of peptide antibiotics isolated from soil fungi and characterized by a high 
percentage of Aib residues. In bilayer membranes, the peptaibols give rise to voltage 
dependent ion channels that are reminiscent of those found at neuronal synapses19 
and, at high cellular concentrations, can cause cell lysis.18c α,α-Disubstituted 
residues are also found in non-peptaibol peptides, such as chlamydocin,20 where 
they may have similar conformational effects. 
β-Amino acids are found in animals, microorganisms, marine organisms, either in 
free form or as derivatives, and possess a wide range of pharmacological 
properties.21 They are found in peptide natural products that exhibit antibiotic and 
antifungal, as well as cytotoxic activity. They are also employed to develop  
β-peptides for use as therapeutics. Short chain β-peptides have been shown to inhibit 
an intestinal membrane bound cholesterol- and lipid-transporting protein,22 while 
others have been shown to possess antimicrobial and haemolytic  
activities.5a,23 Cationic β-peptides cross bacterial and mammalian cell membranes 
and can be considered a new group of cell-penetrating peptides.24 β-Peptides also 
show high stability against peptidases and proteases, both in vitro and in vivo, 
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compared with that of their α-peptide equivalents.25 Finally, the early investigation of 
polymeric β-peptides indicated that they are able to adopt stable helical 
structures,22,26 with later studies revealing that sheet structures and turns can also be 
adopted.3,27
The pharmacological importance of non-ribosomal peptides justifies the 
considerable effort devoted to their synthesis.  
Chemical synthesis is useful for structure proof and for providing ample quantities 
of compounds that might not be available in suitable amounts from natural sources or 
through fermentation procedures. For peptide-based pharmaceuticals, synthetic 
manipulation of a lead compound may be required to reduce its toxicity or enhance 
its activity, selectivity, or bioavailability, or in some other way modify its 
pharmacological profile. An efficient laboratory synthesis of these peptides requires 
efficient syntheses of the constituent amino acids. Although it is often underestimated, 
the coupling of these unusual residues is sometimes difficult, due to the amino acid 
structures that can complicate the amide bond formation by conventional synthetic 
methods. 
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Chapter 2 
β-Amino Acids and Derivatives 
The use of peptidomimetics has emerged as a powerful mean for overcoming the 
limitations typical of peptides, thus for improving the therapeutic potential of the 
peptides themselves. A peptidomimetic approach that has emerged in recent years 
with significant potential, is the use of β -amino acids. β -Amino acids are similar to  
α -amino acids have two carbon atoms that separate amino group and carboxyl 
function, as represented by compound 1; more in particular, the compounds with 
general formula 2, that have a substituent at the C-2 position, are generally defined 
β2-amino acids or α-substituted β-amino acids; compounds with general formula 3, 
with a substituent at C-3 position are usually called β3-amino acids or β-substituted  
β-amino acids and compound as 4 with both the C-2 and C-3 positions substituted, 
are usually named 2,3-disubstituted β-amino acids or α,β-disubstituted β-amino 
acids.1
H2N OH
O
H2N OH
OR
H2N OH
OR2
R1
β-amino acid
(β-alanine)
1
β2,3-amino acid
or
α ,β-disubstituted β-amino acid 
4
R
H2N OH
O
β2-amino acid
or
α-substituted β-amino acid
2
β3-amino acid
or
β-substituted β-amino acid
3  
In all these compounds there is no direct interaction between carboxyl function and 
amino group: that obviously leads to significant differences between β- and α-amino 
acids, considering both physical properties and chemical reactivity. 
β-Amino Acids in Nature 
β-Amino acids, although not as abundant as their α-parents, are crucial structural 
subunits of numerous biologically active and natural products,2 and have recently 
emerged as increasingly important class of compounds in medicinal chemistry.  
In nature, β-amino acids are present either in free form or as building blocks in 
natural products and possess a wide range of pharmacological properties. They also 
exist in space, and have been detected, together with various α-amino acids, in 
meteorites.3
Probably the most common, and perhaps the most important, β-amino acid is  
H-βhGly-OH, β-alanine (4), an ‘essential’ amino acid component of pantothenic acid, 
coenyzme A, and carnosine in muscle tissue. Its conformational flexibility renders  
β-alanine a building block not only suited for helices and turns, but also for 
incorporation into linear peptide segments.4
Several β-amino acids are components of important antibiotics:5 for example  
(3S)-β3-lysine (5) is largely produced in Streptomices species and is present in 
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antibiotics such as Streptomycin F and Streptocrocyn.6 β2-Tyrosine (6) and isoserine 
(7) are present in Edeines,7 a huge group of peptidic antibiotic. 
OH
O
H2N
NH2
HO
O
NH2
HO
H2N OH
O
OH
β-alanine
4
β-lysine
5
OH
O
H2N
β-tyrosine
6
isoserine
7
 
Emeriamine (8) has hypoglycaemic and antiketogenic activities in rats after oral 
intake.8 Cispentacin (9) is an antifungal antibiotic.1  
Functionalized β-amino acids are key components of a variety of bioactive 
molecules such as taxol (10) one of the most active antitumor agents which contains 
phenylisoserine as its side chain.2c  
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The unsaturated β-amino acid ADDA (11) is present in the antibiotics cyanovinfin RR, 
nodularin, and microcystin LR.9  
Furthermore, β-amino acids are also segments in peptidic natural products 
with various biological activities.  
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Steglich et al. have demonstrated that (R)-β-dopa, 3,4-dihydroxy-β-phenylalanine 
(12;) is present in mushroom Cortinarius violaceus as the Fe(III)–catechol complex, 
which gives to the fruit its blue-violet color.10 Moreover several cyclic peptides, 
characterized by the presence of at least one β-amino acid residue are known;  
β-tyrosine, a β-aryl-β-amino acid, for example, is present in jasplakinolide (13), a 
sponge metabolite with potent insecticidal and antifungal properties.11
Other representative examples include cryptophycin 1 (14) a potent tumor-
selective depsipeptide,12 and the aminopeptidase inhibitors bestatin (15) and 
amastatin (16).13 
2,3-Diamino Acids 
2,3-Diamino acids are important non-proteinogenic amino acids, usually components 
of both natural and synthetic bioactive compounds.14 Their origins and their functions 
are highly diversified: several studies have shown that a great number of 2,3-diamino 
acids are present in plants and microorganisms and show interesting 
pharmacological properties. For instance, they act as antibiotics, anticancer drugs, 
inhibitors of aminotransferases and inhibitors of proteases. 
They are currently well recognized as key structural moieties in a variety of 
biologically active molecules.  
(S)-2,3-Diaminopropanoic acid (DAP) (17), for example, represents an important 
structural element of capreomycin15 (18) that, isolated from Streptomyces capreolus, 
represents a potent antitubercular drug employed as second-line therapeutic agent in 
combination with other antibiotics. 
H2N
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H
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IA: R=OH  R'=β-lysine
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IIA: R=OH  R'=H
IIB: R=H  R'=H
capreomycin 18
 
2,3-Diaminobutanoic acids16 DABs (Figure 2.1) are present in several molecules 
with biological activity. The (2S,3S) diastereomer (19) is a component of several 
tuberculostatic heptapeptide antibiotics, including antrimycin17 (23), cirratiomycin18 
(24), isolated from Streptomyces xanthocidicus and S. cirratus respectively. It was 
also found in the highly potent antibiotic hexapeptide lavendomycin19 (25), isolated 
from culture filtrates of Streptomyces lavendulae; the latter has a low toxicity and a 
high antibiotic activity towards Gram-positive bacteria both in vivo and in vitro. 
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Figure 2.1  The four isomers of 2,3-Diaminobutanoic acids (DAB) and the natural molecules of which 
DAB is a component 
Moreover, DAB is present in plant extracts of acacia20 and in some dipeptides with 
antimycotic activity,19 such as 26 and 27, isolated from Micromonospora and 
Streptomyces spp.; the antifungal activity is partially due to their ability to inhibit 
selectively glucosamine-6-phosphate synthetase of Candida albicans. 
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2,3-Diaminoacids are also used in the synthesis of mimics of biological active 
molecules.  
(2S,3R)-2,3-Diamino-4-phenylbutanoic acid21 (28), for instance, is incorporated22 
in aminodeoxybestatin (29). The latter is a modified version of bestatin (30), a 
dipeptide isolated from Streptomyces olivoreticuli, with immune modifying, anticancer 
and analgesic activity. In aminodeoxybestatin, the hydroxy function is substituted by 
an amine function; this modification does not change the biological activity of the 
molecule that acts as an aminopeptidases-M (AP-M) inhibitor like bestatin itself. 
Ph
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(2R,3S)-2,3-Diamino-3-phenylpropanoic acid (31) has been considered as an 
alternative side chain in the anticancer drug Taxol,23 (32) in order to improve its 
solubility in biological media. 
OPh
BzHN
NH2
OH
AcO
OH
OAc
O
O
OH
OBzmimic of taxol
32
OHPh
BzHN
NH2
O
31  
Day by day, the synthesis of 2,3-diamino acids is becoming more and more 
interesting mainly because of their use as building blocks in peptidomimetic 
synthesis; diamino-acid-containing peptides, indeed, have significant resistance to 
proteases24 and are conformationally constrained.25 When incorporated into 
peptide, with either β- or α-amino group as part of the backbone, this class of amino 
acids might provoke changes in polarity, additional hydrogen-bonding interactions, 
and basic character. Interest in 2,3-diamino acids also stems from their occurrence 
in cyclic peptides.  
2,3-Diaminopropanoic acid, for example, is a component of MEN 10627, a highly 
constrained molecule corresponding to two 14-membered bicyclic peptides fused 
together in a bicyclic structure, made up of a peptidic bond between the amino 
group of DAP and the carboxylic function of aspartic acid side chain. MEN10627 is 
a potent, highly selective and long lasting, peptide-based neurokinin A receptor 
antagonist.26 NKA receptor antagonists may represent a new class of agents, useful 
in inflammatory diseases of first respiratory ways, such as asthma, and in other 
diseases, in which smooth muscle contraction caused by Tachykinins (a family of 
peptides widely distributed in the central and peripheral nervous system of 
amphibians and mammals) play a pathogenic role, for example exaggerated 
intestinal motility. The biological and pharmacological features of MEN 10627 are 
closely related to the conformational rigidity of its bicyclic structure.27  
Moreover, the use of 2,3-diaminoacids for the synthesis of β-lactams is 
noteworthy,14 main structures of several natural and synthetic antibiotics. 
Finally, the usefulness of simple chiral 1,2-diamines as auxiliaries and controller 
groups in asymmetric synthesis (e.g., dihydroxylation,28 conjugate addition,29 
olefination,30 allylation,31 epoxidation,32 and aldol reactions33) is also well 
documented. Chiral diamines from 1,2-diaminocyclohexane are used as chiral 
ligands to co-ordinate osmium during cis- hydroxylation of olefins with OsO4.34 With 
the same aim are also used some derivatives of N,N’-dipentyl-2,2’-bipyrrolidine.35 
Finally chiral bicyclic phosphonamides present a remarkable diastereofacial 
selectivity in asymmetric olefination and alkylation of ketones.17
The use of chiral 1,2-diamines to resolve racemic mixtures of chiral allylic alcohols 
has been reported as well.36 Chiral recognition in the coordination of olefins to 
transition-metal fragments is a topic of great interest37 because it can offer simple 
procedures for thermodynamic36c or kinetic38 resolutions of racemic mixtures or for 
analytical determination of enantiomeric abundances.39
2-Alkyl-β3-Amino Acids 
This class of β-amino acids are components of important natural substances of 
biological and pharmacological interest. Their origin and their functions are several: 
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most of them are generated in microorganisms and have a variety of 
pharmacological properties. There are several examples where these molecules are 
components of antibiotics,40 anticancer and antifungal drugs. 
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3-Amino-2-methylpentanoic acid, for instance, is an important structural element of 
dolastatin 11 (33), a depsipeptide with potent anticancer activity, originally isolated 
from the mollusk Dolabella auricularia.41  
The same β2,3- amino acid is a component of another peptidic structure, the 
majusculamide42 C (34), a cyclic depsipeptide that, isolated from a toxic blue-green 
alga, Lyngbya majuscule, inhibits the growth of a number of fungal plant pathogens.43
(2R,3R)-3-amino-2-methylhexanoic acid and its diastereomer, (2S,3R)-3-amino-2-
methylhexanoic acid, are components of a series of bioactive peptides44 called 
ulongamides A-F and are isolated from cyanobacteria Lyngbya sp. The first of these 
amino acids is found in compounds 35-37 and the other one in compounds 38-40. All 
of them, except the last one, exhibit a slight cytotoxicity towards tumoral cells such as 
KB and LoVo.45
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The β2,3-amino acid ADDA (3-amino-10-phenyl-2,6,8-trimethyl-9-methoxy-4,6-
decadienoic acid, 11) was also found as an essential constituent in complex 
structures, such as cyclic peptides microcistyne-LR (41) and nodularine46 (42). These 
structures, originated from bacteria Microcystis aeruginosa and Nodularia 
spumigena,47 are toxins that act on the hepatic human system. 
HN
N
NH
O
O
HN
COOH Me
NH
O
O
H
N
O
H
N
Me
O
Me
COOH
N
H2N NH2
Me
Me
Me
MeMe
OMe
microcistina-LR
41
N
O
Me Me
HNH
NH
HN
O COOH
Me
COOHO
NH
Me
O
N
H2N NH2
Me
OMe
Me
nodularina
42
O
O
 
26 
β-Amino Acids and Derivatives 
 
Finally, the major interest in β2,3-amino acids is due to some peculiar characteristics: 
they increase the proteolytic stability of the peptides made up of them and promote 
formation of stable secondary structures such as helices, β-turns and β-sheets;48 
these special properties of β2,3-amino acids depend on their conformational rigidity, 
that is also a consequence of their configuration.25
Isotopically Labeled β-Amino Acids 
Isotopically labeled molecules are important synthetic targets, as they reveal valuable 
information regarding the mechanism of enzymatic processes.49 Especially attractive 
are the chiral isotopically labeled amino acids, which have been used to obtain 
firsthand knowledge about the stereochemistry of such processes.50  
Due to the interesting biological properties51 of β-amino acids, and their role in 
natural product biosynthesis,52 isotopically labeled β-amino acids are logical synthetic 
targets. They have been used to determine the stereochemical outcome and 
mechanism of various enzymatic processes as well as for the synthesis of important 
biosynthetic intermediates.53  
The simplest member in the β-series is 3-amino propanoic acid, or β-alanine; for 
its stereocontrolled labeling different approaches were developed, from biocatalytic 
approaches to asymmetric syntheses, involving self-regeneration of stereogenic 
centers, using a method developed by Seebach and co-workers.54  
Apart from β-alanine, other similar isotopically labeled β-amino acids are also 
invaluable entities for revealing their role in natural product biosynthesis. They have 
mostly been prepared by enzyme-mediated transformations55 or chemical methods.56
Moreover, isotopically labeled compounds are used in several analytical 
techniques: two of the most important are the ICAT method57 (Isotope Coded Affinity 
Tag), for the accurate quantification and concurrent sequence identification of the 
individual proteins within complex mixtures., and the SIDA method (Stable Isotope 
Dilution Assay), for the analytical determination of trace compounds in food. Both 
these methods use isotopically labeled molecules as synthons for the preparation of 
more complex reagents (see ICAT) or as internal standard (see SIDA).58 
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Chapter 3 
Synthesis of β-Amino Acids 
Introduction 
Given the significance of β-amino acids, it is not surprising that the development 
of their syntheses, mainly stereoselective ones, has become an important and 
challenging goal for organic chemists in recent years. Numerous methodologies have 
emerged, and most of the work prior to 1998 has been extensively reviewed.1 There 
are eight main approaches available to date for stereoselective synthesis of β-amino 
acids including homologation of α-amino acids, enzymatic resolution, addition of 
enolates (or equivalents) to imines, Curtius rearrangement, conjugate addition of a 
nitrogen nucleophile to α,β-unsaturated esters or imides, hydrogenation, amino 
hydroxylation and β-lactam synthesis.2  
Each approach has its own advantages and limitations. The development of an 
efficient process suitable for large-scale synthesis, which is easy to operate, practical 
and inexpensive, remains a significant challenge. No doubt, the growing interest in 
enantiopure β-amino acids will stimulate the developement of new and improved 
methods for their synthesis in the near future. 
The Chiral Pool Approach: α-Amino Acids as Starting Materials 
Stereoselective Synthesis of β-Amino Acids Starting from Aspartic Acid 
Aspartic acid is a naturally occurring α-amino acid which possesses a β-amino 
carboxylic acid moiety. This feature makes aspartic acid an attractive precursor for 
the preparation of many β-amino acid derivatives. Jefford and co-workers discovered 
that 3-(N-tosylamino)-butano-4-lactone 2, which is derived from aspartic acid 1 via 
tosylation, anhydride formation and selective NaBH4 reduction, was a useful template 
for the stereoselective synthesis of β-amino acid derivatives (Scheme 3.1, 4, method 
A).3 The same methodology was also extended to the synthesis of α-hydroxy  
β-amino acid, where lactone 2 was hydroxylated followed by ring opening with TMSI 
and substitution with organocuprates to yield 6 with syn configuration (Scheme 3.1). 
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Scheme 3.1  Stereoselective synthesis of β-amino acids starting from aspartic acid. 
Dexter and Jackson reported a mild and convenient method for the synthesis of 
functionalized zinc reagents replacing organo-cuprates.4 The zinc reagent obtained 
from 3 is allowed to undergo a palladium catalyzed coupling reaction with aromatic 
iodides giving β−amino esters 4 in moderate to good yields (Scheme 3.1, Method B). 
Seki and Matsumoto have explored the use of oxazolidin-2-one-4-acetic acid 
derivative 7 (Scheme 3.2), prepared from L-aspartic acid, in β-amino acid synthesis.5  
The compound 7 is prepared from L-aspartic acid through the acylation of 
benzene or phenyllithium with α-amino carboxyl group of the L-aspartic acid  
skeleton. Alkylation of the dianion derivatives of 7 with alkyl halides and subsequent 
hydrogenation afforded anti-disubstituted β-amino acids in high stereoselectivities. 
Complete reversal of stereoselection is realized by the alkylation6 of 4-phenyl-3-tert-
butoxycarbonylamino-4-butanolide 8 which was obtained in a single step from 7. The 
2,3,4-trisubstituted amino lactone thus obtained is hydrogenated to give syn-
disubstituted β-amino acids 9. 
HO2C CO2H
NH2
1, L-aspartic acid
4 steps
MeO
O
NHO
Ph
O
1. LDA, RX
2. H2/Pd/C
    HCl
MeO Bn
O
R
NH3+Cl-
convertible 
in a single
step
O
BocHN
Ph
O
1. LDA, RX
2. H2/Pd/C
    HCl
MeO Bn
O
R
NH3+Cl-
7
anti-9
syn-9
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Scheme 3.2  Seki and Matsumoto approach to 2,3-disubstituted β-amino acids. 
Stereoselective Synthesis of β-Amino Acids from Asparagine and 
Derivatives 
Diastereoselective alkylation to introduce substitution at the α-carbon is by far the 
most efficient method for preparing 2,2-disubstituted β-amino acid derivatives. Better 
diastereoselectivities are often obtained using cyclic auxiliaries, which give higher 
differentiation of the two diastereotopic faces. The alkylation of heterocyclic 
compound perhydropyrimidin-4-one 10 (Scheme 3.3), has been extensively studied.7 
The high trans diastereoselectivity found in the addition of enolate 10-Li to 
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electrophiles is probably due to the axial orientation of the tert-butyl group, as 
revealed by an X-ray crystallographic structure of perhydropyrimidinone 10. In this 
way, the chirality center at C(2) induces the stereoselective formation of the new 
stereogenic center at C(5) of the heterocycle. 
Various electrophiles were allowed to react with 10 with almost complete 
stereocontrol (95% de) providing the trans alkylated product 11 in good yields, which 
upon hydrolysis using HCl gave 2-substituted β-amino acids 12 with R configuration 
(Scheme 3.3).  
N
N
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N
N
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O
R
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R
HCl
Dowex
LDA
RX
1. LDA
2. H+
N
N
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HO
H2N
O
R
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Dowex
10 trans-11>95% de (R)-12
(S)-12cys-1185-90% yield
 
Scheme 3.3  Diastereoselective alkylation of heterocyclic compounds according to Seebach (see ref. 
7). 
Alternatively, the β-amino acids with S configuration were conveniently prepared by 
epimerization of the trans adducts. The key step in this transformation was the highly 
diastereoselective protonation of enolates generated from trans-11.  
In an extension to their methodology, Juaristi and co-workers demonstrated the 
application of the same chiral 3-amino-propionic acid derivative 10 in the synthesis of 
2,2-disubstituted β-amino acids 14 (Scheme 3.4).8  
Furthermore, the same authors9 investigated the alkylation of iminoester 15 using 
different electrophiles: the reactions furnished the trans products 16, precursors to 
3,3-disubstituted β-amino acids 17, with excellent diastereoselectivities (Scheme 3.4). 
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Scheme 3.4  β2,2- and β3,3-amino acids according to Juaristy (references 8, 9). 
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Arndt–Eistert Homologation 
The Arndt–Eistert reaction is the oldest method for one carbon chain elongation of a 
carboxylic acid (Scheme 3.5).10  
R OH
O
1. SOCl2
2. CH2N2
R CHN2
O
H2O/Ag2O
OH
O
R
18 19 20  
Scheme 3.5  Arndt-Eistert homologation. 
Taking the advantage of ready availability, low cost, and high enantiomeric purity of 
α-amino acids, the direct homologation to prepare β-amino acids following the  
Arndt–Eistert procedure has found many applications in small molecule as well as 
natural product synthesis.  
Seebach and co-workers have extensively utilized this approach in β-peptide 
synthesis. As outlined in Scheme 3.6, the N-protected α-amino acids 21 are 
converted to mixed anhydrides using Et3N/ClCO2Et. The addition of CH2N2 then 
affords diazoketones 22 with good yields and without any racemization. Wolff 
rearrangement of diazoketones to β-amino acid derivatives is then achieved by UV 
light initiation or by the use of a catalytic amount of silver benzoate in triethylamine 
and methanol.11 In addition, diazoketones 22 may be trapped with the amine 
terminus of another carboxyl protected β-amino acid fragment to provide β-peptides 
directly. A modified procedure using N-Fmoc-protected α-amino acids and  
i-BuOCOCl/N-methylmorpholine to form the mixed anhydride was later proposed by 
Seebach et al. for solid phase synthetic applications.12  
N
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O
P
R
1. Et3N/ClCO2Et
2. CH2N2 NH
C
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R H
N2
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or cat. PhCO2Ag
in Et3N/MeOH
N
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P
R
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Scheme 3.6  Homologation of α-amino acids by the Ardnt-Eistert homologation procedure. 
Several modifications were then proposed to convert diazoketones 22 to β-amino 
esters13 and to apply this homologation procedure to the synthesis of 2-substituted  
β-amino acids14 and β-lactams15 as well as to the total synthesis of compounds such 
as dipeptides containing a β-arginine fragment, or TAN-1057 A,B, anti MRSA 
(methicillin-resistant Staphylococcus aureus) antibiotics.16  
Results and Discussion 
The Arndt–Eistert protocol works very well for the preparation of enantiomerically 
pure substituted β-amino acids from α-amino acids. Unfortunately, it is not suitable 
for large scale preparations due to the high cost of the silver catalyst and, even more, 
the difficult handling of the hazardous reagent CH2N2.  
A few years ago an alternative way to homologate α-amino acid was developed in 
our labs 17. It consisted of the reduction of N-protected α-amino acids 24, followed by 
conversion of the resulting β-amino alcohols 25 to β-amino iodide 27, and then to β-
amino cyanides 28 (Scheme 3.7). The key step of this transformation was the 
generation of the iodides in high yields and without racemization using 
triphenylphosphine-iodine complex. 
34 
Synthesis of β-Amino Acids 
 
R
CO2Me
PGHN
PGHN
R
I
PGHN
R
OH
NH2
R
OH PGHN
R
OH
O
Ph3P/ I2/ Im (PG = Boc, Cbz, Fmoc)
HCl/MeOH
N-protection reduction
242526
27
PGHN
R
CN
28
(PG=H, Cbz, Fmoc)
29
Et4N+CN-
 
Scheme 3.7  Homologation of α-amino acids. 
The subsequent replacement of the iodine atom in 27 by a cyano group, and 
hydrolysis (or alcoholysis) of the latter, complete the synthetic sequence leading to 
N-protected and/or C-protected β-amino acids. 
This method allows the direct conversion of N-protected α-amino acids into their  
β-homologs with complete retention of configuration, using the common 
alkoxycarbonyl protections of the amino function. This method is extremely useful: all 
the reactions are really simple, the reagents being also cheap and easy to handle. 
Synthesis of Isotopically Labeled β-Amino Acids 
The method described above was also modified to be adapted to the preparation of 
deuterium labeled molecules, the interest of which was already discussed in Chapter 
2.  
Thus, 2,2-2H-β3-amino acids were directly and easily prepared from α-amino 
acids.  
N-protected 2,2-2H β-amino alcohols were prepared from N-protected α-amino 
acid mixed anhydrides by sodium borodeuteride reduction.  
BocHN
OH
O
R
1) MeOCOCl, 
    NMM, THF
2) NaBD4, THF
BocHN
OH
R
D D
30a-e 31a-e
a) R= Me
b) R= CH2Ph
c) R= (CH2)4NHBoc
d) R= H
e) R=CH2OBn  
Scheme 3.8  Synthesis of isotopically labeled N(Boc)-β-amino alcohols. 
In Table 3.1 we have summarized the results obtained using as starting materials 
some proteinogenic α-amino acids. 
It is noteworthy that during the reduction, the percentage of bis-deuteration is 
excellent, being in all instances higher than 98% (1H- and 13C-NMR, MS 
measurements). 
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Table 3.1  2,2-2H N-(Boc)-β-amino alcohols from N(Boc)-α-amino acids (Scheme 3.8) 
 Ra Pb m.p. (°C) α D25 (c)c Yield %d 2H % 
31a Ala  58.2-59.1 -9.8 (1.32) 92 >99 
31b Phe  97.3-98.9 -23.1 (1.15) 90 >99 
31c Lys Boc oil -10.1 (1.92) 85 >99 
31d Gly  oil  75 >99 
31e Ser Bn 64.9-65.7 +14.8 (1.71) 75 >99 
a Side chain of starting α-amino acids. b Protection at side chain. c CHCl3 solutions (cell 
sample with a pathlenght of 1 dm). d Yield of the pure product, after recrystallization. The 
yields are the same as those reported for non-deuterated N(Boc)-amino alcohols.18
The N-protected β-amino alcohols 31a-e are then converted to N-protected β-amino 
iodides 32a-e as reported in Scheme 3.9. 
Triphenylphosphine-iodine complex, in the presence of imidazole, accomplishes 
the OH?I replacements in high yields and under very mild conditions. This preserves 
N- and side chain- protections, and does not affect the configuration of the C-3 
stereogenic center as well as the percentage of deuteration at the C-2 position. 
Moreover, it is possible to use a polymer bound triarylphosphine, like polystyryl 
diphenylphosphine; this permits that phosphine oxide, which is formed as the only 
by-product, is linked to a polymeric matrix and, thus, can be separated by simple 
filtration. This avoids time consuming circumstantial purification procedures to obtain 
the pure products. If isolation of iodide derivatives is not necessary, the use of 
dichloromethane soluble and much less expensive triphenylphosphine-iodine 
complex is anyway the best choice and the reaction is also successful. 
1) I2, PH3P, Im,
    CH2Cl2BocHN OH
R
D D
31a-e
a) R= Me
b) R= CH2Ph
c) R= (CH2)4NHBoc
d) R= H
e) R=CH2OBn
BocHN
I
R
D D
32a-e
BocHN
CN
R
D D
33a-e
2) Et4N+CN-, 
    CH2Cl2
 
Scheme 3.9  Synthesis of 2,2-2H-β-amino cyanides 
When we used N-protected β-amino iodides as such in the conversion to N-protected 
β-amino cyanides without any purification, soluble triphenylphosphine could be used 
(Scheme 3.9). 
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Table 3.2 2,2-2H-N-(Boc)-β-amino cyanides from 2,2-2H-N-(Boc)-β-amino alcohols 
 Ra Pb m.p. (°C) α D25 (c)c Yield %d 2H % 
33a Ala  68.2-70.0 -120.1 (1.38) 80 >99 
33b Phe  123.8-125.0 -18.2 (1.15) 74 >99 
33c Lys Boc 60.7-64.0 -45.2 (0.57) 70 >99 
33d Gly  42.4-45.0  88 >99 
33e Ser Bn oil -9.7 (1.62) 65 >99 
a Side chain of starting α-amino acids. b Protection at side chain. c CHCl3 solutions (cell 
sample with a pathlenght of 1 dm). d Yield of the pure product, after recrystallization. The 
yield are the same of that already reported for not deuterated N(Boc)-amino alcohols.18
The preparation of N-protected β-amino cyanides has been very seldom reported.  
N-tosyl β-amino nitriles18 were prepared from N-tosyl aziridines by 
cyanotrimethylsilane in the presence of lanthanoid tricyanide as catalyst;  
N,N-dibenzyl β-amino cyanides have also been obtained by deoxygenation of  
N,N-dibenzyl α-amino aldehyde cyanohydrins19 or by an intriguing monosubstitution 
operated by LiCN in DMF onto the dimethyl diester of the N,N-diprotected amino diol 
coming from aspartic acid reduction.20 To the best of our knowledge, the conversion 
of N(Boc)-(R)-phenylglycinol tosyl ester to the corresponding β-amino cyanide by 
NaCN (or KCN) in DMSO (90 °C, 1h) represents (although questionable) the only 
example of synthesis of N(alkoxycarbonylamino)-protected β-amino cyanides.21 In 
our hands, N(Boc)-protected β-amino iodides were smoothly converted to their 
corresponding cyanides by 4h reflux with tetraethylammonium cyanide22 in 
dichloromethane (Scheme 3.9). The work-up of the reaction is also very simple: when 
the starting β-amino iodide is fully consumed (TLC monitoring), silica gel is added to 
the reaction mixture and the solvent is evaporated under reduced pressure. The solid 
is then mechanically collected from the reaction flask and transferred directly onto a 
short silica gel column (petroleum ether-ethyl acetate) to afford the product that is 
finally crystallized from dichloromethane-hexane. This is the only chromatographic 
purification step of the whole process. 
Thus, the N(Boc)-protected β-amino cyanides 33a-e were hydrolyzed under acid 
conditions with HCl in methanol 10 N for 12 h at room temperature; under those 
conditions the Boc-group is cleaved, and the C-2 fully deuterated β3-amino methyl 
esters 34a-e were obtained. 
a) R= Me
b) R= CH2Ph
c) R= (CH2)4NHBoc
d) R= H
e) R=CH2OBn
BocHN
CN
R
D D
33a-e
HCl, MeOH -Cl +H3N CO2Me
R
D D
34a-e
 
Scheme 4.0  Synthesis of 2,2-2H-β-amino methyl esters. 
The deuterium content does not change throughout the whole process and the 
isotopic labelling is always higher then 99% (Table 3.3). 
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Table 3.3 2,2-2H-N-(Boc)-β-amino cyanides from 2,2-2H-N-(Boc)-β-amino alcohols 
 Ra Pb m.p. (°C) α D25 (c)c Yield %d 2H % 
34a Ala  250 dec. +0.19 (2.5 in MeOH) 87 >99 
34b Phe  255 dec. +4.28 (1.38) 85 >99 
34c Lys  oil +8.49 (0.56) 82 >99 
34d Gly  102.4-106.0  90 >99 
34e Ser Bn oil +0.68 (0.74) 80 >99 
a Side chain of starting α-amino acids. b Protection at side chain. c CHCl3 solutions (cuvette 
with a pathlenght of 1 dm). d Yield of the pure product, after recrystallization. The yields are 
the same as those reported for not deuterated N(Boc)-amino cyanides.18
In conclusion the entire process is very simple and general; it gives excellent yields 
and the reactions are easy to handle. Moreover it is possible to scale up the process, 
without encountering particular difficulties. 
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Chapter 4 
Synthesis of 2,3-Diamino Carboxylic Acids 
The development of simple and efficient methods to produce enantiomerically pure 
2,3-diamino carboxylic acids from readily available starting materials represents a 
fascinating goal from both chemical and pharmaceutical point of view. Several 
asymmetric syntheses have been reported so far.  
One of the most practical approaches to 2,3-diamino acids expolits β-lactams 
as starting materials. The synthesis of β-aminoalanine derivatives, such as the one 
reported by Baldwin,1 involves formation of L-quisqualic acid 17 from N-benzyloxy  
β-lactam 18, in excellent yield. 
N
O
BocHN H
OBn
N
O
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O
O
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17 18
H2N NH2
O
NHBco
19
 
Scheme 3.1  Retrosynthetic analysis of β-aminoalanine as reported by Baldwin1
In a similar way, Hecht2 reported the synthesis of (2S)-3-amino-2-[(tert-butoxy-
carbonyl)amino]propionamide 19 from (2S)-N-(benzyloxy)-2-azetidin-one 18 
(Scheme 3.1). 
More recently, Ojima and co-workers3 have illustrated the use of enantiomerically 
enriched 3-amino-β-lactams for the construction of 3-substituted 2,3-diamino acids 
via acid catalyzed ring opening. 
NH
H2N H
Ph
O
H+ Ph
CO2H
NH2
NH2
20 21  
Scheme 3.2  3-Substituted 2,3-diamino acids via acid catalyzed ring opening 
Many other procedures for the synthesis of 2,3-diamino acids from β-lactams have 
been reported.4  
Several methodologies use proteinogenic α-amino acids to prepare 2,3-diamino 
acids; they are often quite expensive because of the use of stoichiometric amounts of 
chiral reagents.  
For instance, 2,3-diaminopropanoic acid and 2,3-diaminobutanoic acid are 
synthesized from aspartic acid,5 L-serine6 and treonine.7  
Rapoport and co-workers developed a general method for the stereoselective 
synthesis of 3-substituted 2,3-diamino acids via alkylation of an aspartic acid 
derivative. The Rapoport-type aspartate alkylation consisted of the incorporation of 
the C-3 substituent as a positive synthon (a halide was used as a suitable synthetic 
equivalent). 
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An alternative pathway consists in diastereoselective addition of Grignard reagents, 
negative synthons, to α-amino nitrones from L-serine,6 that provides a method for the 
synthesis of optically active 3-substituted 2,3-diamino acids 
Both diastereoisomers of 2,3-diaminobutanoic acids are easy accessible through 
a nucleophilic substitution reaction on derivatives of β-substituted L- or  
D-threonines,7 but in that case the methodology is not versatile.  
The Mitsunobu reaction on serine,8 the Hofmann and Curtius rearrangements of 
asparagine derivatives,9 and the Schmidt reaction of aspartic acid10 were used to 
access chiral 2,3-diaminopropanoic acids. 
A variety of other syntheses have also been reported: the conjugate addition11 of 
homochiral lithium N-benzyl-N-α-methylbenzylamide to α,β-unsaturated esters and in 
situ amination with trisyl azide, the asymmetric Rh(I)-phosphine-catalyzed 
hydrogenation of diastereoisomeric enamides,12 and the ring opening of  
cis-3-alkylaziridine-2-carboxylates coming from Sharpless asymmetric 
aminohydroxylation of α,β-unsaturated esters.13
Although several methods for preparing chiral diamino acids are known, our 
interest was to find a general procedure for stereoselective formation of C-N bonds, 
for the direct introduction of an amino function onto C-2 position of β3-amino acids. 
Electrophilic Amination of Nucleophilic Carbons 
Stereoselective formation of C-N bonds on starting materials easy to handle and 
available is an important goal of organic synthesis. 
Various stereoselective procedure for the introduction of an amino group onto the 
C-α of carbonyl compounds are reported in the literature;14 in general, direct 
stereoselective addition of nitrogen-containing functional groups onto carbon atoms 
is the simplest approach for the formation of stereogenic centers having nitrogen 
atoms.  
Results and Discussion 
The synthetic approach we decided to follow, is based on a direct stereoselective 
reaction of α-amination of β-amino methyl esters using di-tert-butylazodicarboxylate 
(DBAD) as nitrogen source (Figure 3.6), as already reported in literature by Seebach 
et al.15
Recently, we have described the preparation of enantiomerically pure  
2-hydroxy-β3-amino acids by hydroxylation of chiral enolates of β3-amino acids.16 We 
found that the replacement of Boc- or Cbz-groups, used by Seebach15 as protections 
of the amino function of methyl 3-amino-butanoate in a similar reaction, with benzyl 
groups gave better results, assuring good yields and excellent diastereoselectivity. 
According to the same scheme, we decided to introduce different electrophile to 
generalize the use of this kind of protections. 
Thus, we have prepared 2,3-diamino acids through electrophilic amination. 
For the preparation of the starting materials we used the methodology17 devised 
in our own lab and described in this thesis (Chapter 2).18 
N N
OtBu
OtBu
O
O Di-tert-butylazodicarboxylate
DBAD
22
 
Figure 3.6  DBAD 
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In the literature several reagents for electrophilic amination, such as derivatives of 
hydroxylamines,19 sulphonylazides,20 oxaziridines,21 and azodicarboxylate esters. We 
have reported the use of the latter because especially the di-tert-butyl ester is a 
crystalline solid, stable and commercially available; moreover it reacts with 
remarkable diastereofacial selectivity in reactions with different kinds of chiral 
enolates.22 Finally, the tert-butyloxycarbonyl groups on the nitrogen atoms are easily 
removed under mild conditions and the reductive cleavage of N-N bonds is possible 
in good yields. 
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Scheme 3.3  Conversion of  α-amino acids into 2,3-diamino acids 
Thus, N,N-dibenzylated β3-amino esters (25a–c), in anhydrous THF at –78 °C and 
under anhydrous nitrogen atmosphere, were treated with potassium 
bis(trimethylsilyl)amide (KHMDS) to generate the corresponding enolates. The use of 
more common bases, such as LiHMDS and LDA, for the enolate generation was 
neglected since in our experience16 such bases lead to significantly poorer results. 
After 1 h, solid di-tert-butyl azodicarboxylate (DBAD) was added to the reaction 
mixture that was kept at –78 °C for an additional hour. Under such conditions, the 
Boc-protected hydrazino derivatives of the starting 25a–c were obtained. The double 
protection of the amino group is necessary to avoid formation of by-products coming 
from the abstraction of the N–H proton in the enolate generation step. Consequently, 
common protecting groups that are stable under basic conditions, such as Boc or 
Cbz, could not be used under our reaction conditions. Therefore, in a first attempt, 
the 4-methoxybenzyl group, we had already used elsewhere,16 was chosen for its 
peculiar removal conditions (CAN, CH3CN/H2O). Unfortunately, although the group 
turned out to be stable under the reaction conditions, we could not use it because the 
deprotection of the final 3-[di(4-methoxybenzyl)amino]-2,3-diamino esters led to a 
plethora of products coming from oxidative cleavage of the C2–C3 bond. Eventually, 
we used a double benzylic protection that eliminated such deprotection problems and 
represented at the same time a very bulky nitrogen substituent, suitable to affect the 
stereochemical outcome23 of the enolate coupling with the electrophile DBAD. As a 
matter of fact, the coupling afforded a mixture of anti:syn Boc-protected 2-hydrazino 
derivatives of 25a–c with excellent diastereoisomer ratios.  
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 Table 3.1.  Functionalization at C-2 of the fully protected β3-amino esters 25a–c 
Boc protected 2-hydrazino 
derivatives 26a–c 
 
anti-2,3-Diamino esters 
(27a–c), yield 
(%)a
 
Protected β3-amino 
ester 
 
R 
Yieldb(%) anti/syn Yield (%) 
25a Ph 92 93:7 70 
25b Bn 90 97:3 78 
25c CH2OBn 90 94:6 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Overall yield after Boc removal and reductive cleavage of the hydrazine 
moiety in the anti diastereoisomers 8a–c. 
b) Yield of both diastereoisomers. 
Due to the complexity of the 1H NMR spectra of the Boc containing hydrazino 
derivatives, they were converted into the corresponding diastereoisomeric mixtures 
of diamino esters (e.g., 27) to determine the diastereoisomeric ratio. The synthetic 
path is depicted in Scheme 3.3 and the results obtained for selected N-protected  
β3-amino esters, namely the methyl esters of β3-phenylglycine 25a, β3-phenylalanine 
25b, and β3-serine 25c, are reported in Table 3.1. 
The more abundant anti diastereoisomers were submitted to removal of the Boc 
protections (TFA in CH2Cl2) and cleavage of the N–N bond by hydrogenolysis with 
Ni(Ra) at low pressure and room temperature in an ultrasound bath. The reduction of 
hydrazines to amines is reported to be accomplished at high temperature, under high 
hydrogen pressure.24 The use of ultrasound reduces significantly both temperature 
and pressure.25 As a matter of fact, the hydrogenolysis under such conditions was 
complete after only 4 h and no traces of C-2 epimerization products could be 
detected by 1H NMR spectroscopic analysis. The anti configuration of the more 
abundant diastereoisomers coming from the couplings of 25a–c with DBAD could be 
attributed, in the case of 26a, as follows: the final product 27a was debenzylated and 
treated, without isolation, with 1,1’-carbonyldiimidazole to afford the imidazolidinone 
29 (Scheme 3.4). The 1H NMR coupling constant of 9.6 Hz supported26 the cis 
configuration of the H-4 and H-5 protons and, thus, the anti configuration of the 
starting diamino compound. 
i ii
i. Pd/C, H2, AcOH, 50°C, 90%; ii. 1,1'-carbonyldiimidazole, TEA, THF, 0 °C, 85%.
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Scheme 3.4  Synthesis of cis-imidazolidinone (29). 
In the light of this result, in agreement with our previous work on the hydroxylation at 
C-2 of β3-amino esters, it seems likely that the stereochemical outcome of the 
functionalization at C-2 is independent of the nature of the electrophile used, being 
only a function of the relative stabilities of the enolate conformations.
The high diastereoselectivity, found in all the cases examined, could be explained 
on the basis of the same theory, already used for the interpretation of the 
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stereochemical outcome of the α-hydroxylation reaction, in which the anti 
diastereoisomer is also the major product. 
The asymmetric induction is exerted by the stereogenic center of the starting 
amino acid, the contribution of which is, in fact, probably amplified by the presence of 
the cumbersome amine protection. As a matter of fact, PM3 calculations carried out 
for the enolate ion produced from the starting compound 25b showed that its more 
favoured conformation was the one with the enolate group between the hydrogen 
atom and the protected amino group (Figure 3.7, A).  
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Figure 3.7  Conformational energies for the enolates 
Its energy is lower than the energy of B. The attack of the DBAD reagent takes place 
from the less hindered  face of the enolate moiety (opposite to the bulky substituted 
nitrogen group), it provides an excess of the anti diastereisomer. Accordingly, in the 
case of the enolate from 25a, the same conformation had a much smaller energy 
advantage, and this may account for the lower diastereisomeric ratio achieved in its 
amination. 
This model explains how the diastereoisomeric ratio is related to the hindrance of 
alkyl residue present on the asymmetric carbon; indeed, the bigger R, the more 
stable is the conformer A in respect with conformer B, with formation of the isomer 
anti as major product. 
Models based on cyclic intermediates were discarded: previous studies, carried 
out on the α-hydroxylation, demonstrated that the use of lithium 
bis(trimethylsilyl)amide (LHMDS) instead of potassium bis(trimethylsilyl)amide 
(KHMDS) gives the same diastereoisomeric ratio. It is known that K+ ion is scantly co-
ordinated, as compared to the smaller Li+ ion, and the amine function, with double 
cumbersome protections, such as benzyl groups, is not a good electron donor.  
Moreover, the type of electrophile used in the reaction with the enolates 
influences little the stereochemical outcome of the reaction. In Table 3.2 are shown 
the diastereoisomer ratios of both α-hydroxylation and α-amination processes with 
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the methyl esters of N-protected β3-phenylalanine 25b: both the processes give rise 
to comparable diastereoisomer ratios. 
Table 3.2. Functionalization at C-2 of fully protected β3-amino esters 
α-Hydroxylation 
product 
Yield1 
% 
d.r.2 
% α-Amination product 
Yield1 
% 
d.r.2 
% 
NBn2
OH
CO2MePhCH2
 
63 99:1 
NBn2
NBocNHBoc
CO2MePhCH2
 
90 97:3 
1 Total yield of both diastereoisomers. 
2 Diastereomeric ratio determined by 400 MHz 1H NMR and by GC-MS. 
Conclusions 
This amination procedure of β3-amino esters offers several advantages, if compared 
with many other reported procedures. First of all, it does not require the use of either 
chiral reagents or chiral auxiliaries: in fact, the observed selection in the coupling 
step is merely due to the influence of the existing stereogenic center of the starting  
β3-amino ester, enhanced by the presence of two bulky substituents on the nitrogen 
atom. Moreover, it is noteworthy that the amino groups in the final 2,3-diamino esters 
have a different protection status: this implies a broad flexibility of their use in peptide 
synthesis. For instance, the free amino group can be Boc protected and the benzyl 
groups then removed hydrogenolytically ready for a Fmoc protection, or vice versa. 
Accordingly, in connection with our current interest in the synthesis of glycosyl amino 
acids, we have prepared the compound 32 as shown in Scheme 3.4 
27a
i ii
i. Boc2O, TEA, dioxane, 0 °C, 98%; ii. Pd/C, H2, methanol, 50 °C, 90%;
 iii. FmocOSu, Na2CO3, DMF/dioxane, 0 °C, 65%.
30
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Scheme 3.4  Preparation of orthogonally protected 2,3-diamino acid ester 32. 
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Chapter 5 
Synthesis of 2,3-Disubstituted β-Amino 
Acids 
Introduction 
Stereoselective synthesis of β-amino acids represents an important task for organic 
chemists, especially considering the growing interest for the application of β-amino 
acids in various areas. The peculiar characteristics of β-peptides that can be obtained 
stimulated scientists to look for new methodologies to obtain enantio-pure β-amino 
acids. In this respect several articles,1 reviews2 and even books3 were dedicated to 
the synthesis of highly pure β2-, β3-  and β2,3-aminoacids.4,5,6  
For the synthesis of the latter compounds several methods are known; some of 
these use, as starting materials, natural α-aminoacids,7 and the construction of  the 
second stereogenic center by hydroboration1e or via N-tosylated allyl amine 
intermediates.8 In a second approach L-aspartic acid9a,b,d,10 is used to prepare syn- 
and anti-β2,3-amino acids, via an oxazolidone intermediate,11 as already discussed in 
Chapter 3, and ester enolates have been used in conjunction with tert-butylsulfinyl 
imines to afford these compounds.12
Asymmetric synthesis of β2,3-aminoacids can be obtained by conjugated addition 
of chiral lithium amides on methyl and tert-butyl crotonates and cinnamate esters,13 
by chiral Lewis acids mediated conjugate addition of amines on imides and 
oxazolidinones,14 by 1,3-dipolar cycloadditions of oximes and allylic alcohols,15 and 
by conversion of the Baylis-Hillmann adducts.16 An extension of Davies protocol1c,d is 
reported by Gellman17 et al. to prepare protected syn-2,3-dialkyl β-amino acids that 
contain lysine-like side chains.  
Great part of these synthetic methodologies have the advantage of being highly 
diastereo- or enantio-selective; however they are often limited by low yields and high 
number of synthetic steps.  
Recently new strategies have been developed for the synthesis of β2,3-aminoacids 
using both homogeneous18 and heterogeneous catalysis of specific β-amino acid 
precursors.2d,6c These approaches are, however, limited by the need of expensive 
chiral auxiliaries. 
Finally, the alkylation of β3-amino acids, readily obtained from α-amino acids via 
Arndt-Eistert homologation (Chapter 3), was investigated by Seebach as a mean to 
obtain 2,3-dialkyl β-amino acids.19
Since in our lab a stereoselective method for the synthesis of 2-hydroxy  
β3-aminoacids20 had been devised, and since a suitable procedure was optimized as 
part of this thesis work to prepare 2-amino β3-amino acids (Chapter 4), we thought to 
exploit this methodology to the synthesis of 2-alkyl-β3-amino acids as well.  
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Synthetic Strategy 
Stereoselective carbon-carbon bond forming reactions in α-position to carbonyl 
groups and their derivatives, is one of the most important tools in asymmetric 
synthesis.21 Indeed diastereoselective reaction of chiral molecules, bearing 
nucleophylic carbons to electrophylic alkylating agents, represents an easy approach 
to the formation of new stereogenic centers. 
β3-Aminoesters present relatively acidic protons in α position to the ester function 
and, in the presence of strong bases, form enolates that are able to undergo coupling 
reactions with different electrophiles.22 The synthetic strategy we developed, inspired 
by former studies on α-hydroxylation20 and α-amination of β3-aminomethylesters, 
exploits the reactivity of β3-aminoesters to undergo stereoselective coupling reactions 
using different and economic commercially available carbon electrophiles such as 
methyliodide, benzylbromide and formaldehyde, in order to introduce at C-2 of β3-
aminoacids, side-chain analogues to those present in natural α-aminoacids, such as 
methyl (alanine), benzyl (phenylalanine) and hydroxymethyl (serine) groups.  
Moreover, alkyl chains with a large number of carbon atoms could be introduced 
which is interesting, since it is reported that peptides23 “conjugated” with lipidic α-
amino acids show increased permeability through cell membranes and enhanced 
biological stability. 
Under the optimized reaction conditions (Scheme 5.1), a base was added at -78 
°C in anhydrous THF to the fully protected β3-aminomethylester, to generate an 
enolate, that is in turn allowed to react with an electrophile, added in situ at -78 °C 
under nitrogen atmosphere, to yield the desired β2,3-amino methyl ester. 
P2N OMe
OR
base
THF, -78°C
P2N OMe
O- M+R
electrophile
-78°C, THF
P2N OMe
OR
E  
Scheme 5.1  Conditions for α-alkylation of β3-amino methyl esters 
Yields and stereochemical outcome of these reactions were highly dependent up on 
the experimental conditions chosen. 
A first factor to be considered is the selection of the correct enolate counterion, 
because of the different ability of lithium and potassium to co-ordinate the enolate 
anion. 
Crucial for yields are the ratios of β-aminoester, base, and electrophile. 
Finally the amino protecting group has to be considered. In such a case the benzyl 
group, as reported in the literature,24 showed the best results in terms of yields and 
diastereomeric ratios. First of all, the double protection avoided side reactions with 
the strong base used, and then the steric clash on the diastereotopic faces induced a 
specific bias toward the addition to the enolate.25 Since we chose to alkylate  
β3-serine having a benzyl protection on the OH of the side chain, we considered to 
use the p-methoxybenzyl group as protection of the β-amino function in all the 
substrates employed, to have all orthogonal protecting groups on the β-amino acid. 
The high diastereoselectivity of these reactions could be explained on the basis of 
the theory, already used for the interpretation of the stereochemical outcome of the 
α-hydroxylation and the α-amination reactions, as already illustrated in Chapter 4. 
Models based on cyclic intermediates were discarded: first studies conducted on 
the α-hydroxylation process showed, indeed, that the use of LHMDS in the place of 
KHMDS causes in some case a decrease in diastereoselection; furthermore, it is 
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known that K+, being bigger than Li+, has a weaker coordination character; finally the 
N,N-dibenzylated amino function is not prone to act as electron donor. 
Reagent ratios, nature of the base and temperature were optimized on β-alanine 
as a model substrate for α-alkylation and α-hydroxymethylation reactions. The best 
conditions devised were then applied to more complex β3-aminoacids such as  
β3-homophenylalanine, β3-homophenylglycine and β3-homoserine. 
α-Alkylation Reactions 
As mentioned above, reaction conditions were optimized on β-alanine bearing two  
p-methoxybenzyl protecting groups at the amino function. As depicted in Table 2, 
reaction conditions already optimized for the other hetero-functionalizations (1:2:1.8; 
substrate:base:electrophile) yielded a dialkylated product, together with the expected 
monoalkylated one that suggested us to reduce the equivalent of electrophile used to 
1.1. 
Table 5.1  α-Alkylation reactions of N,N -(MPM)-β-alanine methylester with KHMDS and LiHMDS 
(MPM)2N OMe
O
THF-78°C, MHMDS
(MPM)2N OMe
O
R
electrophile
1 2   R =  CH3 
3   R =  CH2Ph
 
 
Base 
 
Electrophile 
Subs:Base:Electr. 
Equivalents 
Time (min) and 
Temperature (°C) 
 
Yield%a
KHMDS CH3I 1 : 2 : 1.8 60, -78 40b
KHMDS CH3I 1: 2 : 1.1 90, -78 61 
LiHMDS CH3I 1 : 2 : 1.1  90, -78 45 
LiHMDS PhCH2Br 1 : 2 : 2.2 150, -78 30b
LiHMDS PhCH2Br 1 : 2 : 1.1 150, -78 40 
KHMDS PhCH2Br 1 : 2 : 1.1 150, -78 65 
KHMDS PhCH2Br 1 : 2 : 2.2 150, -78 50b
aYields of the product isolated and characterized after chromatographic purification. 
bDialkylation product formation was observed. 
Chemical yields are good, and confirm also the outcome of some monodeuteration 
experiments (not reported), KHMDS affords greater yields than LHMDS, especially if 
one considers some recovered unreacted starting materials. This result is explained 
in terms of co-ordination ability of the enolate counterion: different from Li+, K+ is 
weakly co-ordinating and determines higher electron density on the Cδ- of the enolate, 
that is therefore more easily attached by electrophiles. 
The optimized conditions were applied to more complex substrates. The results of 
α-alkylation reaction on N,N-(MPM)-β3-phenylalanine methylester (4) are reported in 
Table 5.2. KHMDS was chosen as base, and 1:2:1.1 ratios between starting material, 
base, and electrophile were used. 
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Table 5.2 α-Alkylation reactions of N,N -(MPM)-β3-phenylalanine methylester with KHMDS 
(MPM)2N OMe
O
THF-78°C, KHMDS
(MPM)2N OMe
O
R
electrophile
Ph Ph
4 5 R = CH3
6 R = CH2Ph  
 
Electrophile
Subs:Base:Electr.
Equivalents 
Time (min) and  
Temperature (°C)
 
Yield%a
 
d.r.%b
CH3I 1 : 2 : 1.1 120,-78 54 93:7 
CH3I 1: 2.8 : 1.1 180,-78 36 93:7 
CH3I 1 : 2 : 2.2 120,-78 97 93:7 
PhCH2Br 1 : 2 : 2.2 150,-78 90 97:3 
aTotal yield considering both diastereoisomers. bDiastereomeric ratios 
were determined by GC-MS and 1H NMR analysis. 
In order to improve the yields of the reactions, we tried to increase the equivalents of 
both base and electrophile, hoping that the steric hindrance of the residue at C-3 
position of the β3-amino acid could prevent formation of dialkylated products. 
It is noteworthy, in fact, that the excess of the electrophile (2.2 equiv. versus 1.1) 
did not yield dialkylation, and afforded only a diastereomeric mixture of 
monoalkylated products. 
The results obtained for N,N-(MPM)-β3-phenylglycine methylester (7) are reported 
in Scheme 5.2 
(MPM)2N OMe
O
(MPM)2N OMe
O
R
Ph Ph
8   R =  CH3 
       80%, ad.r. 9:1
9   R =  CH2Ph
       75%, ad.r. 92:8
1) KHMDS (2eq), THF, 
    -78 °C
2) 2.2 eq CH3I, 4h, 
    THF, -78 °C
    (or BnBr, 3h)
aDiastereomeric ratios were determined by GC-MS and 1H NMR analysis.
7
 
Scheme 5.2  α-Alkylation reactions of N,N -(MPM)-β3-phenylglycine methylester with KHMDS. 
In this case, the best conditions for α-methylation and α-benzylation were the same 
as for β3-phenylalanine. 
The lower diastereoisomer ratio is due to the lower hindrance exerted by the 
phenyl group of β-phenylglycine in comparison with the benzyl group of 
phenylalanine. 
Finally in Scheme 5.3 are reported the results obtained in the alkylation of  
N,N-(MPM)-β3-serine methylester (10), under the conditions already experienced. 
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(MPM)2N OMe
O
(MPM)2N OMe
O
R
OBn OBn
10
11   R =  CH3 
       89%, ad.r. 94:6
12   R =  CH2Ph
       78%, ad.r. 96:4
1) KHMDS (2eq), THF, 
    -78 °C
2) 2.2 eq CH3I, 4h, 
    THF, -78 °C
    (or BnBr, 3h)
aDiastereomeric ratios were determined by GC-MS and 1H NMR analysis.  
Scheme 5.3 α-Alkylation reactions of N,N -(MPM)-β3-serine methylester with KHMDS 
α-Hydroxymethylation Reaction 
The introduction of polar chains at C-2 position of β3-amino acids is of great interest 
for creating peptidic scaffolds with different side chains and there are only few 
methods to do it.17,26
For this reason, we considered, besides the α-alkylation reactions, the 
introduction of a group at C-2 position.  
Also in this case, the best conditions were found using β-alanine as model. The 
electrophile was paraformaldehyde, that is cracked to formaldehyde, before the use 
and transfer into the reaction flask with a nitrogen flow. 
The results are summarized in Table 5.3. 
The difference between KHMDS and LHMDS was confirmed in this reaction as well. 
As shown in the Table, in fact, under the same reaction conditions, KHMDS reacted 
faster and gave better yields. 
The temperature plays a crucial role; the enolate formation has to be carried out 
at -78 °C, but formaldehyde has to be added at higher temperature, to prevent its 
polymerization during the transfer from the cracking flask into the reaction system; at 
this temperature the reaction product 13 undergoes elimination to give 14. In order to 
minimize this elimination process, cooling the system immediately after the addition 
of formaldehyde was necessary. 
Table 5.3. α-Hydroxymethylation reaction of N,N- (MPM)-β-alanine methylester 
(MPM)2N OMe
O
1) THF-20°C, MHMDS
2) (CH2O)n
(MPM)2N OMe
O
OH
+ (MPM)2N OMe
O
1                                                                 13                                     14  
 
Base 
Subs:Base:Electr.
Equivalents 
Time (min) and 
Temperature (°C)
Yield of 
13a
Yield of 
14a
LiHMDS 1 : 2 : 4 10, -20 32 30 
KHMDS 1: 2 : 4 10, -20 40 50 
KHMDS 1 : 2 : 8 10, -20 50 30 
KHMDS 1 : 2 : 8 90, -78 85 -- 
aYields after chromatographic purifications. 
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One more time, the reaction was extended to other β3-amino acids, used in the other 
functionalizations as well. 
As shown in Table 5.4, the diastereoisomeric ratios, as well as the yields are 
really good, especially considering that similar reactions operated on different starting 
materials work worst.26
Table 5.4  α-Hydroxymethylation reaction of N,N- (MPM)-β3-phenylalanine, phenylglycine and serine 
methylesters 
(MPM)2N OMe
O 1) THF-78°C, 
   KHMDS (2 eq)
2) (CH2O)n (8 eq)
(MPM)2N OMe
O
OH
R R
15-17  
R 
Time (min) and 
Temperature 
(°C) 
Yield%a d.r.%b
CH2Ph 60, -78 65 99:1 
Ph 60, -78  88 97:3 
CH2OBn 60, -78 78 95:5 
aYield of products 15-17 after chromatographic 
purification. bEstimated by GC-MS and 1H NMR. 
Lipo-amino Acids and Lipo-peptides 
Lipo-conjugates prepared by introduction of a lipophilic moiety into a peptide 
sequence have been demonstrated to increase its overall hydrophobicity. This 
represents a powerful tool to solve the problem of insufficient bio-availability of some 
potentially bioactive peptides that may be related mainly to their poor membrane 
solubility.23d
In this respect, particular attention has been focused on lipidic α-amino acids. 
These unnatural α-amino acids contain long hydrocarbon side chains and have an 
amphiphilic nature that influences their physical properties.23a
Peptides conjugated with lipo-amino acids show increased permeability through 
cell membranes and increased biological stability, both of which are essential 
properties for good drug delivery.23b,c
Moreover, lipo-conjugated peptides show better resistance towards proteolytic 
enzymes than the unmodified sequences.27
To the best of our knowledge, there are no examples in the literature of β-
analogues of lipo-amino acids, having hydrophobic side chains on the 2-position of β-
aminoacids. 
For this reason, having optimized a method to introduce stereoselectively different 
kinds of substituents on the C-2 position of β-amino acids, we tried to use the same 
conditions to introduce one or two hydrophobic chains on β-amino acids. 
First, we prepared a good electrophile: using a reaction devised in our lab, we 
accomplished the OH?I replacement exploiting the formation of PPh3/I2 complex as 
described in Chapter 3 and as shown in the Scheme 5.4: 
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I2, PPh3, Imidazole
CH2Cl2, reflux, 1h
CH3(CH2)13CH2OH CH3(CH2)13CH2I
18 19Yield 96%  
Scheme 5.4  Synthesis of pentadecyl iodide 
This reaction confirms that the method works really well also on simple alcohols, 
besides β-amino alcohols. 
The compound 19 was used as electrophile in the alkylation of the enolate of  
β-alanine methyl ester. 
It is noteworthy that the enolate is generated at -78 °C and, at this temperature, 
the pentadecyl iodide is not soluble in THF. For this reason, we were forced to 
operate at higher temperature (-20?0 °C). The difficulty to operate at these 
temperatures is due to the intrinsic instability of the enolate. Moreover, the iodide 
also becomes less stable; indeed, due to the basicity of the solution, the elimination 
process on the electrophile becomes more probable and competes with the 
substitution reaction.  
Having all this in mind, we tried to use the same conditions devised for the other  
α-alkylations, except for higher temperatures. 
Table 5.5  Alkylation of N,N-di-p-methoxylbenzyl β-AlaOMe 
(MPM)2N OMe
O
1) THF, -78°C, KHMDS
2) CH3(CH2)13CH2I
(MPM)2N OMe
O
1 R X
R = CH2(CH2)13CH3
20 X= H
21 X= R
 
Subs:Base:Electr.
Equivalents 
Time and 
Temperature Yield
 a% 
1 : 2 : 2.2 120 min, 0 °C 50 
1 : 2 : 1.1 180 min, 0 °C 13 
1 : 1.1 : 1.1 90 min, 0 °C 4 
aOverall yield of mono- and di-alkylation products. 
As shown in the table, under all the conditions already tested for the other alkylations, 
we had formation of di-alkylation product in addition to the mono-alkylated one, as 
already experienced for the methylation and benzylation of β-alanine; this could also 
not be prevented by reduction of the amount of both base and electrophile. 
With the aim to use both the products for the preparation of peptides, it was 
necessary to optimize the process to discriminate mono- and di-alkylation. 
However the first problem, that we considered, was the possibility to remove from 
the final products all the protections. It is known, in fact, that hydrolysis of hindered 
esters could be difficult; if we consider that our lipoamino acids are scarcely soluble 
in water, this deprotection is very intriguing. Thus, we tried, first, to isolate the mono- 
and di-alkylated products, to optimize their deprotections. 
Actually, whereas the product 20 (Scheme 5.5) is easily deprotected on both 
amino and carboxyl functions, for the product 21, especially the hydrolysis of the 
methyl ester group was hard to accomplish. 
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(MPM)2N OMe
O
R H
R= CH3(CH2)13CH2
CAN,
H2O/CH3CN
   12 h
yield 96%
H2N OMe
O
R H
1) NaOH,
    MeOH/H2O
    12 h
2) Boc2O, 
    H2O/CH3CN
    12 h
BocHN OH
O
R H
20 23 (73%)22
 
Scheme 5.5  Deprotection of mono-alkylated product. 
As shown in Scheme 5.6, we first attempted to deprotect the amino group, using 
CAN in a mixture of H2O/CH3CN (1:4, v:v). The reaction run for 2 days giving the 
product 24 with only 30% yield. Moreover, the hydrolysis of 24 with NaOH in 
MeOH/H2O attempted for 12 h at room temperature and for 10 days at 50 °C without 
giving any result. Also hydrolysis with Me3SiCl/NaI, that proceeds via an acyl iodide 
intermediate, did not afford any product. 
(MPM)2N OMe
O
R R
R= CH3(CH2)13CH2
CAN,
H2O/CH3CN
   12 h
yield 30%
H2N OMe
O
R R
NaOH,
MeOH/H2O
2 h, r.t.      10d 50 °C H2N OH
O
R R
21 24
 
Scheme 5.6  Deprotection of di-alkylated product. 
For this reason, we replaced the methyl ester with the more easy to cleave tert-butyl 
ester. The latter can be cleaved under mild acid conditions. It was also necessary to 
replace the MPM protections with simple benzyl groups. MPM deprotection, in fact, is 
carried out with CAN in H2O/CH3CN, namely strong oxidative conditions. Instead, the 
benzyl group is cleaved by hydrogenation on Pd/C in AcOH. 
According to a published procedure,28 we prepared the N,N-dibenzyl-β-alanine-
tert-butyl ester 25, as shown in Scheme 5.7. 
H2N OH
O
H2N OtBu
O
Bn2N OtBu
O
BnBr, DIPEA
Toluene, reflux, 3h
97%
Ref
25
 
Scheme 5.7  Preparation of protected β-alanine 
The compound 25 was then used as starting material for optimization of the reaction 
with pentadecyl iodide. 
Mono-α-alkylation 
From the first experiments, it was possible to conclude that, under any conditions, 
with KHMDS, both mono- and di-alkylated products are always obtained. 
Thus, we considered the use of LHMDS. 
Li+ ion, in fact, is smaller than K+ ion, and it is able to form aggregates in solution. 
Its co-ordinating character is stronger than that of K+ and, thus, Li+ is able to form 
with the enolate a more covalent (compared with that produced by K+) bond, 
decreasing in this way nucleophilicity and thus reactivity of the Cδ- of the enolate. 
Actually, treating 25 with LHMDS (2 eq) and electrophile (2.2 eq), as reported in 
entry 2 of Table 5.6, we obtained only mono-alkylated product with 95% yield. Also 
reiteration of the reaction on 26 did not lead to the di-alkylated product. 
Using, under the same conditions, KHMDS as base (entry 1, Table 5.6), we had 
an excellent yield, 95%, but a mixture of products, with 25% of di-alkylation. 
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Table 5.6  Alkylation of N,N-dibenzyl β-AlaOtBu and N,N-dibenzyl β-AlaOMe 
Bn2N OR'
O
Bn2N OR'
O
R R"
R = -CH2(CH2)13CH3
R' =Me, tBu
1) MHMDS (2eq.)
2) RI (2.2)
25  R' = tBu   
28  R' = Me 26  R'= tBu, R"= H  MONO
27  R'= tBu, R"= R  DI
29  R'= Me, R"= H  MONO
30  R'= Me, R"= R  DI  
Subs. Base Time and Temperature Total Yield 
MONO/DI 
Ratio 
25 KHMDS 60 min, 0° C 95% 3:1 
25 LiHMDS 30 min, 0° C 95% > 99:1 
28 KHMDS 60 min, 0° C 70% 2.3:1 
28 LiHMDS 3 h, 0° C 60% > 99 : 1 
We also wanted to compare the reactivity of N-protected β-homoalanine having 
different ester groups, namely the reactivity of 25 with that of 28 (Table 5.6); thus, we 
prepared 28 from H-β-Ala-OMe, and then we alkylated 28, exploiting the same 
conditions used to alkylate 25: employing LHMDS as base, we had again only mono-
alkylation but with lower yield; instead, the use of KHMDS gave both the products 
with total yield of 70%. 
The different reactivity shown by 25 and 28 with LHMDS is probably due to the 
steric hindrance of tert-butyl ester; the enolate coming from 25 is less co-ordinated 
Li+ and thus more reactive. 
Double-alkylation in the α-position 
In order to accomplish the double alkylation, obviously we used KHMDS as base, 
because only with this we observed traces of dialkylated product. 
Using the conditions shown in Scheme 5.8, we afforded mixtures of mono- and di-
alkylated products, for both 25 and 28 as starting materials. 
Bn2N OtBu
O
1) THF, KHMDS (2eq) 
    -78 °C
2) CH3(CH2)13CH2I (3 eq)
    60', 0 °C
            Yield 95%25
R = CH2(CH2)13CH3
Bn2N OtBu
O
R H
26
Bn2N OtBu
O
R R
27
Bn2N OMe
O
1) THF, KHMDS (2eq) 
    -78 °C
2) CH3(CH2)13CH2I (3 eq)
   60', 0 °C
            Yield 81%
Bn2N OMe
O
28
R H
29
Bn2N OMe
O
R R
30
MONO:DI
Ratio
3:1
MONO:DI
Ratio
1:1.5
 
Scheme 5.8  Double alkylation of N,N-dibenzyl β-AlaOtBu and N,N-dibenzyl β-AlaOMe. 
Also in this case, we could note a different reactivity between 26 and 29. The latter 
reacts faster to give the di-alkylated product 30, the major product of the double 
alkylation reaction of 28. The compound 26, instead, is alkylated with more difficulty 
and only 25% of it is converted to di-alkylated product 27. This different behaviour is 
again due to the larger steric hindrance of tert-butyl ester compared with that of 
methyl ester; tert-butyl ester on one hand facilitates the entrance of the first chain 
onto C-2 of 25 (for the reason already discussed above), but on the other hand, 
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makes difficult the access of the second chain on the already alkylated C-2 position 
of 26. 
However, we decided to use the compound 25 as starting material for the 
preparation of lipo-amino acids, because of the problem met during the hydrolysis of 
methyl ester of highly hindered substrates such as 30. 
To improve the amount of di-alkylated product we increased the amount of base 
used, from 2 to 2.5 equivalents, and the results are shown in Scheme 5.9. 
Bn2N OtBu
O
1) THF, KHMDS (2.5 eq) 
    -78 °C
2) CH3(CH2)13CH2I (3 eq)
    30', 0 °C
            Yield > 99%
Bn2N OtBu
O
25
R H
26
R = CH2(CH2)13CH3
Bn2N OtBu
O
R R
27
MONO:DI
Ratio
1:2.5  
Scheme 5.9  Double alkylation of N,N-dibenzyl β-AlaOtBu. 
Peptide Coupling 
The first experiments were carried out on the mono-alkylated product. The latter 
consist of a racemic mixture, which was used as such, without performing any 
resolution, because this compound was considered just as a model for couplings. We 
tested, in fact, the reactivity of both its amino and carboxyl functions, making them to 
react with carboxyl and amino groups of a protected β-alanine, respectively. Thus, 
using the mono-alkylated amino acid as building block, we prepared a dipeptide and 
a tripeptide still made up of it but containing a spacer of β-alanine in the middle. 
BocHN
O
OH
BocHN
O
OH
H2N
O
N
H
O
OMe
R
BocHN
O
N
H
O
OMe
H2N
O
OMe
I2/ PPh3/ Im
CH2Cl2, 80%
TFA/ CH2Cl2
99%
I2/ PPh3/ Im
CH2Cl2, 60% R
R
R
BocHN
O
N
H
O
N
H
O
OMe
RR
23
22
31 32 33
34R= CH3(CH2)13CH2
Scheme 5.10  Synthesis of a tripeptide 
The activation of carboxyl function for all the couplings was performed using PPh3/I2 
complex to form an acyl iodide intermediate, that reacts in turn with the amino 
function of another amino acid. 
As shown in Scheme 5.10, the amino function of the mono-alkylated β-alanine 22 
reacts well, without suffering from any steric hindrance; the same is true for the 
carboxyl function of 23 that reacts with good yield. Thus, we obtained the tripeptide 
with a total yield of ~50%. 
The dipeptide was prepared using the same conditions, with 80% of yield 
(Scheme 5.11). 
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BocHN
O
OH
H2N
O
OMe
I2/ PPh3/ Im
CH2Cl2, 80%
R
R
BocHN
O
R
N
H
O
OMe
R
3523
22 R= CH3(CH2)13CH2
 
Scheme 5.11  Synthesis of a dipeptide 
The same procedure was followed for the di-alkylated β-alanine. 
At first, we prepared the starting materials for the couplings, as shown in Scheme 
5.12. 
Bn2N OtBu
O
R R
H2N OtBu
O
R R
BocHN OH
O
R R
H2, Pd/C, AcOH
3h, 45 °C
91%
TFA, CH2Cl2
30 min, r.t.
> 99%
1) OxCl, DMF
    CH2Cl2, 1h, r.t.
2) TEA, DMAP
    CH2Cl2, o.n., r.t.
            50%
O
N
H
O
OtBu
R R RR
H2N
27 36
38
39
R= CH3(CH2)13CH2
2) Boc2O, TEA
CH2Cl2, o.n., r.t. 
95%
Bn2N OH
O
R R
37
1) H2, Pd/C, AcOH
3h, 45 °C
 
Scheme 5.12  Synthesis of a dipeptide. 
As could be expected, the activation of the carboxyl function in 38 was difficult, 
because of the hindrance of the two long-hydrophobic chains. Some classical 
methods for peptide-coupling failed (PPh3/I2, DCC/HOBt) and also the coupling with a 
stronger activating agent, such as HATU, proceeded with modest yield (58%). 
The use of SOCl2 as activating agent was, instead, successful. The activation 
gave acyl chloride in quantitative yield, as tested by quenching the reaction with 
MeOH. 
The next step was the reaction of the acyl chloride intermediate with the amino 
function of 36 that proceeded with 50% yield. 
Under these conditions, it was, however, precluded the possibility to use the Boc 
group as N-protection of the β-amino acid. In fact, the acidity of the medium during 
the activation step causes the loss of the protecting group. 
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Scheme 5.13  Synthesis of a tetrapeptide. 
So, we decided to keep the benzyl group and to use directly the compound 37 in the 
coupling with 36 to prepare dipeptide 40 and then tetrapeptide 42. 
Conclusion 
The method described represents a convenient synthesis of protected lipophilic 
amino acids containing one or two alkyl side chains (C 15). The length of the chain 
can be modulated just choosing the right electrophile, and the method is general.  
Resolution of the racemic mixture of 26 or 29 and extensive application of the 
pure enantiomers of these lipophilic amino acids in peptide synthesis is in progress in 
our laboratories.  
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Chapter 6 
Sweetness and Artificial Sweeteners 
The sense of taste plays a critical role in the life and nutritional status of humans and 
animals as well. The ability to identify sweet-tasting foodstuffs is particularly important 
as it provides us and other vertebrates with a mean to seek out needed 
carbohydrates with high nutritive value. Sweetness can be a sensory cue for energy 
to fuel metabolic needs and physical activity. Foods that are naturally sweet, such as 
fruit and breast milk, contain important nutrients to support health. Sweet foods and 
beverages offer a pleasurable addition to a meal or a snack. Sweet-tasting 
compounds help mask unpleasant tastes, thereby enabling the development of more 
palatable foods, health care products, and medicines. The perception of bitter, on the 
other hand, is essential for its protective value, enabling humans to avoid potentially 
deadly plant alkaloids and other environmental toxins.  
Sweet taste is stimulated by a wide variety of compounds including sugars, sugar 
alcohols, and dipeptides, that elicit pleasurable sensations with (nutritive) or without 
(non-nutritive) energy. Nutritive sweeteners provide a sweet taste and a source of 
energy; non-nutritive sweeteners are sweet without energy.  
Because of an exponential growth in the number of patients suffering from 
diseases caused by the consumption of sugar, such as obesity1 or diabetes2 mellitus, 
there is increased interest in dietary factors that cause energy intake to exceed 
energy expenditure3.  
Existing evidence does not support the claim that diets high in nutritive 
sweeteners by themselves have caused an increase in obesity rates or other chronic 
conditions4 (eg, hyperlipidemia, diabetes, dental caries, behavioral disorders). 
Nonetheless, consumers who want the taste of sweetness without added energy may 
select non-nutritive sweeteners to assist in the management of weight, diabetes, and 
other chronic diseases. Non-nutritive sweeteners also have, in fact, the potential to 
assist in control of blood glucose, and in prevention of dental caries. 
The FDA has approved five non-nutritive sweeteners and regulates them as food 
additives: saccharin, aspartame, acesulfame potassium (or acesulfame K), sucralose, 
and most recently neotame.  
Mode of Action  
Compounds that stimulate the sweet sensation interact with taste receptors in the 
mouth and throat. Through a transduction mechanism, the sweet chemical message 
is changed to a nerve signal for the perception of sweet taste. Models of sweet 
transduction are being tested under speculation that nutritive sweeteners have 
different mechanisms than non-nutritive sweeteners.5
First, the diversity of chemical structures (including sugars, sulfamates, heterocycles, 
ureas, arylguanidines, peptides, proteins, oximes, and terpenes) which can evoke 
sweet taste is really huge. This suggests that there must be more than one receptor 
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type.6 It is unlikely that a single receptor binding site could accommodate all of the 
known sweet-tasting compounds.  
Secondly, we know that it is easy for humans to distinguish different taste 
qualities for different high-potency sweeteners. Most consumers can readily tell the 
difference between sugar and high-potency sweeteners and trained panellists can 
detect taste differences among different high-potency sweeteners. Third, blends of 
structurally different sweeteners (aspartame plus acesulfame, for example) produce 
synergy, a higher-than-predicted sweetness intensity based on potencies of the two 
individual sweeteners.7 On the other hand, structurally similar sweeteners, such as 
saccharin and acesulfame, do not show synergy; they are simply additive. Many 
more studies of this type would be required to get an estimate of the number of 
different types of sweetness receptors that might be involved. 
Finally there are reasons to suspect that sugars do not bind to a specific receptor 
site. First, sugars taste sweet only at high concentration (about 0.1 M); this is in sharp 
contrast to the concentrations required for hormones, neurotransmitters, etc. to 
trigger their receptors (typically nanomolar or picomolar concentrations). Furthermore, 
it is well known that D- and L-sugars have comparable sweetness potencies. These 
observations suggest that sugars might act indirectly on receptors or ion channels, 
through effects on the properties of the surrounding membrane lipids.  
In summary, the available evidence indicates that high-potency sweeteners utilize 
a different mechanism than sugars to trigger the response of taste cells. In addition, it 
appears that the receptors which mediate the sweetness of aspartame are different 
from those which respond to saccharin and acesulfame. 
Mechanism for Sweet Transduction 
Taste receptor proteins have not yet been isolated or unequivocally identified. There 
are two major reasons for that:  
1. Traditional receptor isolation methods have usually involved the use of a  
high-affinity ligand (half-maximal binding at nanomolar concentrations or less) 
which can be used to monitor the progress of purification. Sugars trigger 
sweetness only at concentrations of ~0.1 M; aspartame (1), saccharin (2), and 
acesulfame-K (3) elicit sweetness at concentrations of few millimoles per liter. 
At these concentrations, it is nearly impossible to distinguish receptor-specific 
binding from non-specific binding to other components of the tissue from 
which the receptors might be extracted.  
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2. The difficulty in isolating taste-active cells. These are specialized epithelial 
cells which are embedded in taste buds among a large number of no  
taste-active cells. When these cells are separated from their nerve cells, they 
rapidly de-differentiate back into ordinary epithelial cells. Thus, it has not been 
possible to grow taste-active cells in cell cultures.  
Despite these difficulties there is now good evidence indicating that sweetness is 
mediated in many cases by G-protein-coupled receptors8 (GPCR), that are 
responsible for the detection of many neurotransmitters, hormones, odorants, and 
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even photons. They are proteins having seven α-helical segments embedded in the 
cell membrane.  
 
Figure 6.1  Schematic representation of a taste cell, indicating likely components of the taste 
transduction system. The initial stimulus may be either a high potency sweetner or a sugar; 
the final step is cell depolarization, which may involve loss of potassium ions and a sharp 
increase in the concentration of free intracellular calcium ions. [from Wiley-VCH 
Angewante Chemie Int. Ed. (ref. 8)]. 
When extracellular ligands bind to the receptor (Figure 6.1), they induce a 
conformational change in the protein causing the intracellular portion to interact with 
one or more GTP-binding proteins (the G proteins). The G proteins may, in turn, 
modify the activity of an enzyme, which increases or decreases the amount of a 
‘second messenger’ molecule: adenylyl cyclase may be induced to make higher 
levels of cyclic AMP (cAMP), or a phosphodiesterase may degrade cyclic nucleotides, 
or a phospholipase may convert phosphatidylinositol lipids to diacylglycerol and 
inositol trisphosphate (IP3). These second messengers may alter calcium ion 
concentrations or modify ion channel activities leading to depolarization of the taste 
receptor cells (TRCs) which, in turn, sends a nerve signal to the brain. It seems5 that 
sucrose and other sugars trig sweet transduction via adenylyl cyclase and cAMP, 
whereas artificial sweeteners via IP3 production; all transduction pathways are 
proposed to converge on common elements that mediate a rise in intracellular Ca2+ 
followed by neurotransmitter release. These two pathways (diagrammed in Fig. 6.2) 
coexist in the same TRCs. 
It is presently unclear how these receptors could selectively mediate cAMP 
responses to sugars and IP3 responses to artificial sweeteners, but recently  
sweet-responsive receptors have been cloned and expressed5 and so it should be 
possible, with next studies, to test definitively these various models of sweet 
transduction. 
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Figure 6.2  Proposed transduction mechanisms in vertebrate taste receptor cells underlying taste 
qualities [from The American Society for Biochemistry and Molecular Biology, The Journal 
of Biological Chemistry (ref. 5)]. 
Structure-Activity Relationship 
As illustrated above, the perception of sweetness is initiated by an interaction 
between a ligand and a receptor on the surface of a taste cell. In 1967 Shallenberger 
and Acree proposed that the ligands involved in this reaction must have a bipolar 
functional group capable of forming a cyclic hydrogen bonded transition state.9  
In order to explain the initial chemistry of the transduction mechanism in rodents, 
three proposals have been made, as already briefly mentioned above and 
summarized below:  
1. The sugar receptor (SR) mechanism: a cellular response is brought about by a 
specific 7-trans-membrane receptor protein, coupled to a G-protein and a 
second messenger cascade. Certain polyol structures (sweet ligands) interact 
with the protein receptors causing a G protein to release the intracellular 
second messenger cAMP (Hepler & Gilman, 1992). 
2. The glycine receptor (GR) mechanism: amino acid-like ligands bind to a 
second 7-transmembrane receptor protein interacting with another G-protein 
to release the intracellular second messenger IP3 (Naim, Bernhardt, Zehavi & 
Levinson, 1996). 
3. The direct G-protein interaction (DGI) mechanism: certain ``amphiphilic'' 
compounds (having both polar and non-polar functions) penetrate the cell and 
interact with the G proteins causing second messenger release, usually IP3, in 
much the same way that some drugs behave pharmacologically (Naim et al., 
1996). 
Relating the structure of sweet tasting molecules to their sensory properties, the most 
commonly used tool to generate hypotheses about ligand binding in human systems 
is a process called structure-activity relationship (SAR). 
The four most frequently mentioned SAR models, consistent with both SR and 
GR receptor mechanisms, are: the Shallenberger theory or the bipolar hydrogen 
bonding (AH-B theory);9 the three-point attachment theory (AH-B-γ);10 the multi-point 
attachment theory;11 the α-helix receptor protein theory.12
All these theories13 are consistent with the idea that sweet-tasting compounds 
contain a hydrogen bond donor (AH) and a hydrogen bond acceptor (B) that reacts 
with a complementary AH-B pair on the receptor, forming two hydrogen bonds and/or 
interrupting an intramolecular hydrogen bond on the receptor protein.  
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Shallenberger and Acree utilized this model to analize different kinds of 
sweetners and to establish if their molecules had the intramolecular system AH-B. 
(Figure 6.3) 
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Figure 6.3  AH-B system in some sweeteners 
This theory was then developed in 1972 by Kier,11 who proposed that a potent 
sweetener must interact with the sweetness receptor through three interactions, two 
of which by hydrogen bonding according to Shallenberger and Acree and the third 
one by dispersion (van der Waals) or hydrophobic interaction with the so called γ site. 
This interaction is to increase the affinity of an amino acid with an AH-B glycophore 
at the receptor site, thus enhancing the sweet taste potency. Therefore, if γ is not 
required for binding, it may function to modulate the potency of the ligand. The 
degree of enhancement is governed by the distance and position of γ from AH-B 
system, as evident from observations on the taste of aspartame analogues.14 
Goodman15 et al. in 1987 sought to deduce basic principles of taste perception from 
consideration of the energy-minimized structures and the tastes of a series of 
dipeptide isomers and derivatives. It was found that the structures of sweet-tasting 
dipeptides adopt the L-shape shown in Figure 6.4 while their retro-inverso analogues 
do not. Only the L,L-isomer of aspartame tastes sweet, since only this isomer can 
adopt the L-shape prerequisite for sweet taste while the other three isomers are bitter. 
 
Figure 6.4  Required L-shaped molecule for sweet aspartyl compounds.18
In 1991, this model was developed by Tinti and Nofre12 who suggested that, when a 
sweetener interacts with its receptor, it splits both ionic and H-bonding interactions in 
the sites, triggering profound conformational changes in the receptor and allowing it 
to expand. Presumably, this allosteric effect is responsible for initiating transduction. 
Sweetness potency can then be correlated with the number of additional sites 
involved at the receptor during interaction. This is consistent with the role of γ as an 
amplifier of potency but unnecessary for sweetness.  
Another model for the sweet taste receptor has been introduced by Suami and 
Hough13 in 1991 who postulate that the AH-B interaction of sweet molecules is at the  
N-terminus of a receptor protein which has a right-handed α-helical conformation. 
These ideas are consistent with the chiral specificity of the sweet taste response.  
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So all these models, although they differ in details, include an AH-B interaction and 
the modulation of hydrogen bonds as essential to the initiation transduction. 
Commercial Synthetic non-Nutritive Sweeteners 
In the last few years, an intense research effort has been expressed for the discovery 
of new intensive sweeteners. 8 The screening of new active compounds has been 
made by systematic examination of natural compounds from plants and classical 
methods of drug design of synthetic compounds, from known active leads. Despite 
these efforts, to date the two synthetic compounds, aspartame and saccharin, remain 
the undisputed leads of the market of intensive sweeteners. 
Aspartame 
Aspartame (1) is currently the most widely used non-nutritive sweetener worldwide. 
Although this compound was known in the literature, its sweetness was discovered 
by James Schlatter, who in 1965 while working on an antiulcer compound licked his 
fingers.16 Several analogues, especially more stable esters,17 were made and 
evaluated for sweetness potencies, taste profile, and toxicities. In the end, however, 
it was the first compound to be chosen for commercial development.  
At high pH aspartame cyclizes to the corresponding diketopiperazine. In aqueous 
solution, the maximum stability18 is at pH 4.3. At higher or lower pH, the half-life of 
aspartame diminishes quickly. The ester group of the aspartame is very susceptible 
to hydrolysis and hence avoidance of excessive heat is desirable since degradation 
with concomitant loss of sweetness can be rapid. It can be used in almost all food 
categories, but the major consumption is in beverages.19  
Intestinal esterases hydrolyze aspartame to aspartic acid, methanol, and 
phenylalanine.20 These components are found in much greater amounts in the 
normal diet in fruit, vegetables, meat, and milk. For example, a serving of non-fat milk 
provides about six times more phenylalanine and 13 times more aspartic acid, 
whereas a serving of tomato juice has about six times more methanol than an equal 
volume beverage sweetened 100% with aspartame.21  
Detailed studies have been conducted to determine how ingestion of aspartame 
influences plasma levels of aspartic acid, phenylalanine, and methanol (or the 
byproduct formate). In studies with healthy adults,22 plasma aspartate concentrations 
or blood levels of formate did not change with a bolus load up to four times the ADI 
(Acceptable Daily Intake) for aspartame (i.e., 200 mg/kg).  
Plasma phenylalanine response to aspartame (as well as to other dietary sources 
of phenylalanine) varies in persons with phenylketonuria (PKU), a homozygous 
recessive inborn error of metabolism, that prevent metabolism of  
phenylalanine. People with this rare (frequency is approximately one in 10,000 whites) 
inborn error, in consequence of excess intake of this amino acid, can suffer an 
increasing of plasma phenylalanine levels and then its adverse effects.23 For this 
reason, the FDA requires that foods containing aspartame have the prominent 
display of the following label: “PHENYLKETONURICS: CONTAINS 
PHENYLALANINE”.24  
Aspartame breaks down to diketopiperazine in liquid systems with excessive heat 
exposure. Animal toxicity studies show that, even if all aspartame were converted to 
diketopiperazine in beverages, the amount would be well below the FDA-established 
ADI of 3 g/kg bw/day for this compound.25 Some individuals report allergic reactions 
to aspartame, including edema of the lips, tongue, and throat, besides dermatologic 
reactions and respiratory problems.26 However, two double-blinded challenge studies 
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report difficulty in recruiting individuals who claim an allergic response to aspartame 
and a failure to reproduce the allergic reaction in controlled experimental 
conditions.27  
A comprehensive review of the safety of aspartame has recently been 
published,28 that support the safety of aspartame as a food additive and negates 
claims of its association with a range of health problems including brain tumors.  
Towards New Sweeteners 
Although aspartame can be used in a wide variety of foods and beverages, its 
stability remains a problem. Extending shelf life by improving the stability of 
sweeteners, in general, in different food products, in particular diet beverages, would 
have significant economic impact.  
The stability of aspartame can be improved forming inclusion complexes with  
β-cyclodextrin that are able to complex a wide variety of guest molecules,29 and the 
formation of inclusion complexes with aspartame has been demonstrated30. For 
aspartame, studies have indicated that the β-CyD/aspartame complexation occurs 
via the inclusion of the phenyl ring within the β-CyD cavity, with the methyl ester 
exposed outward, away from the complex. On the basis of this model,30 it is possible 
to explain the decrease in the rate of formation of diketopiperizine that takes place, 
because formation of the inclusion complex in this manner prohibits intramolecular 
cyclization. However, the model cannot entirely account for the concomitant 
decrease of α-L-aspartyl-L-phenylalanine formation because the methyl ester group is 
expected to be still exposed to the solution environment.  
A number of companies and universities are still actively pursuing the search for, 
and development of, new non-nutritive synthetic sweeteners. Economic issues are 
driving these compounds to be extremely potent on a sweetness-to-weight basis 
when compared to sucrose. Since the discovery31 of aspartame, the special interest 
in dipeptide sweeteners has increased and a large number of analogues related to 
aspartame have been synthesized.8 These potential next-generation sweeteners 
contain a diverse array of functionality ranging from dipeptide derivatives32 such as 7 
and 8 to guanidines33 and ureas.34  
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Neotame (7), for example, is a derivative of the dipeptide phenylalanine and aspartic 
acid. This compound is 8000 times sweeter than sucrose and can be prepared by a 
reductive alkylation of aspartame (1).24 This new sweetener appears to have 
increased stability under a variety of conditions relative to 1. It is partially absorbed in 
the small intestine, rapidly metabolized by esterases, and excreted in urine and feces. 
Methanol is released during the hydrolysis; the amount released is insignificant even 
at the 90th percentile of estimated daily intake of neotame. A small percentage 
(<20%) of phenylalanine from the ingested neotame may be released into  
plasma. This amount is not clinically significant for individuals with PKU. Thus, the 
label for products with neotame does not need to alert phenylketonurics that the 
product contains phenylalanine. Furthermore, no organs were found to concentrate 
neotame or its metabolites. 35-36
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Dipeptide Taste Ligands Containing homo-β-Amino Acid Residues 
Recently Miyoshi37 et al reported the synthesis of several aspartame dipeptide 
analogues, whose backbone was elongated by one methylene group, to analyse the 
steric effect in relation with the potency of sweetness. It has been demonstrated32k 
that the sweet-tasting activity of the dipeptide is preserved if the aspartyl moiety is 
restricted to L-Asp or to the shorter homologue aminomalonic acid in which the side 
chain methylene group is missing; elongation of the side chain as in the higher 
homologue NH2-L-Glu-L-Phe-OMe led to bitter compounds.38
Later in 1999, Benedetti39 et al. described the synthesis and conformational 
properties of a series of dipeptide taste ligands, differing from the commercial 
aspartame by the presence of a methylene group between the C-1 and the C-2 
carbon atoms (as in β3-residues) in either L-Asp or L-Phe residues (9-11).  
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The relationship between conformation and sweet taste showed that the lengthening 
of the peptide skeleton at the L-Asp site (as in 9) results in a loss of sweetness with 
the production of tasteless compounds, thus confirming that (i) the  
C-terminal end is the most important function in imparting the sweet taste to the 
molecule and (ii) the orientation of the amide group linking Asp and Phe residues of 
aspartame analogues plays a decisive role in obtaining very sweet compounds. On 
the other hand, lengthening of the skeleton at the C-terminal L-Phe site (as in 10 and 
11) maintains the sweet character in both NH2-L-Asp-β3-L-Phe-OMe and  
NH2-L-Asp-β3-L-Phg-OMe. Anyway, all these compounds present a decreased 
sweetness potency with respect to aspartame; this could be ascribed to an increase 
of the skeleton chain flexibility due to the methylene insertion. 
The conclusion was that the sweet power of aspartame analogues can only be 
modulated by modifying the C-terminal moiety of the molecule. 
For a sweet-tasting ligand the ‘bioactive conformation’ was proposed to be an  
‘L-shaped’ structure,39-40 as mentioned above. The analysis of the conformational 
behaviour of the synthesized dipeptides showed that all of the compounds can adopt 
preferentially extended and ‘L-shaped’ conformations.  
Data of structure–taste relationships accumulated so far prompted us to 
investigate the effect on taste attained by insertion of a substituent at C-2 position of 
a β3-amino acid, that replaces the L-Phe residue in dipeptide analogues. For this 
purpose, using our homologation procedure40 in the preparation of β3-amino acids, 
and the already illustrated reaction for the introduction of substituents onto C-2 
position of β3-amino acids, also devised in our lab, we prepared a series of new taste 
ligand dipeptide analogues, that will be presented in the next section. 
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Chapter 7 
Synthesis of Aspartame Analogues 
Following the discovery of aspartame, the interest in dipeptide sweeteners has 
increased, and the possibility of designing and synthesizing new analogues1 of this 
molecule has stimulated numerous studies of structure-activity relationship. 
The strongest interest is in finding aspartame analogues that are more stable to 
enzymatic degradation: as mentioned in chapter 6, indeed, aspartame is hydrolyzed 
by intestinal esterases to aspartic acid, methanol, and phenylalanine. Thus, as 
source of phenylalanine, aspartame could be dangerous for people with 
phenylketonuria.  
In recent years, several efforts have been made in order to elucidate the 
stereochemical basis of sweet taste and two models have emerged as the most 
appropriates: Temussi’s2 and Goodman’s3. The first one proposes as bioactive 
conformation of aspartame an extended structure; the second suggests that a sweet-
tasting molecule possesses an L-shape conformation: the stem of the L is formed by 
the zwitterionic (AH and B) ring of the aspartyl residue and the base of the L is 
formed from the hydrophobic group X (see Fig. 6.4, Chapter 6). The difference 
between the two models is then the bioactive conformation of peptide tastants like 
aspartame and consequently there is the difficulty to elucidate which is the bioactive 
conformation of these aspartame-like sweeteners. 
In order to develop a three-dimensional receptor model, several conformationally 
restricted analogues of aspartame have been synthesised and studied. Since it has 
been shown that many changes in the Phe-residue4 of the dipeptide are well 
tolerated, and taking into consideration that one approach involves the use of 
constrained amino acids,5 the Phe residue of aspartame has been replaced by 
different conformationally restricted amino acids.6
On the other hand, the synthesis of peptides in which each amino acid residue is 
replaced by a β-amino acid has also been reported.7 (1-3). 
The insertion of β-amino acids as new molecular tools in bioactive products 
represents a way to improve both resistance to biodegradation and pharmacokinetic 
properties of these molecules. 
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Conformational studies7 of the dipeptides 1-3 showed that they are able to adopt an 
L-shape conformation, as required for a good interaction with the receptorial sites of 
the sweet taste. Moreover it is evident from these studies, as it was shown by 
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others,8 that the elongation of the peptide skeleton at the L-Asp site (like in 1) results 
in a drastic loss of sweetness with the production of tasteless compounds, showing 
the importance of the C-terminal site of the peptide for its interaction with the receptor. 
On the other hand, lengthening of the skeleton at the C-terminal L-Phe site (like in 
2 and 3) preserves the sweet taste, causing only a slightly decrease of sweet-tasting 
activity compared with that of aspartame. This loss of activity is probably due to an 
increasing flexibility of the peptide, caused by the introduction of a methylene group 
that allows C2-C3 bond of β3-Phe to be less rigid.  
To the best of our knowledge, Phe residue of aspartame has never been replaced 
by 2,3-disubstituted β-amino acids. Since it is reported that 2,3-disubstituted β-amino 
acids are more conformationally constrained than simple β2 and/or β3-amino acids,24 
we decided to investigate the effect on taste of the systematic insertion of a 
substituent at C-2 position of the β3-phenylalanine that replaces the Phe-residue of 
aspartame. 
Results and Discussions 
We planned to investigate the design and synthesis of β2,3-disubstituted amino acid 
containing peptides as new aspartame analogues: the L-Asp residue is linked to a  
β3-Phe functionalised at C-2 position with both polar and non-polar groups. In 
particular, we prepared the dipeptides 4-7, containing respectively hydroxyl, amino, 
methyl and benzyl groups. 
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The presence of one substituent at C-2 position of the β3-Phe should reduce, as 
mentioned before,24 the flexibility of the β-amino acid residue, and should not 
compromise the formation of L-shape, requested by bioactive conformation. 
Moreover, the presence of a polar substituent, like in 4 and 5, could improve 
water solubility of the molecules, whereas the non-polar residues, like in 6 and 7, 
could influence the interactions of the compounds with the hydrophobic γ site within 
taste-receptors. 
Preparation of 2,3-Disubstituted β-Amino Acids 
The 2,3-disubstituted β-amino acids are prepared as described in Chapters 4 and 5. 
For the introduction of both polar and non-polar groups, we devised a 
stereoselective coupling reaction between the enolate of N,N-diprotected  
β3-phenylalanine methyl ester and appropriate electrophiles. The starting β-amino 
acid is prepared, as described in Chapter 3, for direct homologation of α-
phenylalanine, using the procedure reported in 1995 by Caputo9 and co-workers 
(Scheme 7.1). 
H2N OMe
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OPhCH2
BocHN
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Scheme 7.1  Retrosynthetic scheme for the preparation of 2,3-disubstituted β-amino acids. 
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Thus, N(Boc)-phenylalanine 8 is converted (Scheme 7.2), into a mixed anhydride by 
methylchloroformate and N-methylmorpholine. Reduction by NaBH4 of the mixed 
anhydride then gave phenylalaninol used to prepare the corresponding α-amino 
iodide by reaction with triphenylphosphine/iodine complex in the presence of 
imidazole. The iodide obtained is then treated with tetraethylammonium cyanide to 
lead to β-amino cyanide 10. The methanolysis of the cyano group with HCl (12 N) 
gives, after alkaline work-up, the β-amino methyl ester in 35% overall yield. Finally, 
the amino function of β-phenylalanine methyl ester is protected as N,N-dibenzyl 
amine with benzyl bromide and diisopropylethylamine. 
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Scheme 7.2  Synthesis of N,N-dibenzyl β3-phenylalanine by homologation of N(Boc)-α-phenylalanine. 
Exploiting the acidity of the two protons at C-2 of β-amino methyl ester, it is possible 
to introduce onto this position miscellaneus substituents, entrapping the enolate with 
appropriate electrophiles (Scheme 7.3). 
(P)2N
R O
OMe
(P)2N
R
(P)2N
R O
OMe
(P)2N
R
E
-
Electrophile
E = OH, NH2, CH3, CH2Ph
n
Base
OMe
O-
OMe
O
 
Scheme 7.3  Functionalization of β-amino methyl esters. 
Synthesis of anti-2-Hydroxy-β3-Phenylalanine Methyl Ester 
The introduction10 of the hydroxyl group is carried out by treating N,N-dibenzyl  
β3-phenylalanine methyl ester 12 with potassium bis(trimethylsilyl)-amide (KHMDS), 
and allowing the resulting enolates to react with racemic 2-[(4-methylphenyl)sulfonyl]-
3-phenyloxaziridine to afford the α-hydroxy derivatives 13 (Scheme 7.4).  
α-Hydroxylation proceeded smoothly at −78 °C with high yields and good 
diastereomeric ratios.  
The compound 13 is then protected at the hydroxyl group with tert-
butyldiphenylsilyl chloride (TBDPSCl), giving 14, that in turn is deprotected with H2 
and Pd/C to give 15, then used for coupling with aspartic acid. 
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Scheme 7.4  Asymmetric hydroxylation of homo-β-amino methyl esters. 
Synthesis of anti-2-Amino-β3-Phenylalanine methyl ester 
As reported in Chapter 4, under the conditions we have devised, the enolate of  
N,N-diprotected β3-phenylalanine is treated with KHMDS in anhydrous THF and at -
78 °C; under nitrogen flow, solid DBAD is then added to obtain after 1h the 
compound 17 in good yield and high diastereoisomeric ratio (Scheme 7.5). 
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Scheme 7.5  Asymmetric amination of β3-phenylalanine methyl ester. 
With the aim to use 2,3-diamino methyl esters in place of the Phe-residue in the 
aspartame dipeptide, the compound 17 is first protected at the free amino group as 
tert-butylcarboxylate, and then deprotected at β-amino group, with H2 and Pd/C, to 
give compound 19 ready for coupling with aspartic acid. 
Synthesis of anti-2-Substituted-β3-Phenylalanine Methyl Ester 
Following the procedure already described for the preparation of both 2-hydroxy and 
2-amino β3-phenylalanine methyl esters, the enolate of 12 is treated with CH3I or 
BnBr, as shown in Scheme 7.6. 
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Scheme 7.6  Asymmetric alkylation of β3-phenylalanine methyl ester. 
The products 20 and 21 are obtained in good yields and high diastereoisomeric ratio, 
as already shown for the other functionalizations as well. 
For the use in coupling reactions with aspartic acid, both products are 
deprotected with H2 and Pd/C to lead to 22 and 23, ready for the coupling step. 
Peptide Synthesis 
2-Substituted β3-amino acids 15, 19, 22, and 23, prepared as described above, were 
then used in coupling reactions with the aspartic acid derivative 24 (Scheme 7.7), in 
which both β-carboxyl and amino functions are protected as Boc and tert-butyl ester. 
The α-carboxyl function is activated as acyl iodide, using triphenylphosphine/iodine 
complex in the presence of imidazole to accomplish the conversion of the acid into its 
acyl derivative, that is not isolated, due to its readily hydrolysable nature. Its 
formation is monitored by TLC and the reaction works smoothly in 4 hours; then 
compounds 15, 19, 22, or 23 are added to the reaction mixture to give the peptides 
25, 27-29, respectively, in good to excellent yields (Scheme 7.7). 
BocNH
OH
O
O
OtBu
O
H2N
R
Ph
OMe
O
H
N
BocNH
O
O
OtBu
R
Ph
OMe
O
H
N
H2N
O
OH
O
R
Ph
OMe
+
24
25  R = OTBDPS
26  R = OH
27  R = NHBoc
28  R = CH3
29  R = CH2Ph
TFA, CH2Cl2
46-80%
TBAF, THF
80%
TPP/ I2/ Im, 
CH2Cl2
72-97%
15  R = OTBDPS
19  R = NHBoc
22  R = CH3
23  R = CH2Ph
4  R = OH
5  R = NH2
6  R = CH3
 
Scheme 7.7  Coupling reaction between the aspartic acid derivative 24 and α-substituted  
β3-phenylalanine. 
Peptides 4-6 are all white crystalline solids with good water solubility; all of them will 
be tested in toxicological assays and in taste assessment using a volunteer taste 
panel. 
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Circular Dicroism Analyses 
In order to investigate the structure–activity relationships (SAR) of the dipeptide taste 
ligands with respect to the original dipeptide aspartame, conformational analyses in 
solution were carried out by CD. 
For CD experiments all peptides were dissolved in a 1:1 (v/v) TFE–H2O mixture to 
improve the solubility of the dipeptides and to have results comparable with that 
reported in literature.7
In figure 7.2 are reported the spectra for peptides 4-6, and for aspartame itself. 
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Figure 7.2  CD spectra for aspartame and its analogues. 
 
All the spectra may be considered as linear combinations of a medium-intensity CD 
band with a maximum at about 195 nm and a second positive band with a maximum 
between 210 and 220 nm. As reported in literature,7 the CD band between 210 and 
230 nm could be interpreted as the result of superposition of two different 
contributions: a band distinctive of the spectra of β3-amino acid containing peptides 
and a positive contribution of the aromatic phenyl side-chain.11 The band near 195 
nm is a characteristic feature of the spectra of peptides containing a phenyl 
substituent.11 Since the chromophores are more or less the same, the differences in 
intensity among CD spectra should arise from a difference in the number of 
conformers which contribute to the CD. A less intense signal corresponds to a wider 
set of conformers, whose CD contributions tend to cancel with each  
other. Thus, it is possible to conclude that the new peptides are slightly more flexible 
than aspartame. 
As reported in the literature,7 it is not always possible, anyway, to link a CD result 
with sweetness: for example, the dipeptides containing β3-aspartic acid replacing the 
Asp-residue in aspartame show a CD spectrum that closely resembles that of 
aspartame; however, this replacement causes a loss of taste. 
So, our analysis can only give information related to the conformational flexibility 
of the different peptides as compared to aspartame. 
Molecular Modelling Study 
According to the model proposed by Goodman3 et al., the sweet taste is associated 
with an ‘L-shaped conformation’, in which the hydrophobic group projects along the 
+X axis (Fig. 2). A reverse ‘L-shaped’ structure, in which the hydrophobic group 
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points to the - Z axis, is associated with a bitter taste. Other possible topochemical 
arrays would lead to tasteless compounds. 
On the other hand, the model of Temussi2 et al. proposes an extended 
conformation as the active conformation. 
For aspartame as such, it is not possible to discriminate which of the two models 
is valid for the sweet taste responce, because aspartame presents both 
conformations as low energie-conformations, as shown by Molecular Dinamics. 
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Extended structure for aspartame 
From here, the interest of synthetic chemists in synthesizing restricted analogues. 
Unfortunately, our dipeptides are not more rigid then aspartame: indeed, for all 
our dipeptides are possible both extended and ‘L-shape’ low energy type 
conformations. Here the L-Shape conformations of all the dipeptides are reported, 
and those extended only for the dipeptide 6. 
All computer simulations were carried out using the Chem3D program and 
software Amber, using Parm99 as force field. 
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Conclusions 
Herein we have reported the synthesis of new aspartame analogues in which the 
Phe-residue is replaced by a β2,3-disubstituted amino acid with the aim to decrease 
conformation flexibility and, as a consequence, to improve sweetness potency. 
Moreover the introduction of polar substituents on the β-amino acid residue 
afforded encreased water solubility. However, analogues bearing non-polar 
substituents could better fit the γ-site of the taste receptor, improving the sweet-taste 
response. 
Furthermore, the replacement of the α-Phe residue with the β-homologue allows 
the use of these potential sweeteners from phenylketonurics. 
Finally, the more stable α-β peptide bond to typical hydrolysis conditions, could lead 
to the use of these compounds in a wide range of foods and beverages. 
However, from the molecular modelling data, it is not possible to derive which is, 
between the extended and the L-Shape conformations, the active structure for a 
dipeptide taste-ligand. 
Toxicological and sweet taste potency tests are in progress to establish if our 
dipeptides are sweet and can be used in food technology. 
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Chapter 8 
Cell Penetrating Peptides 
Introduction 
The cell membrane is a component of every biological cell; it is a thin and structured 
bilayer of phospholipid and protein molecules that envelopes the cell. The several 
hundred lipid species1 form bilayers of a few nanometer thickness with the lipidic 
alkyl chains pointing towards the center plane and the polar headgroups facing the 
aqueous phases on either side of the membrane. It separates a cell interior from its 
surroundings and controls what moves in and out. 
 
Figure 8.1  Cartoon.type drawing of a biological membrane. 
As a lipid bilayer, the cell membrane is selectively permeable. This means that only 
some molecules can pass unhindered in or out of the cell. These molecules are 
either small or lipophilic. Other molecules can pass in or out of the cell, if there are 
specific transport molecules. Depending on the molecule, transport occurs by 
different mechanisms, which can be separated into those that do not consume 
energy in the form of ATP (passive transport) and those that do (active transport). 
Membranes of eukaryotic cells and organelles, as well as the cell wall and 
membrane of pathogenic microorganisms, thus, constitute a serious barrier for the 
access of hydrophilic drugs to their target molecules inside the cells. To overcome 
problems of conventional and gene drug delivery, various techniques have been 
developed. A conventional procedure for delivering genetic material is to use viral 
vectors, but treating genetic disorders with this method has met with only limited 
success.2 Alternative non-viral methods, such as electroporation, microinjection, and 
the use of liposomes, have been developed for conventional and gene drug  
delivery. These methods have been proved to be effective in vitro and for research 
purposes, but show limited potential for delivery in vivo due to toxicity, cell damage, 
and immunogenicity. They are also technically demanding in their application, lack of 
tissue and cell specificity, and can deliver material to only a limited number of cells.  
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In view of these considerations, transduction peptides and proteins offer a promising 
new tool for non-invasive delivery of hydrophilic drugs and genetic material. Over the 
last 10 years, it has been found that certain peptides and proteins can penetrate the 
cell membrane and enter the cell. A variety of cargo molecules can be attached to 
these peptides and proteins and translocated into the cell. Carrier peptides and 
proteins thus constitute a new class of potential drug delivery vectors. 
Cell-Penetrating Peptides: an Overview 
The commonly used terminology of the carrier peptides is “cell-penetrating peptide” 
(CPP).3 Very generally, CPPs are peptides, which can be internalized by cells by 
mechanisms that require no energy and are receptor mediated or not. The common 
features of all CPPs appear to be a positive charge and amphipathicity. All known 
CPPs are net positively charged at physiological pH. Most CPPs have only one 
negative charge (at the C-terminus) or even none, when the C-terminus is  
amidated. The negative charge does not prevent internalization of CPP into the cells; 
on the contrary, a peptide is known that carries four negative charges in addition to 
five positive ones, and that is effectively internalized.4 With the exception of 
polycationic homopolymers (polyarginines, polylysines and polyornithines),5 all other 
CPPs are amphipathic. Some of them adopt amphipathic character when in an α-
helical structure, while others have distinct hydrophobic and hydrophilic parts. 
Mechanism of Penetration 
The transport of CPPs across membranes has been studied using cultured cells, 
artificial lipid vesicles, tissues and in vivo. CPPs were successfully internalized in a 
number of different mammalian cells.  
The mechanism of internalization of CPPs has not been resolved yet. In spite of 
some common features of these peptides, particularly their highly cationic nature, 
their structural diversity has fuelled the idea that the transduction mechanism is not 
the same for CPPs of different types. A number of investigations of CPP 
internalization in cell lines have been carried out under conditions that should prevent 
active transport of CPPs and their translocation by endocytotic pathways. Efficient 
translocation was observed at low temperatures (0 to +4 °C) and in the presence of 
many different inhibitors of endocytosis.3a Recent results showed, however, that the 
role of endocytosis in internalization of CPP is not negligible.6 At least for some CPPs 
endocytosis could be an exclusive or alternative mechanism of internalization.  
In some cases, an inverted micelle mechanism was suggested, in which positively 
charged peptides interact with negatively charged phospholipids to convert part of 
the membrane into an inverted micelle structure that can open on either the 
intracellular or the extracellular side of the membrane. 6a,7
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Figure 8.2  Proposed mechanisms of cellular delivery of cargos mediated by cell penetrating 
peptides.8
Cationic CPPs conjugated to macromolecules such as peptides, proteins or 
oligonucleotides seem to firstly bind to the plasma membrane via an initial rapid 
electrostatic interaction. Subsequently the complexes are internalized by cells 
through various hypothetical mechanisms.  
On the other hand, internalization of some CPPs appears to be very much 
affected by the membrane composition. The internalization of CPP is a multistep 
process, a sequence of equilibrium states with a non-equilibrium step, namely the 
degradation of CPP in the cell. The first step of internalization is the interaction of 
CPP with the cell surface. After the internalization, there is a fraction of CPP that 
interacts with inner cell structures (intracellular membranes, proteins, etc), and a 
portion that is internalized but not bound (for instance in cytosol). Finally, the 
proteolytic cleavage of the CPP in the cell produces degradation products that 
afterwards are expelled out of the cell ( the non-equilibrium step). 
 
Figure 8.3. Simplified kinetic scheme for cell-penetrating peptide internalization [from Elsevier-
Advanced Drug Delivery Reviews (ref. 3a)]. 
Cargo Delivery Using Cell Penetrating Peptides 
The most interesting application of CPPs is the possibility of attaching on them 
biologically active cargos that have to be translocated into cells.  
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Indeed, since different CPPs have been demonstrated to enter different cells, tissues 
and organs, their use to promote translocation of various types of useful cargoes is 
increased. 
Different types of cargoes can be attach to CPPs, ranging from small molecules to 
proteins and large supramolecular particles, and the translocation works with great 
efficiency and reasonable velocity. 
Cargos can be attached in different ways.  
The link between CPP and cargo is usually a covalent bond. When the cargo is a 
peptide or a protein, CPP and cargo are most often synthesized or expressed in 
tandem as fusion protein.9 Alternatively, a suitable amino acid side-chain or 
bifunctional spacer molecule can be used. For example, the thiol group of cysteines 
is often used to attach cargos: after translocation, the reductive environment in the 
cell readily cleaves to the disulphide bridge between CPP and cargo, causing release 
of the cargo.  
Attachment of cargo to CPP can be achieved also by non-covalent bonds, 
employing for instance the interaction of avidin to a biotin-CPP construct;10 this 
method has been used very seldom.  
Physical interaction between CPP and cargo is even possible. This third category 
has already been used for the cellular delivery of nucleotides.11 To produce the CPP–
cargo construct, the CPP can simply be mixed with the oligonucleotide cargo to form 
a complex through electrostatic interactions between the positively charged domain 
of the peptide and the negatively charged regions of the nucleotide phosphate 
backbone. 
To use CPPs as drug delivery vehicles, CPPs should be: 
– small and simple to synthesize 
– able to be coupled to different cargoes without losing their translocation properties 
– tissue, cell and cell-compartment selective 
– stable cargo carriers but without side effects 
Some of these properties have already been successfully realized. Most CPPs are 
relatively small and can be synthesized using traditional methods that can be 
automated.  
The coupling of cargo is not a problem in most cases but the decrease of rate and 
efficiency of translocation in the case of large cargoes has not been overcome yet.  
The same is true with the selectivity of CPPs. Incorporation of signalling peptide 
sequences into CPPs was suggested and undertaken in order to provide selective 
targeting of the cell nucleus in the case of gene delivery.12 Selectivity toward cancer 
cells would be of great interest. For this purpose, the proteins specifically 
overexpressed in these cells could be used.13 A similar approach could be exploited 
for antiviral drugs carried by CPPs designed to target specific surface proteins of 
virus infected cells.14
The metabolic stability of CPP is an important biopharmaceutical factor since the 
peptides should carry their cargoes to the targets before they are metabolically 
cleaved.  
If on one hand, good extracellular stability would be profitable for efficient cargo 
delivery, on the other hand, high intracellular stability could result in accumulation of 
CPP inside the cells with all the potential, undesirable side effects. In general, the 
stability of peptides, both extracellularly and intracellularly, is poor due to the 
presence of peptidases and proteinases, whose activity leads to rapid hydrolysis of 
most peptides. Stability could be enhanced by protecting the C-terminus by 
amidation, by replacement of the naturally occurring L-amino-acids of the sequence 
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by their non-physiological D-counterparts,15 or by using non-natural amino acids, 
such as β-amino acids.16
Nevertheless, in addition to a negative connotation, metabolization of CPP is also 
a prerequisite for the release of chemically ligated cargoes after internalization, and 
has important consequences for the physiological clearance of CPP and their acute 
and chronic toxicity when used for therapeutic purposes.  
The development of carefully engineered CPP has to require a balance between 
both aspects, in order to avoid premature cleavage of the cargo and to free the cargo 
once internalized. 
Biological Effects: Toxicity and Immunogenicity 
The use of CPPs as drug delivery vehicles needs to keep to a minimum the toxic 
effects of CPPs. Side effects of CPPs have not been explored in detail yet; in fact if 
the in vitro toxicity of CPPs has been frequently characterized, the in vivo studies are 
limited. In general, two types of toxic effect have been observed: toxic effects on 
membranes of cells and organelles, and toxic effects resulting from the specific 
interaction of CPPs with cell components.3a
However, most CPPs show only moderate or very limited side effects when 
applied in vivo and in vitro. 
Polycationic Peptides: Oligoarginine 
A promising approach directed at improving or enabling the cellular uptake of drugs 
or drug candidates involves the use of peptide-based molecular transporters to carry 
these agents actively into cells. Representative of this approach is the use of short 
oligomers of L-arginine (1), that are remarkably efficient molecular transporters of 
drug and probe molecules into cells and tissue. They provide highly water-soluble 
conjugates that rapidly enter cells. In particular, drug conjugates of these arginine 
transporters have been shown to exhibit novel and significant penetration into human 
skin and to release their drug cargoes in targeted T cells.17
The guanidinium headgroups are principally responsible for the uptake of these 
oligomers into cells according to the model that provides initial cell-surface binding of 
the peptide carrying positively charged side chains followed by endocytosis or direct 
penetration-driven delivery and cytoplasmic trafficking. Indeed, the polarity of the 
guanidinium groups could be attenuated through association with cell surface groups 
bearing a complementary charge (phospholipids, fatty acid salts, and sulfates), 
thereby producing a less polar ion pair complex capable of diffusing into the 
membrane. 
Several modifications can be made to the peptide structure, such as the 
backbone chirality, the position of attachment and the length of side chains, the 
backbone composition (for example, branched guanidinium reach oligosaccarides 
and dendrimers), without altering the uptake properties of these molecules.18
Several mechanisms could accommodate the structure-function relationships of 
such a huge range of different compounds, and some could operate concurrently. A 
receptor-mediated process is inconsistent with the broad range of structural 
modifications that promote uptake. Conventional passive diffusion across the non-
polar interior of the plasma membrane is difficult to reconcile with the polarity of the 
arginine oligomers and the dependency of uptake on the number of charges.  
Wender et al.19 provided a mechanistic hypothesis for how short oligomers of 
arginine (such as 1) can migrate across the plasma membrane of a cell. The water-
soluble, positively charged guanidinium headgroups of the transporter form bidentate 
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hydrogen bonds with H-bond acceptor functionality on the cell surface. The resultant 
ion pair complexes partition into the lipid bilayer and migrate across at a rate 
proportional to the membrane potential. The complex dissociates on the inner leaf of 
the membrane and the transporter enters the cytosol. This mechanism is consistent 
with the highly permissive structure-function relationships, the apparent lack of cell-
type specificity and uptake being slowed but not inhibited at 4°C. This hypothesis 
does not preclude competing uptake by other mechanisms including endocytosis, 
which is likely to dominate with large cargoes.20
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Finally, due to the unusual properties of β-peptides built of β2- or β3-homologues of 
proteinogenic α-amino acids (for reviews, see ref 21), β-oligohomoarginine were 
considered suitable candidates as CPPs. Seebach16 et al. have already reported the 
synthesis of short oligomers of β3-arginine, showing that short fluorescently labelled 
oligomers of β3-homoarginine of type 2 are also able to enter living cells efficiently, 
presumably by a non-endocytotic uptake mechanism.16
As part of a project focused on the understanding of uptake pathways of cell 
penetrating peptides (CPPs), we have prepared, in collaboration with Prof. Seebach, 
at Swiss Federal Institute of Technology in Zurich, α,α-dialkylated glycine carrying 
special chains, precursors of arginine side chains. The goal of this study is the 
preparation of α,α-disubstituted α-peptides of type 3, that could be efficient molecular 
transporters of drugs and probe molecules into cells and tissues.  
The synthesis of compounds such as 3 and subsequently the study of their 
binding and cell permeability properties could shed new light on alternative uptake 
pathways and on the understanding of the role of overall charge, charge distribution 
and chain length in the cell-penetration ability of this class of CPPs. 
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Chapter 9 
Attempts at Synthesizing  
α-Substituted Arginine Derivatives  
Introduction 
The increasing number of papers, dealing either with applications of C-α-
disubstituted α-amino acids (α,α-disubstituted glycines) or with new synthetic 
methodologies for their incorporation into peptide sequences, is due to several 
factors. In particular, these non-natural amino acids occur in an important family of 
membrane-active natural antibiotics,1 such as peptaiboils;2 moreover, they are used 
for the construction of conformationally constrained, enzyme-resistant agonists and 
antagonists of bioactive peptides.3 Their severely restricted conformational freedom 
allows the exploitation of such compounds as precise molecular rulers,4 scaffolding 
blocks in the de novo design of protein and enzyme mimetics,5 or suitable models for 
spectroscopic studies.6
As only a few α,α-disubstituted α-amino acids are commercially available, many 
synthetic methods have been devised for their preparation.7
The main problem a peptide chemist has to tackle with α,α-disubstituted α-amino 
acids is their rather poor reactivity, particularly at their nucleophilic amino function, 
due to high steric hindrance at α-carbon of the these residues.8 This prevents one 
from preparing a homo-oligomeric series in good yield and in a relatively short time 
with the coupling methods available to date.4,9
Results and Discussion 
We were interested in the preparation of short oligomers of α,α-dialkylated analogues 
of arginine, as potential efficient cell penetrating peptides (Chapter 8). 
We planned the synthesis of the dialkylated analogue of arginine adapting a 
procedure reported in literature.10 In particular, we thought to introduce the 
guanidinium head by reaction of guanidinylating reagents with an amino group of a 
propyl amino group.11 The amino group can be introduced as azido function that can 
be, in turn, easily reduced by hydrogenolysis or by Staundinger reaction. Thus, we 
prepared the azide 4 (Scheme 9.1) from 3-chloropropanol 1, and we used it as 
‘protected’ electrophile12 in the dialkylation reaction of ethyl isocyanoacetate 5 
(Scheme 9.2). 
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Scheme 9.1  Preparation of ω-iodoazide from 3-chloropropanol. 
To obtain successful and reproducible results, oil-free NaH is necessary in the 
alkylation reaction: in this way, 2 eq. of base are enough to have the dialkylated 
product (6) in 84% yield (Scheme 9.2). 
CN O
O
N3N3
H2N
O
O
N3N3
H2N
OH
O
N3N3
BocHN OH
O
N3N3
EtOH, HCl 37%
96%
0°C, 1h
NaOH (1M), MeOH
r.t (2h)          40°C (1h)
NaOH, H2O/dioxane, Boc2O
0°C         r.t., o.n. 70%
CN O
O
5 6
7
8
9
NaH
DMSO/ether
N3 I
CbzHN OH
O
N3N3
10
84%
NaOH, acetone
CbzCl, 0°C       r.t., o.n.
62%
 
Scheme 9.2  Synthetic results. 
The compound 6 was then converted into α-amino ethyl ester 7 by acid hydrolysis in 
96% yield (Scheme 9.2). 
Finally, the ethyl ester function of 7 was hydrolysed with aq. NaOH in MeOH and 
in turn the amino function protected to have the second building block for peptide 
coupling (9 or 10). 
Early attemps of coupling were carried out using Boc as N-protection. This 
urethane protection is, indeed, as easily introduced as easily removed, being 
especially useful in solution-phase peptide synthesis.  
It is known that, during the peptide coupling, the activation of carboxyl function of 
both peptides and urethane or amide N-protected derivatives leads, via an 
intramolecular reaction, to the oxazol-5(4H)-one heterocyclic skeleton, whose the 
formation of which is greatly favoured by the gem-dialkyl effect (Scheme 9.3).13
H
N
O X
O
R1
R2 N
O
O
R1
R2
- HX
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Scheme 9.3  Oxazol-5(4H)-one formation. 
Unlike oxazolones formed from α-amino acids,14,15 those formed from α,α-
disubstituted α-amino acid derivatives are not prone to racemization (or epimerization) 
since that would require a C-C or C-N bond cleavage. Indeed, the shelf-stable 
oxazolones from α,α-disubstituted α-amino acids and peptides are easily isolated 
and, despite their relatively poor reactivity at room temperature, can be directly 
exploited in peptide synthesis, since the nucleophilic attack of an amino group at the 
C-5 forms a peptide bond. 8
However, when we allowed to react the carboxylic acid derivative 9 with the amine 7 
under peptide coupling conditions (Scheme 9.4), the ligated product 13 was isolated 
in poor yield (Table 9.1).  The oxazolin-2,5-dione derivative 12 (Leuch’s anhydride) 
was observed as main product.  As already reported in literature,16 compound 11 
decomposes to give 12 via retro-ene reaction (Scheme 9.4). Emploiment of Leuchs 
anhydride in peptide synthesis is also reported;16,17 however, in our experience, 
compound 12 is unreactive under the coupling conditions we used, probably due to 
steric hindrance.  
N
O
O
R
R
BocHN
OH
O
R R
R= (CH2)3N3
Activation
O
9
7
BocHN
H
N
O
O
O
N3N3
N3 N3
13
NH
O
O
R
R
O
12
-  (CH3)2C=CH2
11
7
H2N
H
N
O
O
O
N3N3
N3 N3
14
 
Scheme 9.4  Attempted coupling reaction with 9. 
Under all the reaction conditions tested, we could not obtain the dipeptide 13 in good 
yield (Table 9.1). Both HATU and EDC in dichloromethane afforded mainly the 
anhydride by-product (entries 1-2). Moving from dichloromethane to 
dimethylformamide little amounts of the desired product were isolated (entries 3-4). 
DIPEA instead of NMM gave the worst results even after 5 days (entry 5). Taking into 
account that the main product isolated was the unproductive Leuch’s anhydride and 
that many side product were observed as well, we decided to use the Z-protected 
amino acid 10. 
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Table 9.1  Coupling reaction of 7 and 9. 
Reaction Conditions (eq) Solvent Yield of 12(%) 
Yield of 
13(%) 
HATU(1.2)/NMM(3) o.n., r.t. CH2Cl2 31 / 
EDC(1.3)/HOAt(1)/NMM(1) 
5d, .r.t.→ 5d, 55 °C→ MW 
CH2Cl2 Quant. / 
HATU(2)/NMM(3) 4h, r.t. DMF 70 2 
HATU(1.2)/NMM(3) o.n., r.t. DMF 24 5 
HATU(2)/DIPEA(5) 
5d, r.t. →2d, 50 °C→MW 
DMF 8a / 
aTogether with 12, 30% of 7 was recovered, as well as other products. 
Also in this case, an oxazolone intermediate 15 is expected (Scheme 9.5), but should 
not decompose under the coupling conditions, to the  Leuch’s anhydride; thus we 
could recover the peptide product 16 together with the starting materials (Table 9.2).  
10
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Scheme 9.5  Coupling reaction using Z-protection. 
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Table 9.2  Coupling reactions between 7 and 10. 
Reaction Conditions (eq) Solvent Yield of 16% 
HATU(1.4)/NMM(5), 4d, r.t. DMF 38 
EDC(1)/HOAt(1)/NMM(1), 7d, r.t CH2Cl2 15 
T3P(1.4)/NMM(5), 4d, r.t. DMF / 
This coupling reaction is also extremely slow: in a test experiment we allowed 7 to 
react with Boc-Ala-OH, and the desired product could be isolated in good yields 
(Scheme 9.6). This result rules-out the hypothesis that the poor reactivity of the used 
sterically hindered amino acids could be ascribed to the depleted nucleophilicity of 
the amino function.  
Together, these results suggest that our hypothesis about the poor reactivity of 
oxazolone intermediates of this type could be correct, although no investigations on 
its behaviour with less hindered amino acids were carried out.  
BocHN
OH
O
H2N
O
N3 N3
O
HATU/DIPEA
DMF, o.n., r.t.
BocHN
H
N
O
O
N3N3
O
78%
717
18  
Scheme 9.6  Coupling of 7 with Boc-Ala-OH. 
As reported by Toniolo, with the coupling methods available to date, the high steric 
hindrance of these residues makes it difficult to prepare homo-oligomeric compounds 
in good yield and in a relatively short time.4,9
Finally, preliminary studies of hydrolysis of the ethyl ester function in peptide 16 
demostrated the necessity to replace this ester function with a more reactive ester 
such as tert-butyl or trimethylsilyl ethyl ester that can be removed under mild 
conditions. 
Instead, the first attempts of reduction of azido group, with in situ protection of the 
amino function, were encouraging, but also this reaction needs some improvement. 
These experiments are still in progress and will be further carried out by the 
author in following years.  
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General 
NMR spectra were recorded on Varian Inova 500 MHz, Bruker DRX 400 MHz, Varian Gemini 300 
MHz, Varian Gemini 200 MHz spectrometers: chemical shifts are in ppm (δ) and J coupling constants 
in Hz; , spectral splitting patterns are designated as singulet (s), doublet (d), triplet (t), quadruplet (q), 
multiplet or more overlapping signals (m), broad signal (b); solvent CDCl3, unless otherwise specified. 
GC/MS analyses were performed on Hewlett–Packard 6890 GC/5973N MS. Optical rotations were 
determined on Jasco P-1010 polarimeter (1.0 dm cell); solvent CHCl3, unless otherwise specified. 
Infrared spectra were recorded using JASCO FT/IR-430 Spectrometer. Ms: IonSpec Ultima 4.7-T-FT 
ion cyclotron resonance (MALDI or HR-MS in a 2,5-dihydroxybenzoic acid matrix) mass spectrometer; 
in m/z (% of basis peak). Mps were taken on a Gallenkamp apparatus. Elemental analyses were 
performed on a Perkin–Elmer Series II 2400, CHNS analyzer. TLC were carried out on silica gel Merck 
60 F254 plates (0.2 mm layer) and column chromatographies on Merck Kieselgel 60 (70–230 mesh). 
Reactions involving air- or moisture-sensitive reagents or intermediates were performed under argon 
or nitrogen atmosphere in glassware which had been heat gun or flame-dried under high vacuum. 
Indicated reaction temperatures refer to those of the reaction bath, while room temperature (rt) is 
noted as 25 °C. Preparative reactions were stirred magnetically. Tetrahydrofuran (THF), diethyl ether 
(Et2O), methylene chloride (CH2Cl2), and toluene were obtained from a anhydrous solvent system 
(activated alumina columns, positive pressure of argon). All other solvents were used as received in 
Sure/Seal bottles (Aldrich). Triethylamine (Et3N), diisopropylethylamine (i-Pr2NEt), pyridine and 
chlorotrimethylsilane (TMSCl) were distilled from CaH2 immediately prior to use. All other reagents 
were purchased from Aldrich at the highest commercial quality and used without further purification. 
Preparation of Dideuterated β-Amino Acids  
Reduction of Carboxyl Function  
1,1-2H (S)-tert-butyl 1-hydroxypropan-2-ylcarbamate (31a). General procedure  
To a solution of N-methyl-morpholine (NMM) (2.8 mL, 25.4 mmol) and 30a (4.0 g, 21.2 mmol) in 
anhydrous THF (92 mL), under magnetic stirring and at 0 °C, methylchloroformiate was added 
(MeOCOCl) (2.0 mL, 25.4 mmol) dropwise. After 40 minutes, the solution was filtered on Celite® and 
the salts of N-methyl morpholinium were washed with anhydrous THF (3 x 70 mL). To the flow through, 
under magnetic stirring and at 0 °C, a soluction of NaBD4 (0.9 g, 21.2 mmol) in D2O (7.7 mL) was 
added dropwise. The mixture was kept for 10 minutes at room temperature. The solvent was then 
evaporated under reduced pressure, the residue was diluted with EtOAc (2x100 mL) and washed with 
10% aq NH4Cl. The organic layer was washed with brine, dried (Na2SO4), and evaporated in vacuo to 
afford the crude reaction product whose chromatography on silica gel (CHCl3:CH3OH-95:5) gave the 
compound 31a ( 3.47 g, yield 92%). Mp 58.2-59.1 °C (from EtOAc/Hexane); α D25-9.8 (c 1.32). 1H 
NMR (300 MHz) : δ 1.15 (d, JCH3,CH = 6.8, 3H, CH3), 1.43 (s, 9H, CH3Boc), 2.95 (bs, 1H, OH), 3.71 (dd, 
J=6.6, J=6.8, 1H, CH), 4.75 (bd, J=6.6, 1H, NH). 13C NMR (75 MHz): δ 17.1, 28.2, 48.3, 66.5, 79.5, 
156.2. 
Under the same conditions, the other dideuterated N-protected β-amino alcohols were also obtained. 
1,1-2H (S)-tert-butyl 1-hydroxy-3-phenylpropan-2-ylcarbamate (31b) 
Prepared starting from 30b (yield 90%); mp 97.3–98.9 °C (from EtOAc/Hexane); α D25-23.1 (c 1.15).  
1H NMR (300 MHz) : δ 1.43 (s, 9H, CH3Boc), 1.92 (bs, 1H, OH), 2.82 (d, J=7.1, 2H, CH2Ph), 3.78-3.92 
(m, 1H, CH), 4.72 (bs, 1H, NH), 7.18-7.28 (m, 5H, H-Ar). 13C NMR (75 MHz) : δ 28.2, 37.3, 49.1, 53.4, 
79.6, 126.4, 128.4, 129.1, 137.6, 157.7.  
6,6-2H (S)-tert-butyl 6-hydroxyhexane-1,5-diyldicarbamate (31c) 
Prepared starting from 30c (yield 85%); oil; α D25-10.1 (c 1.92, CH3OH). 1H NMR (200 MHz; C6D6, 75 
°C) : δ 0.93-1.32 (m, 6H, 3xCH2), 1.43 (s, 18H, 2xCH3Boc), 2.14 (bs, 1H, OH), 2.78-2.98 (m, 2H, 
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CH2NH), 3.43-3.58 (m, 1H, CH), 4.13 (bs, 1H, NHCH2), 4.51 (bs, NHCH). 13C NMR (125 MHz) : δ 23.0, 
28.7, 30.2, 30.9, 40.0, 52.6, 65.8, 79.4, 79.7, 156.6, 156.7.  
2,2-2H tert-butyl 2-hydroxyethylcarbamate (31d) 
Prepared starting from 30d (yield 75%); oil. 1H NMR (200 MHz): δ 1.43 (s, 9H, CH3Boc), 3.22 (d, J=5.5, 
2H, CH2NH), 3.86 (bs, 1H, OH), 5.10 (bt, J=5.5, 1H, NH). 13C NMR (50 MHz): δ 28.2, 29.5, 42.8, 79.6, 
156.8.  
3,3-2H (R)-tert-butyl 1-(benzyloxy)-3-hydroxypropan-2-ylcarbamate (31e) 
Prepared starting from 30e (yield 75%); mp 64.9–65.7 °C (from EtOAc/Hexane); α D25+14.8 (c 1.71). 
1H NMR (300 MHz) : δ 1.45 (s, 9H, CH3Boc), 2.60 (bs, 1H, OH), 3.67 (dd, J=4.3, J=9.3, 1H, CHaO), 
3.71 (dd, J=3.8, J=9.3, 1H, CHbO), 3.80-3.90 (m, 1H, CH), 4.38 (d, J=12.0, 1H, CH2Ph), 4.62 (d, 
J=12.0, 1H, CH2Ph), 5.22 (bs, 1H, NH), 7.27-7.42 (m, 5H, H-Ar). 13C NMR (75 MHz) : δ 28.8, 51.7, 
63.1, 70.6, 73.4, 79.5, 127.0, 127.2, 127.8, 136.9, 155.1.  
Conversion of N-Protected β-Amino Alcohols into N-Protected β-Amino 
Nitriles 
1,1-2H (S)-tert-butyl 1-cyanopropan-2-ylcarbamate (33a) 
N-protected β-amino iodide. General procedure 
To a solution of iodine (2.7 g, 10.5 mmol) in anhydrous CH2Cl2 (72 mL) was added dropwise a solution 
of triphenylphosphine (2.8 g, 10.5 mmol) in CH2Cl2 at room temperature, in inert atmosphere and 
under megnetic stirring; after 15 minutes solid imidazole (1.4 g, 21.1 mmol) was added. The misture 
was then kept  for 15 minutes at room temperature, and then the compound 31a (1.5 g, 8.4 mmol), in 
anhydrous CH2Cl2, was finally added to the suspension and the reaction was allowed to reflux until the 
starting material was completely consumed (~3h, TLC, CHCl3/CH3OH=8:2). The solvent was then 
evaporated under reduced pressure and the residue, diluted with EtOAc (50 mL) was washed with 
10% aq. Na2S2O4 (40 mL) and then brine (3 x 50 mL) until neutral. The organic layer was finally dried 
(Na2SO4) and evaporated in vacuo to give the compound 32a in mixture with white solid Ph3PO. The 
crude was used as such in the next step of cyanide-substitution. 
N-protected β-amino nitriles. General procedure 
Et4N+CN- (1.4 g, 9.1 mmol) in anhydrous CH2Cl2 was added in one portion to a solution of the crude 
32a (2.2 g, 7.6 mmol) in anhydrous CH2Cl2 (90 mL) at room temperature, under nitrogen atmosphere 
and magnetic stirring. The mixture was refluxed until the starting material was completely consumed 
(~4 h, TLC, Hexane/EtOAc 7:3). The solution was then directly transfered onto a silica gel column and 
eluted with CHCl3, to remove the salts coming from Et4N+CN-. The solid residue (4.4 g), was finally 
purified by chromatography (Hexane:AcOEt  7:3) to give 33a as a white solid, recristallized from 
EtOAc/Hexane (1.1 g, yield 80%). Mp 68.2-70.0 °C. α D25-120.2 (c 1.38). 1H NMR (400 MHz) : δ 1.33 
(d, 3H, J=6.8, CH3), 1.43 (s, 9H, CH3Boc), 3.95-4.15 (m, 1H, CH), 4.69 (bd, 1H, J=7.05, NH). 13C NMR 
(75 MHz) : δ 19.4, 25.0, 28.3, 43.0, 80.1, 117.4, 154.8. 
Under the same conditions, the other dideuterated N-protected β-amino alcohols were also obtained. 
1,1-2H (S)-tert-butyl 1-cyano-3-phenylpropan-2-ylcarbamate (33b) 
Prepared starting from 31b (yield 74%); mp 123.8–125.0°C (from EtOAc/Hexane); α D25-18.2 (c 1.15). 
1H NMR (200 MHz) : δ 1.43 (s, 9H, CH3), 2.86 (dd, J=7.8, J=13.6, 1H, CHaPh), 2.99 (dd, J=5.8, J=13.6, 
1H, CHbPh), 4.00-4.17 (m, 1H, CH), 4.72 (bs, 1H, NH), 7.18-7.28 (m, 5H, H-Ar). 13C NMR (75 MHz) : δ 
28.2, 29.9, 39.3, 48.3, 79.6, 117.3, 126.4, 128.4, 129.1, 137.6, 154.8.  
6,6-2H (S)-tert-butyl 6-cyanohexane-1,5-diyldicarbamate (33c) 
Prepared starting from 31c (yield 74%); mp 60.7–64.0°C; α D25-45.2 (c = 0.57). 1H NMR (200 MHz; 
C6D6, 75 °C) : δ 0.72-1.18 (m, 6H, 3xCH2), 1.38 (s, 9H, CH3Boc), 1.44 (s, 9H, CH3Boc), 2.64-2.81 (m, 
2H, CH2NH), 3.29-3.42 (m, 1H, CH), 3.92 (bs, 1H, CH2NH), 4.21 (bs, 1H, CHNH). 13C NMR (50 MHz) : 
δ 23.0, 28.5, 28.6, 29.9, 30.0, 33.1, 40.0, 47.3, 79.5, 80.3, 117.5, 155.4, 156.4. 
2,2-2H tert-butyl 2-cyanoethylcarbamate (33d) 
Prepared starting from 31d (yield 88%); m.p. 42.4–45.0°C (from EtOAc/Hexane). 1H NMR (200 MHz): 
δ 1.45 (s, 9H, CH3Boc), 3.38 (d, J=6.3, 2H, CH2NH), 4.90 (bs, 1H, NH). 13C NMR (50 MHz): δ 28.1, 
29.5, 36.5, 80.1, 118.0, 155.0.  
3,3-2H (R)-tert-butyl 1-(benzyloxy)-3-cyanopropan-2-ylcarbamate (33e) 
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Prepared starting from 31e (yield 65%); oil; α D25-9.7 (c = 1.62). 1H NMR (300 MHz) : δ 1.50 (s, 9H, 
CH3Boc), 3.60 (dd, J=4.9, J=9.6, 1H, CHaO), 3.70 (dd, J=3.8, J=9.6, 1H, CHbO), 4.05-4.18 (m, 1H, 
CH), 4.58 (s, 2H, CH2Ph), 5.10 (bd, J=6.4, 1H, NH), 7.31-7.40 (m, 5H, H-Ar). 13C NMR (75 MHz) : δ 
28.1, 29.6  46.8, 69.5, 73.4, 80.1, 117.1, 127.6, 127.9, 128.4, 137.1, 154.8. 
Conversion of N-Protected β-Amino Nitriles into β-Amino Methyl Esters.  
4,4-2H (S)-4-methoxy-4-oxobutan-2-aminium chloride (34a) 
General procedure 
A solution of N-Boc-amino nitrile 33a (0.36 g, 1.95 mmol) in anhydrous methanol (11.5 mL), at –15 °C, 
was saturated with anhydrous HCl (g) and kept at room temperature for 12 h. To this solution few 
water drops (53 mg, 2.93 mmol) were added. After 1 h, the solvent was co-evaporated with anhydrous 
Et2O under reduced pressure (3 x 25 mL), to give the product 34a as a crystalline solid (0.3 g, yield 
87%). 
Mp 250 °C dec. (from MeOH/CHCl3); α D25+0.19 (c 2.5, CH3OH). 1H NMR (200 MHz; CD3OD) : δ 1.47 
(d, J=6.8, 3H, CH3), 3.48 (t, J=6.8, 1H, CH), 3.72 (s, 3H,CH3O), 8.35 (bs, NH3+). 13C NMR (50 MHz; 
CD3OD) : δ 18.3, 38.2, 44.7, 52.2, 170.8. 
Under the same conditions, the other dideuterated N-protected β-amino methyl esters were also 
obtained. 
4,4-2H (S)-4-methoxy-4-oxo-1-phenylbutan-2-aminium chloride (34b) 
Prepared starting from 33b (yield 85%); mp 255.0°C dec (from MeOH/CHCl3); α D25+4.28 (c 1.38, 
CH3OH). 1H NMR (500 MHz; CD3OD): δ 2.94 (dd, 1H, J=8.3, J=14.16, CHaPh), 3.79 (dd, 1H, J=6.35, 
J=14.16, CHbPh), 3.70 (s, 1H, CH3O), 3.82 (t, 1H, J=7.32, CH), 7.05-7.38 (m, 5H, H-Ar). 13C NMR (75 
MHz; CD3OD): δ 39.5, 48.3, 50.3, 52.8, 128.7, 129.4, 130.1, 136.7, 206.2.  
7,7-2H (S)-7-methoxy-7-oxoheptane-1,5-diaminium chloride (34c) 
Prepared starting from 33c (yield 82%); oil; α D25+8.49 (c 0.56, CH3OH). 1H NMR (500 MHz; CD3OD) : 
δ 1.48-1.58 (m, 2H, CH2), 1.68-1.72 (m, 2H, CH2CH), 2.93 (t, J=7.8, 2H, CH2NH), 3.57 (t, J=6.8, 1H, 
CH), 3.75 (s, 3H, OCH3).  
3,3-2H 3-methoxy-3-oxopropan-1-aminium chloride (34d) 
Prepared starting from 33d (yield 90%); mp 102.4-106.0 °C (from MeOH/CHCl3). 1H NMR 
(200 MHz; CD3OD): δ 3.18 (bs, 2H, CH2NH), 3.73 (s, 3H, OCH3). 13C NMR (50 MHz; CD3OD): 
δ 32.1, 36.4, 52.7, 172.6.  
4,4-2H (R)-1-(benzyloxy)-4-methoxy-4-oxobutan-2-aminium chloride (34e) 
Prepared starting from 33e (yield 80%); oil; α D25+0.68 (c 0.74, CH3OH). 1H NMR (300 MHz; CD3OD): 
δ 3.63-3.78 (m, 1H, CH2O), 3.63 (s, 3H, CH3O), 4.48 (d, J=12.0, 1H, CHaPh), 4.54 (d, J=12.0, 1H, 
CHbPh), 4.78 (m, 1H, CH), 7.31-7.40 (m, 5H, H-Ar). 13C NMR (75 MHz): δ 37.0, 48.0, 51.8, 72.4, 73.1, 
127.2, 127.5, 127.8, 138.2, 171.1.  
Synthesis of anti-2,3-Diamino Acids 
N,N-Dibenzyl Protections of β3-Amino Methyl Esters  
Methyl (R)-3-(dibenzylamino)-3-phenylpropanoate (25a): typical procedure.  
A magnetically stirred suspension of β3-phenylglycine methyl ester 24a (8.38 mmol; 1.50 g) and 
diisopropylethylamine (DIPEA) (7.3 mL; 41.90 mmol) in toluene (18.0 mL) was warmed gently until a 
clear solution was obtained. Then, benzyl bromide (6.0 mL; 50.28 mmol) was added in one portion 
and the resulting solution was refluxed for 4 h. The reaction mixture was then cooled in an ice bath, 
diluted with EtOAc (2 x 100 mL) and extracted with 10% aq NH4Cl. The organic layer was washed with 
brine, dried (Na2SO4), and evaporated under reduced pressure to afford a crude reaction product 
whose chromatography on silica gel (petroleum ether/EtOAc, 95:5) gave the pure cristalline compound 
25a, after recrystallization from EtOAc/Hexane (2.56 g; yield 85%). Mp 51.8–53.0 °C. α D25 +71.6 (c 
2.0). 1H NMR (500 MHz): δ 2.73 (dd, J=7.3, J=14.6 , 1H, H-2a), 3.14 (dd, J=8.8, J=14.6, 1H, H-2b), 
3.18 (d, J=13.7, 2H, NCHPh), 3.64 (s, 3H, OCH3), 3.78 (d, J=13.7, 2H, NCHPh), 4.33 (dd, J=7.3, 
J=8.8, 1H, H-3), 7.20–7.41 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 36.9, 51.8, 53.9, 59.1, 127.2, 127.7, 
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128.3, 128.4, 128.8, 129.1, 137.6, 139.8, 172.3. IR (KBr, cm-1): ν 1714. Anal. Calcd for C24H25NO2: C 
80.19, H 7.01, N 3.90. Found: C 80.30, H 7.05, N 3.92. 
Under the same conditions, the following N,N-diprotected esters were also obtained. 
Methyl (S)-3-(dibenzylamino)-4-phenylbutanoate (25b) 
Oil (yield 83%). α D25 -5.4 (c 1.0). 1H NMR (500 MHz): δ 2.33 (dd, J=6.4, J=14.2, 1H, H-2a), 2.56 (dd, 
J=8.8, J=13.2, 1H, H-4a), 2.65 (dd, J=8.3, J=14.2, 1H, H-2b), 3.12 (dd, J= 5.7, J=13.2, 1H, H-4b), 
3.40–3.50 (m, 1H, H-3), 3.56 (s, 3H, OCH3), 3.62 (d, J=13.7, 2H, NCHPh), 3.76 (d, J=13.7, 2H, 
NCHPh), 7.20–7.70 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 35.9, 36.3, 51.6, 53.7, 57.8, 126.4, 127.2, 
128.4, 128.6, 129.1, 129.5, 139.7, 139.8, 172.9. IR (KBr, cm-1): ν 1712. Anal. Calcd for C25H27NO2: C 
80.40, H 7.29, N 3.75. Found: C 80.25, H 7.32, N 3.77.  
Methyl (R)-4-(benzyloxy)-3-(dibenzylamino)butanoate (25c) 
Oil (yield 86%). α D25 +31.6 (c 1.8). 1H NMR (500 MHz): δ 2.55 (dd, J=6.3, J=14.6, 1H, H-2a), 2.68 (dd, 
J=7.8, J=14.6, 1H, H-2b), 3.47–3.54 (m, 1H, H-3), 3.56–3.62 (m, 4H, H-4a and OCH3), 3.66 (d, J=13.7, 
2H, NCHPh), 3.71 (dd, J=9.8, J=5.4, 1H, H-4b), 3.75 (d, J=13.7, 2H, NCHPh), 4.49 (d, J=12.7, 1H, 
OCHPh), 4.52 (d, J= 12.7, 1H, OCHPh), 7.20–7.45 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 34.7, 51.7, 
54.5, 55.2, 70.3, 73.3, 127.1, 127.8, 128.4, 128.6, 129.1, 138.6, 140.1, 173.0. IR (KBr, cm-1): ν 1715. 
Anal. Calcd for C26H29NO3: C 77.39, H 7.24, N 3.47. Found: C 77.25, H 7.27, N 3.48. 
Reactions of Enolates of β3-Amino Methyl Esters with DBAD.  
Methyl (2S,3S)-3-(dibenzylamino)-2-[N’,N”-(di-tert-butoxycarbonyl)-hydrazino]-3-
phenylpropanoate (26a): typical procedure.  
To a magnetically stirred solution of 25a (2.56 g; 7.12 mmol) in anhydrous THF (75 mL), at -78 °C and 
under anhydrous argon atmosphere, 0.5 M KHMDS in toluene (28.5 mL; 14.24 mmol) was added 
dropwise. After 1 h solid di-tert-butyl azodicarboxylate (2.85 g; 12.82 mmol) was added in one portion 
to the reaction mixture, kept at -78 °C under stirring. Within 1 h the reaction was quenched by addition 
of glacial AcOH (1.1 mL) and diluted with EtOAc. The organic layer was washed with brine until neutral, 
dried (Na2SO4), and the solvents evaporated in vacuo. The oily residue, after chromatography on silica 
gel (hexane/EtOAc, 9:1), afforded the pure title compound 26a (foam; 3.86 g; yield 92%; d.r. 93:7). 
α D25 +65.7 (c 1.6).  
The 1H NMR data were not significant, apparently due to the occurrence of mixtures of rotamers. IR 
(KBr, cm-1): ν 3260, 1740, 1720. Anal. Calcd for C34H43N3O6: C 69.25, H 7.35, N 7.13. Found: C 69.17, 
H 7.31, N 7.15.  
Under the same conditions, the following Boc-diprotected 2-hydrazino derivatives were also obtained. 
Methyl (2S,3S)-3-(dibenzylamino)-2-[N’,N”-(di-tert-butoxycarbonyl)- hydrazino]-4-
phenylbutanoate (26b) 
Foam (yield 90%). α D25 -2.3 (c 0.3). IR (KBr, cmK1): ν 3250, 1730, 1712. Anal. Calcd for C35H45N3O6: 
C 69.63, H 7.51, N 6.96. Found: C 69.60, H 7.49, N 7.01. 
Methyl (2S,3R)-4-(benzyloxy)-3-(dibenzylamino)-2-[N’,N”- (di-tert-butoxycarbonyl)-
hydrazino]butanoate (26c) 
Foam (yield 90%). α D25 +45.0 (c 1.5). IR (KBr, cm-1): ν 3270, 1728, 1715. Anal. Calcd for C36H47N3O7: 
C 68.22, H 7.47, N 6.63. Found: C 68.19, H 7.40, N 6.68.  
Reductive cleavages of the hydrazino bonds. 
Methyl (2S,3S)-2-amino-3-(dibenzylamino)-3-phenylpropanoate (27a): typical 
procedure.  
To a magnetically stirred solution of 26a (3.86 g; 6.55 mmol) in anhydrous CH2Cl2 (54 mL), TFA (54 
mL) was added in one portion. After 2 h, the solvent was evaporated under reduced pressure. The 
crude reaction product, redissolved in MeOH (26 mL), was transferred into a flask containing W-2 
Raney nickel (3.86 g, wet) and equipped with a hydrogen inflated balloon. The flask was dipped into 
an ultrasound bath filled with water and sonicated for 4 h at rt till the starting product was completely 
consumed (TLC). The reaction mixture was then filtered through Celite® washing with MeOH (100 
mL). Removal of the solvent under reduced pressure gave a residue that was redissolved in EtOAc 
(200 mL), washed with 10% aq Na2CO3 (2x100 mL), dried (Na2SO4), and evaporated in vacuo, to 
98 
Experimental Part 
afford an oil whose chromatography on silica gel (hexane/EtOAc, 7:3) led to the pure title compound 
27a (oil; 1.71 g; yield 70%). α D25 +62.4 (c 1.1). 1H NMR (300 MHz): δ 1.97 (bs, 2H, NH2), 3.05 (d, 
J=13.5, 2H, NCHPh), 3.82 (s, 3H, OCH3), 3.83–3.88 (m, 3H, H-2 and NCHPh), 4.26 (d, J=10.3, 1H, H-
3), 7.20–7.60 (m, 15H, H-Ar). 13C NMR (50 MHz): δ 51.7, 54.0, 56.3, 67.3, 126.9, 128.1, 128.3, 128.8, 
129.7, 133.5, 139.0, 174.1. IR (KBr, cm-1): ν 3500–3200, 1714. Anal. Calcd for C24H26N2O2: C 76.98, H 
7.00, N 7.48. Found: C 76.81, H 7.06, N 7.52.  
Under the same conditions, the following 2-amino esters were also obtained. 
Methyl (2S,3S)-2-amino-3-(dibenzylamino)-4-phenylbutanoate (27b) 
Oil (yield 78%). α D25 +7.9 (c 0.4, MeOH). 1H NMR (500 MHz): δ 1.63 (bs, 2H, NH2), 2.93 (dd, J=7.3, 
J=13.7, 1H, H-4a), 3.09 (dd, J=6.3, J=13.7, 1H, H-4b), 3.23–3.29 (m, 1H, H-3), 3.60 (s, 3H, OCH3), 
3.61–3.67 (m, 3H, H-2 and NCHPh), 3.70 (d, J=13.7, 2H, NCHPh), 7.10–7.40 (m, 15H, H-Ar). 13C 
NMR (100 MHz): δ 32.7, 52.2, 55.1, 55.6, 63.8, 126.5, 127.4, 128.5, 128.7, 129.4, 129.9, 139.9, 140.5, 
175.9. IR (KBr, cm-1): ν 3530–3210, 1712. Anal. Calcd for C25H28N2O2: C 77.29, H 7.26, N 7.21. Found: 
C 77.19, H 7.25, N 7.23.  
Methyl (2S,3R)-2-amino-4-(benzyloxy)-3-(dibenzylamino)-butanoate (27c) 
Oil (yield 65%). α D25 +30.9 (c 1.0). 1H NMR (500 MHz, C6D6): δ 1.48 (bs, 2H, NH2), 3.22–3.28 (m, 1H, 
H-3), 3.29 (s, 3H, OCH3), 3.58 (d, J=6.8, 1H, H-2), 3.60 (dd, J=5.8, J=9.8, 1H, H-4a), 3.65 (d, J=13.7, 
2H, NCHPh), 3.72 (dd, J=4.9, J=9.8, 1H, H-4b), 3.84 (d, J=13.7, 2H, NCHPh), 7.05–7.40 (m, 15H, H-
Ar). 13C NMR (100 MHz): δ 52.1, 55.4, 55.6, 61.1, 67.2, 73.7, 127.3, 127.9, 128.0, 128.5, 128.8, 129.4, 
138.7, 140.2, 175.7. IR (KBr, cm-1): ν 3510–3200, 1716. Anal. Calcd for C26H30N2O3: C 74.61, H 7.22, 
N 6.69. Found: C 74.59, H 7.20, N 7.01.  
Methyl (4S,5S)-4-methoxycarbonyl-5-phenyl-2-imidazolidinone (29) 
A magnetically stirred solution of 27a (0.020 g; 0.053 mmol) in glacial AcOH (0.5 mL) was 
hydrogenolysed over 30% Pd/C catalyst (0.006 g) for 2 h at 50 8C, under a slightly positive pressure 
given by an inflated balloon (~3 bar). The mixture was then filtered through Celite® washing with 
MeOH (10 mL). Removal of the solvents under reduced pressure gave a residue that was redissolved 
in anhydrous THF (1.1 mL). The solution was cooled to 0 °C. Et3N (0.063 mL, 0.053 mmol) and 1,1’-
carbonyldiimidazole (0.013 g; 0.079 mmol) were then added in sequence. After 30 min at 0 °C and 2 h 
at rt the solvents were evaporated under reduced pressure and the remaining crude residue was 
dissolved in EtOAc and filtered on a short silica gel plug (~3 cm3) with the same solvent (3x10 mL). By 
partial evaporation of the solvent under reduced pressure, a semicrystalline residue could be collected 
whose recrystallization by the same solvent afforded the pure 29 (0.010 g; yield 88%) as a white solid. 
Mp 202–203 °C dec. (lit.1 203–205 °C). 1H, 13C NMR and IR spectra were superimposable to those 
reported.  
Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-(dibenzylamino)-3-phenylpropanoate 
(30) 
To a solution of compound 27a (0.67 g; 1.80 mmol) in dioxane (21 mL) at 0 °C, Et3N (0.42 mL; 2.70 
mmol) and Boc2O (0.89g; 3.60 mmol) were added in sequence. The reaction mixture, warmed up to 
room temperature and stirred for 1 h, was then diluted with EtOAc. The organic layer was washed with 
brine until neutral, dried (Na2SO4), and the solvents evaporated in vacuo to give an oil. Its 
chromatography on silica gel (hexane/EtOAc, 9:1) afforded the pure title compound 30 (oil; 0.78 g; 
yield 92%). α D25 +50.7 (c 1.5). 1H NMR (400 MHz): δ 1.55 (s, 9H, Boc), 3.04 (d, J=13.5, 2H, NCHPh), 
3.86 (s, 3H, OCH3), 3.97–4.02 (m, 3H, H-3, NCHPh), 4.58 (bd, J=8.3, 1H, NHBoc), 5.14 (bt, J=9.7, 1H, 
H-2), 7.24–7.44 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 28.3, 52.3, 54.1, 54.7, 65.0, 80.2, 127.3, 128.3, 
128.5, 129.2, 130.1, 132.6, 139.1, 146.9, 154.9, 172.3. IR (KBr, cm-1): ν 1718, 1705. Anal. Calcd for 
C29H34N2O4: C 73.39, H 7.22, N 5.90. Found: C 73.25, H 7.20, N 5.92.  
Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-amino-3-phenylpropanoate (31) 
A magnetically stirred solution of 30 (0.78 g; 1.66 mmol) in glacial AcOH (7.4 mL) was hydrogenolysed 
over 30% Pd/C catalyst (0.23 g) for 2 h at 50 °C, under a slightly positive pressure given by an inflated 
balloon (~3 bar). The mixture was then filtered trough Celite® and washed with MeOH (100 mL). The 
solvent was removed under reduced pressure and the residue was dissolved in EtOAc (2x100 mL). 
The organic layer was washed with 10% aq Na2CO3 (300 mL), dried (Na2SO4), and the solvent 
evaporated in vacuo to give compound 31 as a white crystalline solid, after recrystallization from 
                                                 
1 Alexakis, A.; Lensen, N.; Tranchier, J.-P.; Mangeney, P.; Feneau-Dupont, J.; Declercq, J. P. Synthesis 1995, 8, 1038–1050. 
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hexane/acetone 9:1 (0.44 g; yield 90%). Mp 110.3–112.3 °C. α D25 +29.0 (c 0.9). 1H NMR (400 MHz, 
C5D5N): δ 1.35 (s, 9H, Boc), 3.62 (s, 3H, OCH3), 5.34 (d, J=7.1, 1H, H-3), 5.77 (bt, J=8.0, 1H, H-2), 
7.21–7.35 (m, 3H, H-Ar), 7.89 (d, J=7.3, 2H, H-Ar), 8.80 (bd, J=8.6, 1H, NHBoc). 13C NMR (100 MHz, 
C5D5N): δ 28.3, 52.4, 57.1, 59.4, 79.3, 128.6, 128.9, 138.0, 140.2, 156.8, 172.0. IR (KBr, cm-1): ν 3350, 
3200, 1765, 1715. Anal. Calcd for C15H22N2O4: C 61.21, H 7.53, N 9.52. Found: C 61.32, H 7.57, N 
9.58.  
Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-(9H-fluoren-9-
ylmethoxycarbonylamino)-3-phenylpropanoate(32) 
To a stirred solution of 31 (0.44 g; 1.48 mmol) in dioxane (5.8 mL) and 10% aq Na2CO3 (0.31 g; 2.96 
mmol) at 0 °C, Fmoc–OSu (0.41 g; 1.18 mmol) dissolved in DMF (1.5 mL) was added slowly. The 
reaction mixture, after 30 min at 0 °C and 2 h at rt, was extracted with CH2Cl2. The organic layer was 
washed with brine until neutral, dried (Na2SO4), and the solvents evaporated under reduced pressure 
to give an oil. The chromatography on silica gel (CHCl3) afforded the pure compound 32, white solid 
after recrystallization from hexane/acetone 9:1 (0.50 g; yield 65%). Mp 166.6–168.1 °C. α D25 +38.7 (c 
0.3). 1H NMR (500 MHz, C5D5N): δ 1.20 (s, 9H, Boc), 3.42 (s, 3H, OCH3), 4.14 (t, J=6.8, 1H, Fmoc), 
4.30 (dd, J=6.8, J=10.3, 1H, CHFmoc), 4.45 (dd, J=6.8, J=10.3, 1H, CHFmoc), 5.31 (t, J=9.3, 1H, H-2), 
5.69 (t, J=9.3, 1H, H-3), 7.05–7.70 (m, 14H, H-Ar and NHBoc), 9.17 (d, J=9.3, 1H, NHFmoc). 13C NMR 
(125 MHz): δ 28.5, 47.5, 52.9, 57.7, 58.0, 67.3, 120.2, 125.4, 126.8, 127.3, 128.4, 128.9, 141.5, 144.1, 
155.9, 156.5, 170.4. IR (KBr, cm-1): ν 3395 (br), 1705. Anal. Calcd for C30H32N2O6: C 69.75, H 6.24, N 
5.42. Found: C 69.82, H 6.27, N 5.43. 
Synthesis of 2,3-Disubstituted β-Amino Acids 
Full Protection of the Amino Group of β-amino acids 
Methyl 3-[Bis(4-methoxybenzyl)amino]propanoate (1) 
A magnetically stirred suspension of β-alanine hydrochloride methyl ester (0.39 g; 2.84 mmol) and 
diisopropylethylamine (DIPEA, 2.9 mL; 14.20 mmol) in toluene (10 mL) was gently warmed until a 
clear solution was obtained. 4-Methoxybenzyl chloride (2.3 mL; 17.04 mmol) was then added in one 
portion, and the resulting solution was heated under reflux until the starting homo-β-glycine, and also 
the intermediate N-monosubstituted derivative, were completely consumed (ca. 5 h, TLC monitoring). 
The reaction mixture was then cooled in an ice bath, diluted with ethyl acetate (0.2 L), and extracted 
with 10% aq. NH4Cl. The organic layer was washed with brine and dried (Na2SO4), and the solvents 
were evaporated under reduced pressure to afford a crude reaction product, chromatography of which 
on silica gel (petroleum ether/ Et2O, 8:2) gave the pure, oily title compound 1 (0.83 g; yield 85%). 1H 
NMR (500 MHz): δ 2.41 (t, J=7.08, 2H, H-2), 2.77 (t, J=7.08, 2H, H-3), 3,45 (s, 3H, OMe), 3.60 (s, 4H, 
2xMpm-CH2), 3.80 (s, 6H, 2xMpm-OMe), 6.85 (d, J=8.2, 4H, 2xMpm-H-3 and H-5), 7.45 (d, J=8.2, 4H, 
2xMpm-H-2 and H-6). 13C NMR (75 MHz): δ 32.4, 48.7, 51.7, 55.0, 57.0, 113.4, 129.7, 131.2, 158.5, 
172.7. Anal. Calcd. for C20H25NO4: C 69.95, H 7.34. Found C 70.20, H 7.30.  
Under the same conditions, the following N-protected esters were also obtained. 
Methyl (S)-3-[Bis(4-methoxybenzyl)amino]-4-phenylbutanoate (4) 
Oil (yield 90%). α D25 -6.2 (c 1.89). 1H NMR (400 MHz): δ 2.31 (dd, J=6.1, J=14.1, 1H, H-2a), 2.53 (dd, 
J=8.8, J=13.5, 1H, H-4b), 2.63 (dd, J=8.6, J=14.1, 1H, H-2b), 3.08 (dd, J=5.7, J=13.5, 1H, H-4b), 3.46 
(m, 1H, H-3), 3.52 (d, J=13.4, 2H, 2xMpm-CHaHb), 3.56 (s, 3H, OMe), 3.66 (d, J=13.4, 2H, 2xMpm-
CHaHb), 3.80 (s, 6H, 2xMpm-OMe), 6.83 (d, J=8.7, 4H, 2xMpm-H-3 and H-5), 7.06-7.26 (m, 9H, 5xH-
Ar, 2x Mpm-H-2 and H-6). 13C NMR (100 MHz): δ 36.0, 51.2, 52.4, 55.1, 57.1, 113.4, 125.9, 128.2, 
129.1, 129.8, 131.5, 139.4, 158.5, 172.7. Anal. Calcd. for C27H31NO4: C 74.80, H 7.21. Found C 74.69, 
H 7.23. 
Methyl (R)-3-[Bis(4-methoxybenzyl)amino]-3-phenylpropanoate (7) 
Oil (yield 83%). α D25 +77.5 (c 2.11). 1H NMR (200 MHz): δ 2.71 (dd, J=7.2, J=14.5, 1H, H-2a), 3.09 (d, 
J=13.6, 2H, 2xMpm-CHaHb), 3.07-3.18 (m, 1H, H-2b), 3.64 (s, 3H, OMe), 3.69 (d, J=13.6, 2H, 2xMpm-
CHaHb), 3.79 (s, 6H, 2xMpm-OMe), 4.29 (dd, J=7.2, J=8.7, 1H, H-3), 6.85 (d, J=8.7, 4H, 2xMpm-H-3 
and H-5), 7.23-7.41 (m, 9H, 5xH-Ar, 2xMpm-H-2 and H-6). 13C NMR (100 MHz): δ 36.4, 51.4, 52.6, 
55.1, 58.5, 113.5, 127.3, 128.0, 128.5, 129.8, 131.6, 137.6, 158.6, 172.0. Anal. Calcd. for C26H29NO4: 
C 74.44, H 6.97. Found C 74.79, H 6.93. 
Methyl (R)-4-(Benzyloxy)-3-[bis(4-methoxybenzyl)amino]butanoate (10) 
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Oil; (yield 85%). 1H NMR (400 MHz): δ 2.51 (dd, J=6.4, J=14.3, 1H, H-2a), 2.64 (dd, J=7.7, J=14.3, 1H, 
H-2b), 3.48 (m, 1H, H-3), 3.52-3.57 (m, 3H, 2xMpm-CHaHb, H-4a), 3.58 (s, 3H, OMe), 3.63-3.68 (m, 
3H, 2xMpm-CHaHb, H-4b), 3.79 (s, 6H, 2xMpm-OMe), 4.48 (s, 2H, 2xH-5), 6.83 (d, J=8.7, 4H, 2xMpm-
H-3 and H-5), 7.21 (d, J=8.7, 4H, 2xMpm-H-2 and H-6), 7.30-7.36 (m, 5H, H-Ar). 13C NMR (75 MHz): δ 
34.5, 51.4, 53.4, 54.7, 55.2, 70.2, 73.1, 113.5, 127.5, 128.3, 129.9, 132.0, 138.3, 158.6, 172.8. Anal. 
Calcd. for C20H25NO4: C 72.55, H 7.18. Found C 72.31, H 7.22. 
Introduction of methyl group  
Methyl 3-(bis(4-methoxybenzyl)amino)-2-methylpropanoate (2) 
To a magnetically stirred solution of 1 (0.45 mmol, 0.15 g) in anhydrous THF (8 mL), 0.5 M KHDMS in 
THF (1.80 mL, 0.93 mmol) was added dropwise, at -78 °C and under anhydrous argon,. After 1 h, 
CH3I (0.49 mmol, 0.31 mL) was added to the solution in one portion, and the reaction mixture was kept 
at -78 °C whilst stirring. Within 90 min, the reaction was quenched by addition of 10% aq NH4Cl (50 
mL) and extracted with ethyl acetate. The organic layer was washed with brine until neutral and dried 
(Na2SO4), and the solvents were evaporated in vacuo. The residue (180 mg) was purified by 
chromatography on silica gel (hexane/ethyl acetate, 9:1) afforded the pure, yellow oily title compound 
2 (0.10 g, yield 61%). 1H NMR (500 MHz): δ 1.10 (d, J=6.3, 3H, CH3), 2.35-2.43 (m, 1H, H-2), 2.70-
2.80 (m, 2H, H-3a and H-3b), 3.40 (d, J=13.3, 2H, 2xMpm-CHaHb), 3.54 (d, J=13.3, 2H, 2xMpm-
CHaHb), 3.64 (s, 3H, OMe), 3.80 (s, 6H, 2xMpm-OMe), 6.83 (d, J=8.4, 4H, 2xMpm-H-3 and H-5), 7.20 
(d, J=8.4, 4H, 2xMpm-H-2 and H-6). 13C NMR (125 MHz): δ 15.5, 38.9, 51.7, 55.5, 57.3, 57.8, 113.7, 
130.2, 131.6, 158.8, 176.5. Anal. Calcd. for C21H27NO4: C 70.56, H 7.61, N 3.92. Found C 70.53, H 
7.59; N 3.90. 
Under the same conditions (but 2.2 eq. of CH3I instead 1.1), the other α-methyl-β3-amino acids were 
also obtained. 
(2S,3S)-Methyl 3-(bis(4-methoxybenzyl)amino)-2-methyl-4-phenylbutanoate (5) 
Oil; (yield 97%, d.r. 93:7). 1H NMR (400 MHz): δ 1.03 (d, J=6.9, 3H, CH3), 2.74 (dd, J=7.1, J=14.2, 1H, 
H-4a), 2.83-2.88 (m, 1H, H-2), 3.10 (dd, J=6.1, J=14.2, 1H, H-4b), 3.24-3.27 (m, 1H, H-3), 3.41 (d, 
J=13.5, 2H, 2xMpm-CHaHb), 3.63 (s, 3H, OMe), 3.69 (d, J=13.5, 2H, 2xMpm-CHaHb), 3.81 (s, 6H, 
2xMpm-OMe), 6.84 (d, J=8.6, 4H, 2xMpm-H-3 and H-5), 7.15 (d, J=8.6, 4H, 2xMpm-H-2 and H-6), 
7.17-7.30 (m, 5H, 5xH-Ar). 13C NMR (100 MHz): δ 16.0, 33.6, 43.2, 51.8, 53.8, 55.6, 62.4, 113.8, 
126.3, 128.7, 129.7, 130.5, 132.1, 141.4, 158.9, 176.2. Anal. Calcd. for C28H33NO4: C 75.14, H 7.43, N 
3.13. Found C 75.17, H 7.45, N 3.15. 
(2S,3R)-Methyl 3-(bis(4-methoxybenzyl)amino)-2-methyl-3-phenylpropanoate (8) 
Oil; (yield 80%, d.r. 9:1). 1H NMR (500 MHz): δ 1.46 (d, J=6.8, 3H, CH3), 2.92 (d, J=13.7, 2H, 2xMpm-
CHaHb), 3.30 (s, 3H, OMe), 3.31-3.37 (m, 1H, H-2), 3.74-3.86 (m, 9H, H-3, 2xMpm- CHaHb and 
2xMpm-OMe), 6.88 (d, J=8.8, 4H, 2xMpm-H-3 and H-5), 7.18-7.40 (m, 9H, 5xH-Ar, 2x Mpm-H-2 and 
H-6).13C NMR (125 MHz): δ 16.5, 42.1, 51.5, 53.1, 55.5, 64.2, 114.0, 127.6, 128.0, 129.6, 130.1, 
131.9, 135.8, 158.8, 175.9. Anal. Calcd. for C27H31NO4: C 74.80, H 7.21, N 3.23. Found C 74.82, H 
7.24, N 3.25. 
(2S,3R)-Methyl 4-(benzyloxy)-3-(bis(4-methoxybenzyl)amino)-2-methylbutanoate (11) 
Oil; (yield 89%, d.r. 94:6). 1H NMR (400 MHz): δ 1.23 (d, J=7.0, 3H, CH3), 2.74-2.84 (m, 1H, H-2), 
3.05-3.10 (m, 1H, H-3), 3.49 (d, J=13.6, 2H, 2xMpm-CHaHb), 3.55 (s, 3H, OMe), 3.65 (dd, J=4.6, 
J=10.0, 1H, H-4a), 3.73 (dd, J=5.5, J=10.0, 1H, H-4b), 3.78-3.83 (m, 8H, 2xMpm-CHaHb and 2xMpm-
OMe), 4.46 (d, J=12.0, 1H, Bzl-Ha), 4.53 (d, J=12.0, 1H, Bzl-Hb), 6.85 (d, J=8.6, 4H, 2xMpm-H-3 and 
H-5), 7.22 (d, J=8.6, 4H, 2xMpm-H-2 and H-6), 7.30-7.45 (m, 5H, H-Ar). 13C NMR (100 MHz): δ 16.3, 
40.9, 51.8, 54.2, 55.7, 59.5, 68.4, 73.6, 113.9, 127.8, 127.9, 128.7, 130.4, 132.5, 138.8, 158.9, 176.7. 
Anal. Calcd. for C29H35NO5 C 72.93, H 7.39, N 2.93. Found C 72.95, H 7.41, N 2.96. 
Introduction of benzyl group  
Under the same conditions of α-methylation (but using BnBr instead CH3I as electrophile) the α-
benzyl-β-amino acids were also obtained (1.1 eq. of BnBr for benzylation of β-alanine and 2.2 eq. for 
the other β3-amino acids). 
Methyl 2-benzyl-3-(bis(4-methoxybenzyl)amino)propanoate (3) 
Oil, (yield 65%). 1H NMR (500 MHz): δ 2.49 (dd, J=6.1, J=12.4, 1H, H-4a), 2.74 -2.82 (m, 3H, H-4b, H-3 
a and H-3 b), 2.94-3.10 (m, 1H, H-2), 3.37 (d, J=13.6, 2H, 2xMpm-CHaHb), 3.57 (s, 3H, OMe), 3.58 (d, J 
=13.6, 2H, 2xMpm-CHaHb), 3.80 (s, 6H, 2xMpm-OMe), 6.84 (d, J=8.3, 4H, 2xMpm-H-3 and H-5),  7.08 
(d, J=7.6, 2H, 2xPh-3H and H-5 ), 7.16-7.31 (m, 7H, 3xPh-H, 2xMpm-H-2 and H-6). 13C NMR (125 
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MHz): δ 36.7, 47.2, 55.4, 55.5, 57.8, 57.9, 113.7, 128.9, 130.2, 130.4, 131.3, 139.5, 158.8, 175.2. 
Anal. Calcd. for C27H31NO4: C 74.80, H 7.21, N 3.23. Found C 74.83, H 7.19, N 3.26. 
(2S,3S)-Methyl 2-benzyl-3-(bis(4-methoxybenzyl)amino)-4-phenylbutanoate (6) 
Oil, (yield 90%, d.r. 97:3). 1H NMR (400 MHz): δ 2.62 (dd, J=5.0, J =13.7, 1H, H-5a), 2.70 (dd, J=10.7, 
J=13.7, 1H, H-5b), 2.85 (dd, J=7.7, J=14.2, 1H, H-4a), 3.04-3.10 (m, 1H, H-2), 3.25 (dd, J=5.5, J=14.2, 
1H, H-4b), 3.34- 3.40 (m, 1H, H-3), 3.42 (d, J=13.3, 2H, 2xMpm-CHaHb), 3.50 (s, 3H, OMe), 3.76 (d, 
J=13.3, 2H, 2xMPM-CHaHb), 3.80 (s, 6H, 2xMpm-OMe), 6.85 (d, J=8.7, 4H, 2xMpm-H-3 and H-5), 
6.80-7.7 (m, 14H, 10xH-Ar, 2x Mpm-H-2 and H-6). 13C NMR (125 MHz): δ 33.8, 36.6, 51.3, 51.8, 53.6, 
55.4, 61.5, 113.6, 126.3, 128.4, 128.7, 128.8, 129.4,129.6, 130.2, 130.4, 131.7, 139.7, 158.8, 174.3. 
Anal. Calcd. for C34H37NO4: C 77.98, H 7.12, N 2.67. Found C 78.00, H 7.15, N 2.70. 
(2S,3R)-Methyl 2-benzyl-3-(bis(4-methoxybenzyl)amino)-3-phenylpropanoate (9) 
Oil, (yield 75%, d.r. 92:8). 1H NMR (500 MHz): δ 2.69 (dd, J=11.6, J =13.6, 1H, H-4a), 3.02 (d, J=13.6, 
2H, 2xMpm-CHaHb), 3.08 (s, 3H, OMe), 3.49 (ddd, J =11.6, J=11.7, 1H, H-2), 3.79-3.92 (m, 9H, H-4b, 
2xMPM-CHaHb and 2xMpm-OMe), 3.90 (d, J=11.7, 1H, H-3), 6.90 (d, J= 8.7, 4H, 2xMpm-H-3 and H-5), 
7.10-7.42 (m, 14H, 10xH-Ar, 2x Mpm-H-2 and H-6). 13C NMR (125 MHz):  δ 37.5, 51.0, 51.1, 53.3, 
55.4, 64.0, 114.1, 126.5, 127.7, 128.0, 128.6, 129.0, 129.8, 130.2, 131.7, 135.0, 140.0, 158.9, 174.3. 
Anal. Calcd. for C33H35NO4: C 77.77, H 6.92, N 2.75. Found C 77.80, H 6.94, N 2.79. 
(2S,3R)-Methyl 2-benzyl-4-(benzyloxy)-3-(bis(4-methoxybenzyl)amino)butanoate (12) 
Oil, (yield 78%, 96:4). 1H NMR (400 MHz): δ 2.55 (dd, J=11.2, J=13.6, 1H, H-5a), 2.98 (ddd, J=3.5, 
J=11, J=11.2, 1H, H-2), 3.18-3.25 (m, 1H, H-3), 3.39 (s, 3H, OMe), 3.51 (dd, J=3.5, J=13.6, 1H, H-5b), 
3.59 (d, J=13.5, 2H, 2xMpm-CHaHb), 3.71 (dd, J=4.61, J=10.1, 1H, H-4a), 3.80 (dd, J=5.85, J=10.1, 
1H, H-4b), 3.86 (s, 6H, 2xMpm-OMe), 3.94 (d, J=13.5, 2H, 2xMPM-CHaHb), 4.50 (d, J=11.9, 1H, Bzl-
Ha), 4.56 (d, J=11.9, 1H, Bzl-Hb), 6.91 (d, J=8.6, 4H, 2xMpm-H-3 and H-5), 7.10 (d, J= 6.8, 2 H, H-Ar), 
7.19-7.45 (m, 12 H, 8xH-Ar, 2 x Mpm-H-2 and H-6). 13C NMR (75 MHz): δ 36.7, 49.3, 51.0, 53.8, 55.1, 
58.6, 67.8, 73.1, 113.6, 126.0, 127.4, 128.2, 130.0, 131.8, 138.2, 139.9, 158.5, 174.6. Anal. Calcd. for 
C35H39NO5: C 75.92, H 7.10, N 2.53. Found C 75.94, H 7.06, N 2.55. 
Introduction of hydroxymethyl group  
Methyl 3-(bis(4-methoxybenzyl)amino)-2-(hydroxymethyl)propanoate (13) 
To a magnetically stirred solution of 1 (0.48 mmol, 0.16 g) in anhydrous THF (8.3 mL), 0.5 M KHDMS 
in THF (1.92 mL, 0.96 mmol) was added dropwise, at -78 °C and under anhydrous argon,. After 1 h, 
the solution is let to reach -20 °C; HCHO (g), generated by cracking of paraformaldehyde (3.84 mmol, 
0.12 mg) at 220 °C is then bubbled into the solution by nitrogen flow and the system is cooled again at 
-78 °C. Within 90 min, the reaction was quenched by addition of 10% aq NH4Cl (50 mL) and extracted 
with ethyl acetate. The organic layer was washed with brine until neutral and dried (Na2SO4), and the 
solvents were evaporated in vacuo. The residue (265 mg) was purified by chromatography on silica 
gel (hexane/ethyl acetate, 7:3) afforded the pure, yellow oily title compound 13 (0.15 mg, yield 85%). 
1H NMR (500 MHz): δ 2.76 (dd, J=4.6, J=12.9, 1H, H-3a), 2.86 (dd, J=10.2, J=12.9, 1H, H-3 b), 2.94-
3.10 (m, 1H, H-2), 3.28 (d, J=13.2, 2H, 2xMpm-CHaHb), 3.65 (s, 3H, OMe), 3.73-3.90 (m, 10H, 
2xMpm-OMe, 2xMpm-CHaHb, 2xCHaHbOH), 6.82 (d, J=8.4, 4H, 2xMpm-H-3 and H-5), 7.20 (d, J=8.4, 
4H, 2xMpm-H-2 and H-6). 13C NMR (125 MHz): δ 44.3, 51.6, 53.8, 55.1, 57.8, 63.9, 113.7, 129.8, 
130.4, 158.7, 172.9. Anal. Calcd. for C21H27NO5: C 67.54, H 7.29, N 3.75. Found C 67.57, H 7.31, N 
3.77. 
Methyl 2-((bis(4-methoxybenzyl)amino)methyl)acrylate (14) 
Oil. 1H NMR (400 MHz): δ 3.27 (s, 2H, 3’-H), 3.50 (s, 4H, 2xMpm-CH2), 3.72 (s, 3H, OMe), 3.79 (s, 6H, 
2xMpm-OMe), 6.00 (s, 1H, H-3a), 6.25 (s, 1H, H-3b), 6.82 (d, J=8.4, 4H, 2xMpm-H-3 and H-5), 7.20 (d, 
J=8.4, 4H, 2xMpm-H-2 and H-6). 13C NMR (50 MHz): δ 51.5, 53.5, 55.1, 57.1, 113.4, 125.8, 129.5, 
131.2, 138.2, 158.5, 167.4. Anal. Calcd. for C21H25NO4: C 70.96, H 7.09, N 3.94. Found C 70.99, H 
7.11, N 3.97. 
Under the same conditions, the other α-hydroxymethyl-β3-amino acids were also obtained. 
(2R,3S)-Methyl 3-(bis(4-methoxybenzyl)amino)-2-(hydroxymethyl)-4-phenylbutanoate 
(15) 
Oil, (yield 65%, d.r. 99:1). 1H NMR (500 MHz): δ 2.66-2.68 (m, 1H, H-2), 2.92 (dd, J=9.06, J=13.6, 1H, 
H-4a), 3.14 (dd, J=4.7, J=13.6, 1H, H-4b), 3.32-3.40 (m, 3H, H-3 and 2xMPM-CHaHb), 3.52 (dd, J=4.89, 
J =11.4,1H, CHaHbOH ), 3.61 (dd, J=6.8, J =11.4, CHaHbOH), 3.70 (s, 3H, OMe), 3.80 (m, 8H, 2xMpm-
CHaHb and 2xOMe-Mpm), 6.57 (d, J=8.7, 4H, 2xMpm-H-3 and H-5), 6.80-7.70 (m, 9H, 5xH-Ar, 
2xMpm-H-2 and H-6). 13C NMR (175 MHz): δ 32.7, 49.5, 51.8, 54.1, 55.4, 59.6, 62.4, 113.9, 126.4, 
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128.5, 129.5, 129.6, 131.6, 140.2, 159.9, 174.2. Anal. Calcd. for C28H33NO5: C 72.55, H 7.18, N 3.02. 
Found C 72.58, H 7.22, N 3.07. 
(2R,3R)-Methyl 3-(bis(4-methoxybenzyl)amino)-2-(hydroxymethyl)-3-phenylpropanoate 
(16) 
Oil, (yield 88%, 97:3). 1H NMR (500 MHz): 2.89 (d, J=13.4, 2H, 2xMpm-CHaHb), 3.39-3.47 (m, 2H, 
2xCH2OH), 3.53-3.59 (m, 1H, H-2), 3.80 (s, 6H, 2xMpm-OMe), 3.84 (s, 3H, OMe), 3.90 (d, J=13.4, 2H, 
2xMpm-CHaHb), 4.10 (d, J=12.2 1H, H-3), 6.70 (d, J=8.7, 4H, 2xMpm-H-3 and H-5), 7.19-7.32 (m, 9H, 
5xH-Ar, 2x Mpm-H-2 and H-6). 13C NMR (125 MHz): 50.2, 51.7, 52.8, 55.9, 60.8, 61.9, 113.5, 127.7, 
128.2, 129.2, 129.7, 131.1, 133.6, 158.4, 174.1. Anal. Calcd. for C27H31NO5: C 72.14, H 6.95, N 3.12. 
Found C 72.17, H 6.99, N 3.15. 
(2R,3R)-Methyl 4-(benzyloxy)-3-(bis(4-methoxybenzyl)amino)-2-
(hydroxymethyl)butanoate (17) 
Oil, (yield 78%, d.r. 95:5). 1H NMR (500 MHz): 3.08-3.13 (m, 1H, H-2), 3.31-3.36 (m, 1H, H-3), 3.36 (d, 
J=13.7, 2H, 2xMPM-CHaHb), 3.65 (s, 3H, OMe), 3.66-3.71 (m, 2H, H-4a, 1xCHaHbOH), 3.73- 3.78 (m, 
2H, H-4b, 1xCHaHbOH), 3.79 (s, 6H, 2xMpm-OMe), 3.85 (d, J=13.7, 2H, 2xMPM-CHaHb), 4.50 (d, J 
=12.2, 1H, Bzl-Ha), 4.55 (d, J=12.2, 1H, Bzl-Hb), 6.82 (d, J=8.3, 4H, 2xMpm-H-3 and H-5), 7.15 (d,  
J=8.3, 4H, 2xMpm-H-2 and H-6), 7.30- 7.40 (m, 5H, 5xBzl-aromatici-H). 13C NMR (50 MHz): 49.0, 51.5, 
53.7, 55.1, 56.4, 61.5, 66.5, 113.4, 127.5, 127.7, 128.4, 130.0, 131.4, 137.7, 158.5, 174.2. Anal. Calcd. 
for C29H35NO6: C 70.57, H 7.15, N 2.84. Found C 70.59, H 7.18, N 2.87. 
Synthesis of Lipo-β-Amino Acids 
Benzylation of the Amino Group of β-Alanine 
tert-Butyl 3-(dibenzylamino)propanoate (25) 
A magnetically stirred suspension of β-alanine tert-butyl ester (0.39 g; 3.40 mmol) and 
diisopropylethylamine (DIPEA, 2.9 mL; 17.0 mmol) in toluene (10 mL) was gently warmed until a clear 
solution was obtained. Benzyl chloride (2.43 mL; 20.4 mmol) was then added in one portion, and the 
resulting solution was heated under reflux until the starting β-alanine tert-butyl ester, and also the 
intermediate N-monosubstituted derivative, were completely consumed (ca. 3 h, TLC monitoring). The 
reaction mixture was then cooled in an ice bath, diluted with ethyl acetate (50 mL), and extracted with 
10% aq. NH4Cl. The organic layer was washed with brine and dried (Na2SO4), and the solvents were 
evaporated under reduced pressure to afford a crude reaction product, chromatography of which on 
silica gel (petroleum ether/ Et2O, 8:2) gave the pure, oily title compound 25 (0.35 g; yield 97%). 1H 
NMR (500 MHz): δ 1.41 (s, 9H, t Bu-H), 2.41 (t, J=7.3, 2H, H-2), 2.80 (t, J=7.3, 2H, H-3), 3.60 (s, 4H, 
2xCH2-Ph), 7.20-7.40 (m, 10H, H-Ar). 13C NMR (125 MHz): δ 28.3, 34.1, 49.6, 58.2, 80.4, 127.1, 128.4, 
129.0, 139.6, 172.2. Anal. Calcd. for C21H27NO2: C 77.50, H 8.36, N 4.30. Found C 77.53, H 8.38, N 
4.33. 
Under the same conditions, the N-benzyl-β-ala-OMe was also obtained. 
Methyl 3-(dibenzylamino)propanoate (28) 
Oil, (yield 90%). 1H NMR (500 MHz): δ 2.50 (t, J=7.3, 2H, H-2), 2.80 (t, J=7.3, 2H, H-3), 3.58 (s, 4H, 
2xCH2-Ph), 3.62 (s, 3H, OMe), 7.41-7.70 (m, 10H, H-Ar). 13C NMR (50 MHz): δ 32.6, 49.1, 51.4, 58.0, 
127.0, 128.1, 128.7, 139.2, 172.9. Anal. Cald. for C18H21NO2: C 76.29, H 7.47, N 4.94. Found C 76.31, 
H 7.49, N 4.97. 
Preparation of the electrophile 
1-Iodopentadecane (19) 
To solid iodine (4.2 g, 16.4 mmol) was slowly added a solution of triphenylphosphine (4.3 g, 16.4 
mmol) in anhydrous CH2Cl2 (120 mL) at room temperature, in inert atmosphere and under magnetic 
stirring; after 15 minutes imidazole (2.2 g, 32.9 mmol) was added. The mixture was then left for other 
15 minutes at room temperature. 1-Pentadecanol 18 (3.0 g, 13.1 mmol), in anhydrous CH2Cl2, was 
finally added to the suspension and the reaction was allowed to reflux until the starting material was 
completely consumed (1h, TLC, petroleum ether). The solvent was then evaporated under reduced 
pressure and the residue, diluted with EtOAc (150 mL) was washed with 10% aq. Na2S2O4 (40 mL) 
and then brine (3 x 50 mL) until neutrality. The organic layer was finally dried (Na2SO4) and 
evaporated in vacuum to give a crude that is finally easily purified by chromatography in petroleum 
ether to give the iodopentadecane as colourless oil 19 (4.3 g; yield 97%). 1H NMR: δ 0.88 (t, J=6.8, 3H, 
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H-15), 1.20-1.44 (m, 24 H, 12xCH2), 1.82 (dt, J=7.3, 2H, H-2), 3.19 (t, J=7.3, 2H, H-1). 13C NMR: δ 7.6, 
14.3, 22.9, 28.8, 29.6-29.9, 30.7, 32.1, 33.8.  
tert-Butyl 2-((dibenzylamino)methyl)heptadecanoate (26) 
To a magnetically stirred solution of hexamethyldisilazane (HMDS, 0.12 mL, 0.58 mmol) and 
butyllithium (1.6 M in hexane, 0.36 mL, 0.582 mmol) in anhydrous THF (5 mL), was added dropwise at 
-78 °C a solution of 25 (0.29 mmol, 0.024 g) in anhydrous THF. After 1 h, iodopentadecane (0.64 
mmol, 0.22 mg) was added to the solution in one portion, and the reaction mixture was let to reach 0 
°C whilst stirring. Within 30 min, the reaction was quenched by addition of 10% aq NH4Cl (50 mL) and 
extracted with ethyl acetate. The organic layer was washed with brine until neutral and dried (Na2SO4), 
and the solvents were evaporated in vacuo. The residue was purified by chromatography on silica gel 
(hexane/ethyl acetate, 99:1) afforded the pure, yellow oily title compound 2 (0.14 g, yield 95%). 1H 
NMR (400 MHz): δ 0.88 (t, J=6.7, 3H, H-17), 1.26-1.30 (s, 26H, H-alifatici), 1.35-1.55 (m, 11H, H-3 and 
OtBu), 2.37 (dd, J=5.5, J=12.4, 1H, H-3’a), 2.53-2.60 (m, 1H, H-2), 2.76 (dd, J=9.1, J=12.4, 1H, H-3’b), 
3.43 (d, J=13.6, 1H, 2xCHaHb-Ph), 3.65 (d, J=13.6, 1H, 2xCHaHb-Ph), 7.18-7.35 (m, 10H, H-Ar) 13C 
NMR (50 MHz):  δ 14.5, 23.1-32.3, 45.7, 56.9, 58.8, 80.3, 127.2, 128.5, 129.3, 139.7, 175.3. Anal. 
Calcd. for C36H57NO2: C 80.69, H 10.72, N 2.61. Found C 80.71, H 10.74, N 2.63. 
Under the same conditions, the mono-alkylated 29 was also obtained. 
Methyl 2-((dibenzylamino)methyl)heptadecanoate (29) 
Oil, (3h, yield 60%). 1H NMR (300 MHz): δ 0.78 (m, 3H, H-17), 1.10-1.26 (m, 26H), 1.28-1.41 (m, 2H, 
H-3), 2.38 (dd, 1H, J=4.3Hz, J=11.5, H-3’a), 2.54-2.72 (m, 2H, H-2 and H-3’b), 3.30 (d, J=13.4, 2H, 2x-
CHaHbPh), 3.53 (s, 3H, OMe), 3.58 (d, J=13.4, 2H, 2xCHaHbPh), 7.05-7.30 (m, 10H, H-Ar). 13C NMR 
(75 MHz):  δ 13.9, 22.5-31.7, 44.7, 51.1, 56.1, 58.2, 126.7, 127.9, 128.8, 139.1, 175.6. 
Under the same condition, but using KHMDS as base and the equivalents reported in Table 5.11 
(Chapter 5), the dialkylated products 27 was obtained. 
tert-Butyl 2-((dibenzylamino)methyl)-2-pentadecylheptadecanoate (27) 
Oil, (Total yield 99%, di-alkylation percentage 75%). 1H NMR (400 MHz): δ 0.88 (t, J=6.8, 6H, 2x H-17), 
1.18-1.34 (m, 52H), 1.39-1.60 (m, 13H, 2x H-3 and OtBu), 2.68 (s, 2H, H-3’), 3.48 (s, 4H, 2xCH2-Ph), 
7.18-7.35 (m, 10H, H-Ar). 13C NMR (50 MHz): δ 14.1, 22.7-32.6, 50.2, 58.8, 60.4, 80.0, 127.0, 128.1, 
129.2, 139.6, 176.8. 
Under the same condition, but using KHMDS as base and the equivalents reported in Table 5.10 
(Chapter 5), the dialkylated products 30 was obtained. 
Methyl 2-((dibenzylamino)methyl)-2-pentadecylheptadecanoate (30) 
Oil, (Total yield 81%, dialkylation percentage 60%). 1H NMR (400 MHz): δ 0.87 (t, J=6.8, 6H, 2x H-17), 
1.10-1.35 (m, 52H), 1.40-1.60 (m, 4H, 2x H-3), 2.72 (s, 2H, H-3’), 3.45 (s, 4H, 2xCH2-Ph), 3.58 (s, 3H, 
OMe), 7.18-7.33 (m, 10H, H-Ar). 13C NMR (50 MHz): δ 14.5, 23.1-32.7, 50.5, 51.8, 59.4, 57.7, 59.5, 
127.3, 128.5, 129.6, 139.9, 178.4. 
Methyl 2-((bis(4-methoxybenzyl)amino)methyl)heptadecanoate (20) 
Oil. 1H NMR (500 MHz): δ 0.95 (t, 3H, J=6.6, H-17), 1.10-1.36 (m, 26H), 1.37-1.56 (m, 2H, H-3), 2.41 
(dd, 1H, J=4.4, J=11.2, H-3’a), 2.65-2.76 (m, 2H, H-2 and H-3’b), 3.31 (d, J=13.4, 2H, 2xMpm-CHaHb), 
3.60 (d, J=13.4, 2H, 2xCH2-Mpm), 3.65 (s, 3H, OMe), 3.80 (s, 6H, 2xOMe-MPM), 6.85 (d, J=8.3, 4H, 
2xH-2 and H-6-MPM), 7.20 (d, J=8.3, 4H, 2xH-3 and H-5-Mpm). 13C NMR (125 MHz):  δ 14,6, 23.1, 
27.7, 30.7, 32.2, 45.0, 51.4, 55.3, 56.0, 57.6, 112.9, 129.3, 130.6, 157.6, 174.7. 
Methyl 2-((bis(4-methoxybenzyl)amino)methyl)-2-pentadecylheptadecanoate (21) 
Oil. 1H NMR (500 MHz): δ 0.90 (t, J=6.8, 6H, 2x H-17), 1.10-1.40 (m, 52H), 1.41-1.60 (m, 4H, 2x H-3), 
2.64 (s, 2H, H-3’), 3.36 (s, 4H, 2xCH2-Mpm), 3.60 (s, 3H, OMe), 3.80 (s, 6H, 2xOMe-Mpm), 6.82 (d, 
J=8.7, 4H, 2xH-2 and H-6-Mpm), 7.20 (d, J=8.7, 4H, 2xH-3 and H-5-Mpm). 
13C NMR (200 MHz): δ 14.1, 22.6-32.4, 49.8, 51.6, 55.2, 57.7, 58.1, 113.7, 129.5, 130.9, 159.0, 177.5. 
Deprotection Reactions 
N-Deprotection 
Methyl 2-(aminomethyl)heptadecanoate (22) 
A magnetically stirred solution of 26 (0.61 mmol, 300 mg) in glacial AcOH (3.1 mL) was 
hydrogenolysed over 30% Pd/C catalyst (90 mg) for 2 h at 50 °C, under a slightly positive pressure 
given by an inflated balloon (~3 bar). The mixture was then filtered trough Celite® and washed with 
MeOH (100 mL). The solvent was removed under reduced pressure and the residue was dissolved in 
EtOAc (2x100 mL). The organic layer was washed with 10% aq Na2CO3 (300 mL), dried (Na2SO4), 
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and the solvent evaporated in vacuo to give the pure, title compound 22, as dark oil (172 mg, yield 
90%). 1H NMR (400 MHz): δ 0.89 (t, J= 6.5, 3H, H-17), 1.23-1.37 [m, 26 H, (CH2)13], 1.39-1.50 (m, 1H, 
H-3), 1.52-1.63 (m, 1H, H-3b), 2.41-2.47 (m, 1H, H-2), 2.82 (dd, J=4.7, J=12.8, 1H, H-3’a), 2.92 (dd, 
J=8.3, J=12.8, 1H, H-3’b), 3.71 (s, 3H, OMe). 13C NMR (100 MHz): δ 14.5, 23.1, 27.7, 29.5-30.5, 32.3, 
44.4, 49.5, 51.9, 176.3. 
Under the same conditions, the dialkylated product 36 was also obtained. 
tert-Butyl 2-(aminomethyl)-2-pentadecylheptadecanoate (36) 
Yellow solid (yield 91%). Mp 46.5-47.8 (from CH3CN). 1H NMR (400 MHz): δ 1.10-1.40 [m, 52 H, 
2x(CH2)13], 1.45 (s, 9H, OtBu), 1.46-1.62 (m, 4H, H-3, H-3”), 2.90 (s, 2H, H-3’). 13C NMR: δ 14.1, 16.9, 
22.6, 23.8, 28.0, 29.3, 29.4, 29.7-31.9, 33.4, 45.3, 48.1, 80.7, 177.9. 
Hydrolysis of methyl ester and Boc- protection of amino function 
2-((tert-Butoxycarbonylamino)methyl)heptadecanoic acid (23) 
To a solution of compound 22 (96 mg; 0.31 mmol) in MeOH (1.8 mL), NaOH (52mg; 1.3 mmol) in H2O 
(1 mL) was added. The reaction mixture was kept at room temperature and magnetic stirring for 12h. 
The solvent was then removed under reduced pressure; the residue was then diluted with H2O (7 mL) 
and Boc2O (135 mg; 0.62mmol) in CH3CN (2 mL). The reaction mixture was kept for other 12 h at 
room temperature and under magnetic stirring. Thus the solvent was removed under reduced 
pressure and the residue was dissolved in EtOAc (2x50 mL). The organic layer was washed with iced 
0.1 M HCl (2x25 mL), dried (Na2SO4), and the solvent evaporated in vacuo to give a crude whose 
purification by chromatography afford to the pure, compound 23 (90 mg; yield 73%). Crystalline white 
solid. Mp 73.2-74.3 (from CH3CN). 1H NMR (400 MHZ) (Mixture of conformers): δ 0.85 (bt, 3H, H-17), 
1.23-1.78 [m, 37H, (CH2)14, Boc], 2.62 (bs, 1H, H-2), 3.10-3.50 (m, 2H, H-3’), 5.00 (bs, 1H, NH). 13C 
NMR (100 MHz): δ (The minor conformer is labelled with *) 14.1, 22.7, 27.0, 28.3, 29.4-29.7, 31.9, 
41.4, 42.7*, 45.6, 79.5, 81.0*, 155.9, 158.0*, 179.0*, 180.4. 
Hydrolysis of tert-butyl ester and Boc- protection of the amino function 
2-((dibenzylamino)methyl)-2-pentadecylheptadecanoic acid (37) 
To a solution of compound 27 (314 mg; 0.42 mmol) in CH2Cl2 (2 mL) was added TFA (1 mL) and the 
reaction was kept at room temperature for 30 min. The solvent is then removed in vacuo and the 
residue diluted with EtOAc. The organic layer was washed with brine until neutral, dried (Na2SO4), and 
the solvent evaporated in vacuo to give a yellow solid. Its recrystallization from CH3CN afforded the 
pure title compound 37 (290 mg; yield >99%). Mp 38.0-39.0. 1H NMR (400 MHz): δ 0.88 (t, J=6.6, 6H, 
H-17, H-17”), 1.10-1.36 [m, 52H, 2x(CH2)13], 1.38-1.62 (m, 4H, H-3, H-3”), 2.87 (s, 2H, H-3’), 3.79 (s, 
4H, 2xCH2Ph), 7.28-7.41(m, 10H, H-Ar). 13C NMR (75 MHz): δ 13.8, 22.4, 23.5, 29.1-29.9, 31.7, 35.5, 
48.0, 56.9, 59.0, 60.1, 127.9, 128.6, 129.5, 135.5, 178.1. 
2-((tert-Butoxycarbonylamino)methyl)-2-pentadecylheptadecanoic acid (38) 
Under the same conditions used to deprotect 26 and 27, the compound 37 (180 mg; 0.21 mmol) was 
also deprotected. The residue coming from the debenzylation of 37 (162 mg) was in turn protected as 
Boc derivative 38. Thus, the crude was diluted with dioxane (3.0 mL); to this solution, at 0 °C, Et3N 
(0.06 mL; 0.27 mmol) and Boc2O (128 mg; 0.78 mmol) were added in sequence. The reaction mixture 
was warmed up to room temperature and stirred for 12 h; then the solvent was removed in vacuo and 
the residue diluted with EtOAc. The organic layer was washed with aq NH4Cl and then brine until 
neutral, dried (Na2SO4), and the solvent evaporated in vacuo to give a oil. Its chromatography on silica 
gel (petroleum ether/Et2O) afforded the pure title compound 38 (122 mg; yield >95%). Oil. 1H NMR 
(200 MHz): δ 0.87 (bt, 6H, H-17, H-17”), 1.10-1.38 [m, 52H 2x(CH2)13], 1.39-1.60 (m, 13H, H-3, H-3”, 
OtBu), 3.26 (d, J=6.2, 2H, H-3’), 4.79 (t, J=6.2, 1H, NH). 13C NMR (50 MHz): δ 14.1, 22.7, 23.9, 28.0-
29.7, 30.2, 31.9, 34.2, 43.8, 50.2, 80.5, 155.9, 181.0. 
Peptide Synthesis 
Preparation of Tripeptide 34 
Coupling product from the reaction between the compounds 22 and 31.  
Methyl 2-((3-(tert-butoxycarbonylamino)propanamido)methyl)heptadecanoate (32) 
To a solution of triphenylphosphine (0.15 mmol, 38.5 mg) in anhydrous CH2Cl2 (5 mL) at room 
temperature, under inert atmosphere of N2 and under magnetic stirring, solid I2 is added (0.15 mmol, 
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37.3 mg) in one portion. After 15 minutes, when the colour of the solution changes from violet to 
orange, solid imidazole is added (0.47 mmol, 32 mg) and the colour changes again to yellow. After 15 
minutes, compound 31 (0.12 mmol, 23.0 mg), is finally added in one portion to the suspension, and 
the mixture goes at room temperature until the end of the starting acid (∼4 h, TLC CHCl3:CH3OH 98:2). 
At that point, the compound 22 (0.15 mmol, 46.0 mg) is added and the reaction goes for 12h at room 
temperature. Then the solvent is removed under reduced pressure and the residue, diluted in EtOAc 
(10 mL), is washed with 10% aq. Na2S203 (2x10 mL). The organic layer is then washed with brine, 
dried (Na2SO4), and evaporated in vacuo to afford a crude reaction product whose chromatography on 
silica gel (CHCl3) gave the pure 32 (47.2 mg, yield 80%) white solid. Mp 59.5-62.5 (from CH3CN). 1H 
NMR (500 MHz): δ 0.84 (t, J=6.5, 3H, H-17), 1.02-1.80 [m, 37H, (CH2)14, Boc], 2.27- 2.35 (m, 2H, H-
6’), 2.55-2.65 (m, 1H, H-2), 3.28-3.42 (m, 3H, H-3’a, H-7’), 3.47-3.57 (m, 1H, H-3’b), 3.70 (s, 3H, 
OMe), 5.18 (s, 1H, NHBoc), 6.02 (s, 1H, NH). 13C NMR (125 MHz): δ 14.3, 22.9, 27.3, 28.6- 29.9, 
32.1, 36.5, 36.9, 40.5, 40.6, 45.2, 45.4, 52.0, 52.2, 76.5, 156.3, 171.7, 175.9. 
Deprotection of 32. 
Methyl 2-((3-aminopropanamido)methyl)heptadecanoate (33) 
The same conditions used to obtaine 37 were also used to obtaine 33 (yield >99%). Mp 94.0-96.2 
(from MeOH/Et2O). 1H NMR (500 MHz, CD3OD): δ 0.90 (t, J=6.6, 3H, H-17), 1.21-1.42 [m, 26H, 
(CH2)13], 1.43-1.54 (m, 1H, H-3a), 1.55-1.65 (m, 1H, H-3b), 2.50-2.70 (m, 3H, H-2, H-6’), 3.16 (t, J=6.3, 
2H, H-7’), 3.30-3.36 (m, 1H, H-3’a), 3.39 (dd, J=5.4, J=13.7, 1H, H-3’b). 13C NMR (50 MHz, CD3OD): δ 
14.3, 23.6, 28.1, 30.4-30.9, 32.6, 33.0, 37.1, 42.0, 46.7, 52.3, 172.4, 176.6. 
Coupling product from the reaction between the compounds 33 and 23 
Methyl 2,2-dimethyl-4,8,12-trioxo-7-pentadecyl-3-oxa-5,9,13-triazatriacontane-15-
carboxylate (34) 
N
H
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O
N
H
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It was followed the same procedure used to prepare 32 (55.1 mg; yield 80%). Mp 86.9-89.2 (from 
CH2Cl2). 1H NMR (500 MHz): δ 0.83 (t, J=6.9, 6H, 2xCH3), 0.98-1.97 [m, 65H, 2x(CH2)14, Boc], 2.20-
2.40 (m, 3H, H-2), 2.45-2.65 (m, 1H, H-10), 3.10-3.60 (m, 6H, H-3, H-7, H-11), 3.68 (s, 3H, OMe), 5.10 
(bs, 1H, NH), 6.30 (bd, 1H, NH), 6.50 (bd, 1H, NH). 13C NMR (75 MHZ): d 14.1, 22.6, 27.1, 27.3, 
28.4, 29.3-30.1, 31.9, 35.5, 35.9, 40.4, 42.5, 45.2, 47.2, 51.9, 79.2, 156.2, 171.7, 174.6, 175.7. Mass 
(ESI+): M/z 765 (M+) for C45H87N3O6. 
Preparation of Dipeptide 35 
Coupling product from the reaction between the compounds 22 and 23 
Methyl 2-((2-((tert-
butoxycarbonylamino)methyl)heptadecanamido)methyl)heptadecanoate (35) 
BocHN N
H
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O O
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Mp 80.0-82.1 (form CH3CN). 1H NMR (400 MHz): δ 0.89 (t, J=6.9, 6H, 2XCH3), 1.17-1.72 [m, 65H, 
2x(CH2)14, Boc], 3.17 (dd, J=8.6, J=13.7, 1H, H-7a), 3.25-3.42 (m, 2H, H-7b, H-3a), 3.47-3.60 (m, 1H, 
H-3b), 3.71 (s, 3H, OMe), 4.81-5.10 (m, 1H, NHBoc), 5.95-6.05 (m, 1H, NH). 13C NMR (100 MHz): δ 
14.1, 22.7, 27.1, 27.3, 28.4, 29.3, 29.4-30.2, 31.9, 40.2, 42.7, 44.9, 47.5, 51.8, 79.2, 156.1, 174.6, 
175.7. 
Preparation of Dipeptide 39 
Coupling product from the reaction between the compounds 36 and 38 
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tert-Butyl 2-((2-(aminomethyl)-2-pentadecylheptadecanamido)methyl)-2-
pentadecylheptadecanoate (39) 
H2N NH
O
OO
R R R R
2
3
6
7
 
To a solution of 38 (96 mg, 0.16 mmol) in anhydrous CH2Cl2 (2.5 mL) at rt was added oxalyl chloride 
(0.07 µL, 0.8 mmol) and DMF [1 drop (0.0016 mmol)]. After stirring for 1 h, the reaction mixture was 
concentrated under reduced pressure and put under high vacuum for 15 min. The residual yellow oil 
was dissolved in CH2Cl2 (4 mL) and at rt was added DMAP (cat.), TEA (45 µL; 0. 83 mmol) and 36 (83 
mg; 16 mmol). After stirring for 5 h, the reaction mixture was washed with brine. The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3x). The combined organic layers were 
dried (Na2SO4) and concentrated under reduced pressure. Purification of the crude product by FC 
(petroleum ether/Et2O 100:0 → 95:5) afforded dipeptide 39 (31 mg, yield 69%) as a white solid. 1H 
NMR (500 MHz): δ 0.84 (t, J=6.3, 12H, 4xCH3), 1.10-1.73 [m, 121H, 4x(CH2)14, OtBu], 3.38 (s, 2H, H-
7), 3.48 (d, J=6.3, 2H, H-3), 6.87 (t, J=6.3, 1H, NH). 13C NMR (125 MHz): δ 14.0, 26.6, 22.6, 23.9, 
24.3, 28.0, 29.3-30.0, 31.8, 32.6, 34.2, 42.6, 47.9, 49.9, 58.1, 80.5, 175.7, 176.2. Mass (HiResMALDI): 
1058.092 (M+1) for C70H140N2O3. 
The same product can be prepared with a yield of 96% from 40, following the same procedure 
reported to have 36. 
Preparation of Tetrapeptide 42 
Coupling product from the reaction between the compounds 36 and 37 
tert-Butyl 2-((2-((dibenzylamino)methyl)-2-pentadecylheptadecanamido)methyl)-2-
pentadecylheptadecanoate (40) 
Bn2N NH
O
OO
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The same conditions used to prepare the dipeptide 39 were also used to obtaine the dipeptide 40 
(yield >99%). Mp 36.8-37.5 (from CH3CN). 1H NMR (500 MHz): δ 0.88 (t, J=7.0, 12H, 4xCH3), 1.02-
1.60 [m, 121H, 4x(CH2)14, OtBu], 2.64 (s, 2H, H-7), 3.27 (d, J=5.8, 2H, H-3), 3.48 (s, 4H, H-Bn), 6.55 
(t, J=5.8, 1H, NH), 7.18-7.34 (m, 10H, H-Ar). 13C NMR (125 MHz): δ 14.0, 22.6, 23.3, 23.8, 28.0, 29.3, 
29.4, 29.5, 29.6-29.7, 30.2, 30.7, 31.8, 32.5, 34.2, 42.2, 49.1, 49.7, 59.2, 59.5, 80.5, 126.7, 128.0, 
129.1, 139.3, 175.7, 176.8. Mass (HiResMALDI): 1238.185 (M+1) for C84H152N2O3. 
Hydrolysis of tert-butyl ester 
2-((2-((Dibenzylamino)methyl)-2-pentadecylheptadecanamido)methyl)-2-
pentadecylheptadecanoic acid (41) 
Bn2N NH
OH
OO
R R R R
2
3
6
7
 
The same procedure to have 37 was used to prepare 41 (yield >99%). Mp 62.9-64.7 (from CH2Cl2). 1H 
NMR (300 MHz): δ 0.84 (t, J=6.6, 12H, 4xCH3), 1.00-2.00 [m, 112H, 4x(CH2)14], 2.40-3.80 (m, 6H, H-3, 
H-7, H-Bn), 7.03-7.43 (m, 10H, H-Ar). 13C NMR (75 MHz): δ 14.1, 22.6, 23.9, 29.3-31.9, 42.6, 45.8, 
46.9, 49.2, 59.2, 127.3, 128.5, 128.8, 135.5, 172.0, 181.0. Mass (HiResMALDI): 1182,123 (M+1) for 
C80H144N2O3. 
Coupling product from the reaction between the compounds 39 and 41 
tert-Butyl 2-benzyl-5,9,13-trioxo-4,4,8,8,12,12,16,16-octapentadecyl-1-phenyl-2,6,10,14-
tetraazaheptadecan-17-oate (42) 
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The same coupling procedure used to prepare 40 was also used to prepare 42 (yield 25%). Mp 62.8-
64.8 (from CH3CN). 1H NMR (300 MHz): δ 0.87 (t, J=6.6, 24H, 8xCH3), 1.05-1.60 [m, 224H, 8x(CH2)14, 
OtBu], 2.64 (bs, 2H, H-15), 3.23-3.30 (m, 2H, H-3), 3.31-3.40 (m, 4H, H-7, H-11), 3.41-3.48 (m, 4H, H-
Bn), 6.38-6.46 (m, 2H, NH), 7.04-7.50 (m, 11H, NH, H-Ar). 13C NMR (75 MHz): δ 14.1, 22.7, 23.5, 24.0, 
28.0, 29.3-31.9, 32.6, 34.6, 34.8, 42.6, 43.3, 48.3, 48.5, 49.1, 49.7, 59.2, 59.5, 80.9, 126.7, 128.1, 
129.3, 139.5, 176.1, 176.5, 177.1. Mass (HiResMALDI): 2222.195 (M+1) for C150H282N4O5. 
Synthesis of Aspartame Analogues 
Synthesis of anti-2-Hydroxy-β3-Phenylalanine Methyl Ester 
Introduction of hydroxyl group  
(2S,3S)-methyl 3-(dibenzylamino)-2-hydroxy-4-phenylbutanoate (13) 
To a magnetically stirred solution of 12 (0.54 mmol, 200 mg) in anhydrous THF (4 mL), 0.5 M KHDMS 
in THF (2.14 mL, 1.07 mmol) was added dropwise, at -78 °C and under anhydrous argon. After 1 h, 
solid 2-[(4-methylphenyl)sulfonyl]-3-phenyloxaziridine (0.9 mmol, 264 mg) was added to the solution in 
one portion, and the reaction mixture was kept at -78 °C whilst stirring. Within 30 min, the reaction was 
quenched by addition of 10% aq NH4Cl (200 mL) and extracted with ethyl acetate. The organic layer 
was washed with brine until neutral and dried (Na2SO4), and the solvents were evaporated in vacuo. 
The residue (470 mg) was purified by chromatography on silica gel (hexane/ethyl acetate, 8:2) 
afforded the pure, oily title compound 13 (130 mg, yield 63%2; d.r. 99:1). α D25 +17.8 (c 0.5). 1H NMR 
(400 MHz): δ 2.87 (dd, J=7.3, J=14.0, 1H, H-4a), 3.08 (dd, J=7.3, J=14.0, 1H, H-4b), 3.49 (dt, J=2.6, 
J=7.3, 1H, H-3), 3.56 (s, 3H, OMe), 3.72 (d, J =14.0, 2H, Ha-Bn), 3.88 (d, J=14.0, 2H, Hb-Bn), 4.57 (d, 
J=2.6, 1H, H-2), 7.00-7.40 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 31.8, 52.6, 55.1, 62.7, 69.7, 126.6, 
127.7, 128.4, 128.6, 129.4, 129.8, 174.7. Anal. Calcd. for C25H27NO3: C 77.09, H 6.99, N 3.60. Found 
C 77.13, H 6.96, N 3.65. 
Under the same conditions, the other α-substituted compounds were also obtained. 
Protection of the hydroxyl group  
(2S,3S)-methyl 2-(tert-butyldiphenylsilyloxy)-3-(dibenzylamino)-4-phenylbutanoate (14) 
To a solution of 13 (0.32 mmol, 125 mg), in anhydrous THF (4 mL) at room temperature, imidazole 
(1.92 mmol, 130 mg) and DMAP (0.014 mmol, 2.2 mg) were added. After complete solubilization of 
imidazole, under inert atmosphere of N2, tert-buthyldiphenilsilylcloride (TBDPSCl, 0.57 mmol, 156.5 
mg), was added with formation of a white precipitate (imidazolium choride). The suspention was kept 
under magnetic stirring until the starting material was completely consumed (∼6h, TLC). The solution, 
diluited with EtOAc (200 mL), was washed with 10% aq NH4Cl (2 x 100 mL) and then with brine. The 
organic layer was finally dried (Na2SO4), and the solvent was evaporated under reduced pressure to 
afford a crude reaction product (664 mg), chromatography of which on silica gel (petroleum ether/ 
Et2O, 95:5) gave the pure, oily title compound 14 (145 mg, yield 72%). α D25 -43.32 (c 1.53). 1H NMR 
(500 MHz): δ 1.10 (s, 9H, 3xCH3), 3.00 (dd, J=9.8, J=14.6, 1H, H-4a), 3.16 (dd, J=3.9, J=14.6, 1H, H-
4b), 3.22 (s, 3H, OMe), 3.41-3.45 (m, 1H, H-3), 3.48 (d, J=13.7, 2H, Ha-Bn), 3.65 (d, J=13.7, 2H, Hb-
Bn), 4.56 (d, J=5.4, 1H, H-2), 7.02-7.75 (m, 25H, H-Ar). 13C NMR (125 MHz): δ 19.8, 27.3, 33.4, 51.3, 
54.6, 63.7, 73.4, 126.1, 126.9, 127.6, 127.8, 128.1, 128.4, 129.1, 129.9, 130.1, 136.2, 136.3, 139.6, 
140.9, 172.8. Anal. Calcd. for C42H47 NO3Si: C 78.59, H 7.38, N 2.23. Found C 78.62, H 7.41, N 2.28. 
Deprotection of the β-amino function 
(2S,3S)-methyl 3-amino-2-(tert-butyldiphenylsilyloxy)-4-phenylbutanoate (15) 
A magnetically stirred solution of 14 (0.23 mmol, 145 mg) in glacial AcOH (4.3 mL) was treated with H2 
over 30% Pd/C catalyst (37 mg) for 2 h at 50 °C, under a slightly positive pressure given by an inflated 
balloon (~3 bar). The mixture was then filtered through Celite® and washed with MeOH (30 mL). The 
solvent was removed under reduced pressure and the residue was dissolved in EtOAc (2x25 mL). The 
organic layer was washed with 10% aq Na2CO3 (25 mL), dried (Na2SO4), and the solvents evaporated 
in vacuo to give the pure, oily title compound 15, (102 mg, yield 99%). α D25 -1.1 (c 0.2). 1H NMR (400 
                                                 
2 Total yield for both diastereoisomers. 
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MHz): δ 1.12 (s, 9H, CH3-OtBu-TBDPS), 1.68 (bs, 2H, NH2), 2.48 (dd, J=9.2, J=13.6, 1H, H-4a), 2.86 
(dd, J=5.1, J=13.6, 1H, H-4b), 3.31 (m, 1H, H-3), 3.46 (s, 3H, OMe), 4.20 (d, J=4.3, 1H, H-2), 7.16-
7.80 (m, 15H, 5xH-Ar, 10xH-Ar-TBDPS). 13C NMR: δ 19.2, 26.7, 39.1, 51.2, 57.0, 76.3, 126.1, 127.3, 
127.5, 128.2, 129.0, 129.6, 129.7, 132.7, 135.6, 135.7, 138.6, 171.5. Anal. Calcd. for C27H33NO3Si: C 
72.44, H 7.43, N 3.13. Found C 72.46, H 7.39, N 3.09. 
Synthesis of anti-2-Amino β3-Phenylalanine Methyl Ester 
Introduction of amino function group  
The procedures to prepare the compounds 16 and 17 have already been reported for the compounds 
26b and 27b in Synthesis of anti-2,3-diamino acids. 
Protection of the α-amino function 
Under the same conditions used to prepare compound 30 in Synthesis of anti-2,3-diamino acids, 
compound 18 was also synthesised. 
(2S,3S)-methyl 2-(tert-butoxycarbonylamino)-3-(dibenzylamino)-4-phenylbutanoate (18) 
Chromatography on silica gel of the crude product in Etp/AcOEt = 95/5 gave the compound 18 (yield 
80%) as pure, oily title compound. α D25 +14.6 (c 0.6). 1H NMR (500 MHz): δ 1.44 (s, 9H, CH3-Boc), 
2.80 (dd, J=7.3, J=13.9, 1H, H-4a), 3.07 (dd, J=6.8, J=13.9, 1H, H-4b), 3.33-3.38 (m, 1H, H-3), 3.63 (d, 
J=13.2, 2H, Ha-Bn), 3.63 (s, OMe), 3.71 (d, J=13.7, 2H, Hb-Bn), 4.61-4.64 (m, 1H, H-2), 5.09 (d, J=9.3, 
2H, NH-Boc), 7.05-7.40 (m, 15H, H-Ar). 13C NMR (125 MHz): δ 28.6, 33.0, 52.3, 53.8, 54.1, 61.7, 
80.00, 126.5, 127.3, 128.4, 128.6, 129.3, 129.6, 139.5, 155.3, 172.7. Anal. Calcd. for C30H36N2O4: C 
73.74, H 7.43, N 5.73. Found C 73.72, H 7.40, N 5.70. 
Deprotection of the β-amino function 
Under the same conditions used to prepare compound 15, compound 19 was also synthesised. 
(2S,3S)-methyl 3-amino-2-(tert-butoxycarbonylamino)-4-phenylbutanoate (19) 
Pure oil (yield 60%). α D25 +21.9 (c 0.3). 1H NMR (500 MHz): δ 1.44 (s, 9H, CH3-Boc), 2.52 (dd, J=9.8, 
J=14.2, 1H, H-4a), 2.91 (dd, J=3.9, J=14.2, 1H, H-4b), 3.23-3.38 (m, 1H, H-3), 3.76 (s, OMe), 4.38 (m, 
1H, H-2), 5.45-5.55 (m, 1H, NH-Boc), 7.18-7.36 (m, 5H, H-Ar). 13C NMR (125 MHz): δ 28.6, 41.1, 52.5, 
55.6, 58.4, 80.34, 126.6, 128.9, 129.5, 138.5, 155.8, 171.9. Anal. Calcd. for C16H24N2O4: C 62.32, H 
7.84, N 9.08. Found C 62.32, H 7.84, N 9.05. 
Synthesis of anti-2-Substituted-β3-Phenylalanine Methyl Ester 
Introduction of alkyl groups. 
The same procedure of the hetero-substitution was followed, starting from compound 12, 2 eq of 
KHMDS and 2.2 eq of CH3I (or BnBr) as electrophile. 
(2S,3S)-methyl 3-(dibenzylamino)-2-methyl-4-phenylbutanoate (20) 
Purified by flash chromatography (silica gel; Hexane /Et2O = 97:3); d.r. 93:7; compound 20: (144 mg, 
yield 97%). Oil; α D25 -6.93 (c 0.2) 1H NMR (300 MHz) :δ 0.94 (d, J=6.9, 3H, CH3), 2.68 (dd, J=6.9, 
J=14.3, 1H, H-4a), 2.72-2.84 (m, 1H, H-2), 3.04 (dd, J=6.04, J=14.3, 1H, H-4b), 3.21 (m, 1H, H-2), 
3.42 (d, J=13.6, 2H, Ha-Bn), 3.54 (s, 3H, OMe), 3.70 (d, J=13.6, 2H, Hb-Bn), 7.00-7.30 (m, 15H, H-
Ar). 13C NMR (75 MHz): δ 15.3, 33.2, 42.7, 51.2, 54.1, 62.2, 125.8, 126.7, 127.8, 128.2, 129.0, 192.2, 
139.4, 140.7, 175.6. Anal. Calcd. for C26H29NO2: C 80.59, H 7.54, N 3.61. Found C 80.62, H 7.58, N 
3.59. 
(2S,3S)-methyl 2-benzyl-3-(dibenzylamino)-4-phenylbutanoate (21) 
Purified by flash chromatography (silica gel; Hexane /Et2O = 98:2); d.r. 9:1; compound 21: (0.477 
mmol, 220 mg, yield 90%). Oil; α D25 -58.9 (c 0.20). 1H NMR (400 MHz): δ 2.61 (dd, J=4.6, J=13.7, 
1H, H-4a), 2.65-2.75 (m, 1H, H-4b) 2.87 (dd, J=7.4, J=14.3, 1H, CHaHbPh), 3.04-3.09 (m,1H, H-2), 
3.25 (dd, J=5.5, J=14.3, 1H, CHaHbPh), 3.36-3.41 (m, 1H, H-3), 3.49 (s, 3H, OMe), 3.52 (d, J=13.6, 
2H, Ha-Bn), 3.86 (d, J=13.6, 1H, Hb-Bn), 6.90-7.40 (m, 20H, H-Ar). 13C NMR (125 MHz): δ 29.7, 34.1, 
42.5, 51.3, 52.9, 54.2, 126.3, 128.4, 128.5, 128.8, 129.2, 138.6, 174.5. Anal. Calcd. for C32H33NO2: C 
82.90, H 7.17, N 3.02. Found C 82.88, H 7.15, N 3.04. 
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Deprotection of the β-amino function 
Under the same conditions used to prepare compound 15, compound 22 and 23 were also 
synthesised. 
(2S,3S)-methyl 3-amino-2-methyl-4-phenylbutanoate (22) 
Pure oil (42 mg, yield 88%). α D25 -14.7 (c 0.2). 1H NMR (500 MHz): δ 1.30 (d, J=7.9, 3H, CH3), 2.48 
(dd, J=2.4, J=13.2, 1H, H-4a), 2.51-2.59 (m, 1H, H-2), 2.95 (dd, J=4.4, J=13.2, 1H, H-4b), 3.16-3.22 
(m, 1H, H-3), 3.73 (s, 3H, OMe), 7.20-7.38 (m, 5H, H-Ar). 13C NMR (125 MHz): δ 14.3, 40.7, 44.5, 
51t.7, 55.3, 126.6, 128.6,129.3,138.4, 175.6. Anal. Calcd. for C12H17NO2: C 69.54, H 8.27, N 6.76. 
Found C69.58, H 8.27, N 6.73. 
(2S,3S)-methyl 3-amino-2-benzyl-4-phenylbutanoate (23) 
Pure oil (10 mg, yield 49%). α D25 -17.1 (c 0.7). 1H NMR (500 MHz): δ 2.58-2.90 (m, 2H, NH2), 2.61 
(bs, 1H, H-4a), 2.75-2.83 (m, 1H, CHaHbPh), 2.90-3.15 (m, 3H, H-2, H-4b, CHaHbPh), 3.18-3.26 (m, 
1H, H-3), 3.72 (s, 3H, OMe), 7.12-7.33 (m, 5H, H-Ar). 13C NMR (125 MHz): δ 29.9, 34.3, 35.9, 51.7, 
54.5, 126.6, 126.7, 128.6, 128.7, 129.0, 129.5, 138.8, 139.2, 174.7. Anal. Calcd. for C18H21NO2: C 
76.26, H 7.47, N 4.94. Found C 76.34, H 7.44, N 4.90. 
Peptide Synthesis 
Coupling product from the reaction of the compounds 24 with 15.  
General Procedure 
(S)-tert-butyl 3-(tert-butoxycarbonylamino)-4-((2S,3S)-3-(tert-butyldiphenylsilyloxy)-4-
methoxy-4-oxo-1-phenylbutan-2-ylamino)-4-oxobutanoate (25) 
To a solution of triphenylphosphine (0.38 mmol, 99.0 mg) in anhydrous CH2Cl2 (1 mL) at room 
temperature, under inert atmosphere of N2 and under magnetic stirring, solid I2 is added (0.38 mmol, 
96.0 mg) in one portion. After 15 minutes, when the colour of the solution changes from violet to 
orange, solid imidazole is added (0.65 mmol, 44 mg) and the colour changes again to yellow. After 15 
minutes, compound 24 (0.32 mmol, 93.7 mg), is finally added in one portion to the suspension, and 
the mixture runs at room temperature until the end of the starting acid (∼1 h, TLC CHCl3:CH3OH 98:2). 
The compound 15 (0.22 mmol, 97 mg) is then added and the reaction was allowed to react for 12h at 
room temperature. Then the solvent is removed under reduced pressure and the residue, diluted with 
EtOAc (10 mL), is washed with 10% aq. Na2S2O3 (2x10 mL). The organic layer is then washed with 
brine, dried (Na2SO4), and evaporated in vacuo to afford a crude reaction product whose 
chromatography on silica gel (petroleum ether/EtOAc, 90:10) gave the pure 25 (80 mg, yield 72%) as 
colourless oil. α D25 -25.3 (c 0.6). 1H NMR (400 MHz): δ 1.13 (s, 9H, CH3-OtBu-TBDPS), 1.43 (s, 9H, 
CH3-Boc), 1.47 (s, 9H, CH3-OtBu-CO2tBu), 2.51 (dd, J=5.1, J=16.6, 1H, H-3’a), 2.70 (dd, J=5.5, 
J=16.6, 1H, H-3’b), 2.86 (d, J=7.8, 2H, H-4), 3.38 (s, 3H, OMe), 4.23-4.39 (m, 2H, H-2, H-2’), 4.50 
(ddd, J=3.8, J=7.8, J=8.8, 1H, H-3), 5.40-5.46 (m, 1H, NHBoc), 6.91 (d, J=8.8, 1H, NHCO), 7.09-7.65 
(m, 15H, H-Ar). 13C NMR (125 MHz): δ 19.9, 27.3, 28.4, 28.7, 36.5, 37.3, 51.1, 52.1, 54.2, 73.8, 80.6, 
81.9, 126.9, 127.9, 128.2, 128.8, 129.6, 130.2, 132.8, 133.2, 136.3, 137.6, 155.8, 170.9, 171.6, 172.5. 
Anal. Calcd. for C40H54N2O8Si: C, 66.82; H, 7.57; N, 3.90. Found C 66.77, H 7.53, N 3.89. 
Coupling product from the reaction of the compounds 24 with 19 
(S)-tert-butyl 3-(tert-butoxycarbonylamino)-4-((2S,3S)-3-(tert-butoxycarbonylamino)-4-
methoxy-4-oxo-1-phenylbutan-2-ylamino)-4-oxobutanoate (27) 
Chromatography on silica gel of the crude product (petroleum ether/EtOAc, 95:5) gave the pure 27 
(yield 80%) as colourless oil. α D25 -0.7 (c 5.5). 1H NMR (500 MHz): δ 1.38 (s, 9H, Boc), 1.44 (s, 18H, 
2xCH3-Boc), 2.50 (dd, J=5.9, J=16.6, 1H, H-3’a), 2.77-2.80 (m, 2H, H-4a, H-3’b), 2.86 (dd, J=6.3, 
J=13.7, 1H, H-4b), 3.59 (s, 3H, OCH3), 4.32-4.40 (m, 1H, H-2), 4.40-4.50 (m, 1H, H-2’), 4.50-4.60 (m, 
1H, H-3), 5.50-5.70 (m, 2H, 2 x NHBoc), 7.15-7.39 (m, 5H, H-Ar), 7.4 (m, 1H, NHCO). 13C NMR (100 
MHz): δ 28.0, 37.3, 51.1, 52.4, 53.3, 55.7, 80.2, 81.6, 126.8, 128.4, 129.3, 136.7, 155.4, 155.8, 170.9, 
170.9, 171.0. Anal. Calcd. for C29H45N3O9: C, 60.09; H, 7.82; N, 7.25. Found C 60.07, H 7.80, N 7.28. 
Coupling product from the reaction of the compounds 24 with 22 
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(S)-tert-butyl 3-(tert-butoxycarbonylamino)-4-((2S,3S)-4-methoxy-3-methyl-4-oxo-1-
phenylbutan-2-ylamino)-4-oxobutanoate (28) 
Chromatography on silica gel of the crude product (petroleum ether/EtOAc, 9:1) gave the pure 28 
(yield 85%) as colourless oil. α D25 -23.54 (c 0.3). 1H NMR (400 MHz): δ 1.15 (d, J=7.2, 3H, CH3), 1.43 
(s, 3H, Boc), 1.45 (s, 9H, OtBu), 2.56-2.65 (m, 2H, H-2, H-3’a), 2.68 (dd, J=8.7, J=13.6, 1H, H-4a), 
2.75-2.91 (m, 2H, H-3’b, H-4b), 3.72 (s, 3H, OMe), 4.20-4.28 (m, 1H, H-3), 4.40-4.48 (m, 1H, H-1’), 
5.60 (bd, J=6.6, 1H, NHBoc), 7.18-7.31 (m, 5H, H-Ar), 7.44 (bd, J=9.5, 1H, NHCO). 13C NMR (75 
MHz): δ 15.1, 37.2, 39.7, 40.2, 46.1, 51.6, 52.8, 81.4, 126.4, 128.4, 129.1, 137.6, 170.6, 175.5. Anal. 
Calcd. for C25H38N2O7: C, 62.74; H, 8.00; N, 5.85. Found C 69.58, H 8.27, N 8.02. 
Coupling product from the reaction of the compounds 24 with 23 
(S)-tert-butyl 4-((2S,3S)-3-benzyl-4-methoxy-4-oxo-1-phenylbutan-2-ylamino)-3-(tert-
butoxycarbonylamino)-4-oxobutanoate (29) 
Chromatography on silica gel of the crude product (petroleum ether/EtOAc, 9:1) gave the pure 29 
(yield 97%) as colourless oil. α D25 -50.84 (c 0.5). 1H NMR (400 MHz): δ 1.43 (s, 9H, Boc), 1.49 (s, 9H, 
OtBu), 2.61-2.98 (m, 7H, H-2, H-4, CH2Ph, H-3’), 3.62 (s, 3H, OMe), 4.27-4.29 (m, 1H, H-3), 4.47-4.48 
(m, 1H, H-2’), 5.60 (bd, 1H, NHBoc), 6.76-7.26 (m, 10H, H-Ar), 7.44 (bd, J=8.8, 1H, NHCO). 13C NMR 
(100 MHz): δ 28.4,28.7, 36.6, 37.6, 40.6, 41.3, 48.6, 51.5, 52.0, 80.6, 81.9, 126.9, 128.8, 129.2, 129.6, 
137.8, 138.6, 155.8, 171.0, 171.7, 174.5. Anal. Calcd. for C31H42N2O7: C 67.13, H 7.63, N 5.05. Found 
C 67.18, H 7.59, N 5.03. 
Deprotection Reactions of Coupling Products 
Deprotection of hydroxyl function of 25 
(S)-tert-butyl 3-(tert-butoxycarbonylamino)-4-((2S,3S)-3-hydroxy-4-methoxy-4-oxo-1-
phenylbutan-2-ylamino)-4-oxobutanoate (26) 
To a solution of 25 (0.152 mmol, 110 mg) in THF (2.5 mL), tetrabutylammoniumfluoride 1M (TBAF, 
0.152 mmol, 0.138 mL) is added dropwise, keeping the solution at 0 °C under magnetic stirring. After 
10 minutes the starting material is completely consumed (TLC: CHCl3/CH3OH = 8:2); the solvent is 
then removed under reduced pressure and the residue, diluted with EtOAc (25 mL) and H2O (25 mL), 
is washed with a saturated solution of NaHCO3 and dried on Na2SO4. The crude product is finally 
purify on silica gel column in CH2Cl2? CH2Cl2/MeOH (9:1), to give the product 26 (58 mg; yield 80 %) 
as a colourless oil. α D25 -4.0 (c 0.4). 1H NMR (400 MHz): δ 1.45 (s, 9H, CH3-Boc), 1.47 (s, 9H, CH3-
OtBu), 2.60 (dd, J=6.5, J=16.8, 1H, H-3’a), 2.78-2.84 (m, 1H, H-3’b), 2.85 (d, 2H, J=7.2, H-4), 3.59 (s, 
3H, OMe), 4.28 (d, J=3.0, 1H, H-2), 4.35-4.45 (m, 1H, H-2’), 4.52-4.68 (m, 1H, H-3), 5.50-5.65 (m, 1H, 
NHBoc), 6.88 (d, J=7.9, 1H, NHCO); 7.18-7.35 (m, 5H, H-Ar). 13C NMR: δ 28.4, 28.7, 35.9, 37.7, 51.3, 
52.9, 53.8, 72.2, 80.8, 82.2, 127.1, 128.8, 129.8, 137.2, 155.9, 171.3, 171.5, 173.2. Anal. Calcd. for 
C24H36N2O8: C 59.98, H 7.55, N 5.83. Found C 59.94, H 7.50, N 5.81. 
Removal of tert-butoxycarbonyl protections  
(S)-3-amino-4-((2S,3S)-3-hydroxy-4-methoxy-4-oxo-1-phenylbutan-2-ylamino)-4-
oxobutanoic acid (4) 
To a solution of compound 26 (0.121 mmol, 58.4mg) in CH2Cl2 (3 mL), at 0 °C under magnetic stirring, 
trifluoroacetic acid is added dropwise (TFA 1.5 mL). The reaction goes until all the starting material 
was consumed (TLC: CHCl3/CH3OH = 8:2). The solvent is then evaporated under reduced pressure 
and the TFA is co-evaporated several times with CH2Cl2. The solid residue is diluted with acetone and 
recrystallized from Et2O, giving the product 4 as a pure hygroscopic crystalline solid (31 mg, yield 
80%). 1H NMR (400 MHz): δ 2.54 (dd, J=7.7, J=16.5, 1H, H-3’a), 2.79 (dd, J=4.3, J=16.5, 1H, H-3’b), 
3.13 (dd, J=5.2, J=13.7, 1H, H-4a), 3.51 (dd, J=9.7, J=13.7, 1H, H-4b), 3.67 (s, 3H, OMe), 3.78-3.83 
(m, 1H, H-3), 3.92 (dd, J=4.3, J=7.7, 1H, H-2’), 4.63 (d, J=3.4, 1H, H-2), 7.20-7.30 (m, 5H, H-Ar). 13C 
NMR (100 MHz): δ 42.6 (2xC), 51.9, 52.2, 53.7, 63.3, 126.9, 128.1, 128.9, 129.7, 130.2, 136.0, 169.7, 
170.1, 174.1. Anal. Calcd. for C15H20N2O6: C 55.55, H 6.22, N 8.64. Found C 55.59, H 6.17, N 8.68. 
Under the same conditions, the following deprotected dipeptides were also obtained. 
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(S)-3-amino-4-((2S,3S)-3-amino-4-methoxy-4-oxo-1-phenylbutan-2-ylamino)-4-
oxobutanoic acid (5) 
Dipeptide 5 (40 mg; yield 80%). Crystalline solid, mp 134.2-136.4 °C (from Acetone/Et2O). α D25 -13.9 
(c 0.3, H2O). 1H NMR (400 MHz): δ 2.76 (dd, J=5.1, J=17.7, 1H, H-3’a), 2.83 (dd, J=6.2, J=17.7, 1H, 
H-3b’), 2.98 (dd, J=10.1, J=14.1, 1H, H-4a), 3.14 (dd, J=5.9, J=14.1, 1H, H-4b), 3.86 (s, 3H, OMe), 
4.06 (bt, J=5.5, 1H, H-2’), 4.31 (d, J= 2.6, 1H, H-2), 4.61-4.82 (m, 1H, H-3), 7.28-7.37 (m, 5H, H-Ar). 
13C NMR (100 MHz): δ 36.5, 36.6, 50.3, 52.1, 54.3, 56.6, 127.8, 129.4, 129.6, 136.7, 168.2, 170.5, 
175.8. Anal. Calcd. for C15H21N3O5: C 55.72, H 6.55, N 13.00. Found C 55.77, H 6.59, N 13.03. 
(S)-3-amino-4-((2S,3S)-4-methoxy-3-methyl-4-oxo-1-phenylbutan-2-ylamino)-4-
oxobutanoic acid (6) 
Dipeptide 6 (yield 46%). Crystalline solid, mp 91-93 °C (from Acetone/Et2O). α D25 -8.3 (c 0.1). 1H 
NMR (400 MHz, D2O): δ 1.11 (d, J=7.0, 3H, CH3), 2.57-2.70 (m, 4H, H-4a, H-3b, H-3’a, H-2), 2.93 (dd, 
J=4.6, J=14.1, 1H, H-4b), 3.57 (s, 3H, OMe), 3.92 (m, 1H, H-2’), 4.22 (m, 1H, H-3), 7.11-7.86 (m, 5H, 
H-Ar) 13C NMR (100 MHz, D2O): δ 13.8, 37.5, 44.0, 44.1, 50.4, 52.8, 53.8, 127.1, 129.0, 138.3, 168.7, 
174.1, 177.3. Anal. Calcd. for C16H22N2O5: C 59.61, H 6.88, N 8.69, found C 59.65, H 6.82, N 8.65. 
CD Studies 
CD measurements were carried out on a Jasco J715 spectropolarimeter. A single Jasco cylindrical 
cuvette with a pathlenght of 1 cm was used for all measurements. The spectra were recorded using a 
scan speed of 5 nm min-1, with a resolution of 0.2 nm, a sensitivity di 50 mdeg, a time costant of 16 
sec and a spectral window from 260 to 190 nm. 
Peptides 8 and 9, and aspartame wild-type were dissolved in water-trifluoroethanol 1:1 (v:v) at 
concentrations of 6.2 x 10-4 mM.  
The spectra for these peptides are shown below. 
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Molecular dynamics  
 carried out using the Chem3D program. 
eans of MM2 force field, as 
ptide 6 were found using software Amber, 
Synthesis of Dialkylated Analogue of Arginine 
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All computer simulations were
Molecular Mechanics and Molecular Dynamics were achieved by m
implemented in Chem3D. Molecular Dynamics trajectories were collected in periods of 1ns, using a 
step interval of 1 fs, and a target temperature of 373 K.  
The extended conformations of aspartame and dipe
emploing as Force Field Parm99, specific for amino acidic structurs. 
Alkylation of ethyl isocyanoacetato 
Ethyl 5-azido-2-(3-azidopropyl)-2-cyanop
To a solution of ethyl isocyanoacetate (1 g; 8.8 mmol) in anhydr
was added the 1-azido-3-iodopropane (3.7 g, 17.6 mmol) and NaH (0.6 g; 26.5 mmol washed from 
mineral oil) at room temperature. The reaction mixture was allowed to react for 15 min at r.t. then H2O 
(5 mL) was added and the mixture was washed with ether. The organic layer was then washed with 
brine, dried (Na2SO4) and the solvent removed to afford 2.5 g of the crude product. Purification by 
flash cromatography (silica gel, hexane:ether 9:1→ 7:3) gave the compound 6 (2.1 g; 85%) as 
colorless oil. IR (neat): 2938.9m, 2100.2s, 1748.6s. 1H NMR (400 MHz): δ 1.34 (t, J=7.1, 3H, CH3), 
1.50-1.65 (m, 2H, CH2), 1.70-1.85 (m, 4H, CH2), 2.00-2.12 (m, 2H, CH2), 3.25-3.45 (m, 2H, CH2N3), 
4.29 (q, J=7.1, 2H, CH2O). 13C NMR (100 MHz): δ 14.12, 23.90, 36.32, 50.61, 63.08, 67.59, 160.51, 
168.12. Anal. Calcd for C11H17N7O2: C 47.30, H 6.13, N 35.10. Found: C 47.52, H 6.07, N 34.82 
Hydrolysis of isocyanate3
 
3 Ref Procedure: J. Org. Chem. 1989, 9, 2170-2178. 
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Ethyl 2-amino-5-azido-2-(3-azidopropyl) pentanoate (7) 
Cl in EtOH (5.5 mL of 38% acqueus 
o)pentanoic acid (9) 
OH (3 ml) is 
g reaction between 9 and 7 
 (0.5 mL) was added the amine 7 (40 mg, 0.15 mmol) 
2x(CH2)2], 3.28-3.47 (m, 4H, 2xCH2), 5.78 (bs, 
H, CH3), 1.45-1.65 (m, 17H, Boc, 4xCH2), 1.70-1.95 (m, 2H, 
)pentanoic acid (10) 
 added and the 
2 2 2 2
(m, 4H, CH2), 5.09 (s, 2H, OCH2Ph), 5.79 (s, 1H, NHCbz) 7.30-7.51 (m, 5H, H-Ar). 13C-NMR (100 
                                                                   
The compound 6 (2 g; 7.2 mmol) was dissolved in 16 mL of 5% H
HCl in 60 mL of absolute ethanol) and the reaction was stirred at 40°C for 12 h. Then the solvent was 
removed under vacuum, the crude was dissolved in EtOAc and washed with HCl 1M to remove other 
organic residue. The aqueous layer was then basified with NaOH 1M (pH≈10) and washed with EtOAc. 
Finally, the organic layer was washed with brine and dried to give 1.8 g of product 7 as colorless oil 
(yield 96%). IR (neat): 2934.5s, 2094s, 1726.1s. 1H NMR (400 MHz): δ 1.29 (t, J=7.1, 3H, CH3), 1.44-
1.72 (m, 8H, 2xCH2, 2xCHaHb and NH2), 1.79-1.86 (m, 2H, 2xCHaHb), 3.22-3.34 (m, 4H, 2xCH2N3), 
4.20 (q, J=7.1, 2H, CH2O). 13C NMR (100 MHz): δ 14.3, 23.6, 37.1, 51.5, 60.4, 61.4, 96.9, 176.2. Anal. 
Calcd for C10H19N7O2: C 44.60, H 7.11, N 36.41. Found: C 44.63, H 7.13, N 36.19. 
Hydrolysis of ester function and Boc-protection 
5-Azido-2-(3-azidopropyl)-2-(tert-butoxycarbonylamin
To a solution of compound 7 (0.4 g; 1.5 mmol) in 9.8 ml of MeOH, 1 N Na
added and the solution is stirred at 40°C untill the disappearance of the starting material 
(TLC). Then the solvent is removed under vacuum and the crude is dissolved in 5.3 ml of 
dioxane and 1.7 ml of 1 N NaOH. To this solution 2 g of Boc2O are added in tree portions. 
The reaction is allowed to react over night at room temperature. Then the solvent is removed 
under vacuuo and the residue dissolved with EtOAc and washed with 10% KHSO4 and brine. 
Purification by FC (Silica gel, CH2Cl2: MeOH 9:1) gives 0.35 g of product 9 as white solid 
(yield 70%). 1H-NMR (400 MHz): δ 1.36-1.45 (m, 11H, Boc, CH2), 1.54-1.63 (m, 2H, CH2), 1.91 (ddd, 
J=4.5, J=12.3, 2H, CH2), 2.30-2.50 (m, 2H, CH2), 3.20-3.30 (m, 4H, CH2), 5.79 (s, 1H, NHBoc). 13C-
NMR (100 MHz): δ 23.5, 27.7, 32.5, 51.2, 65.7, 80.1, 155.2, 175.1. ESI-MS: 365.18 [(M+Na)+], 342.18 
[(M+H)+]. 
Couplin
To a solution of 9 (50 mg, 0.15 mmol) in DMF
and NMM (0.05 mL, 1.76 mmol). After 5 min, HATU (68 mg, 0.18 mmol) was added and the reaction 
was allowed to react for 12h at 25 °C. The solvent was then removed, the residue was dissolved in 
EtOAc and washed with 10% KHSO4, brine, 10% KHCO3, brine; then dried to recover 108 mg of 
crude. Purification by flash cromatography (Hexane:EtOAc / 8:2→7:3) afforded to coupling product (4 
mg, 5%). 
4,4-bis(2-Azidoethyl)oxazolidine-2,5-dione (12) 
(Yield 24%). 1H NMR (300 MHz): δ 1.42-2.10 [m, 8H, 
131H, NH). C NMR (75 MHz): δ 23.3, 34.4, 50.7, 66.7, 152.1, 171.7. 13C (75 MHz): 23.3, 34.4, 50.7, 
66.7, 152.1, 171.7. 
Ethyl 5-azido-2-(5-azido-2-(3-azidopropyl)-2-(tert-butoxycarbonylamino)pentanamido)-
2-(3-azidopropyl)pentanoate (13) 
1H NMR (300 MHz): δ 1.29 (t, J=7.1, 3
4xCH2), 2.10-2.30 (m, 2H,CH2), 2.40-2.58 (m, 2H, CH2), 3.11-3.40 (m, 8H, 4xCH2N3), 4.28 (q, J=7.1, 
2H, CH2O), 5.40 (s, 1H, NHBoc), 7.11 (s, 1H, NH).ESI-MS: 615.2 [(M+Na)+], 593.3 [(M+H)+], 493.4 
[(M+-Boc)]. 
Hydrolysis of ester function and Cbz-protection 
5-Azido-2-(3-azidopropyl)-2-(benzyloxycarbonylamino
To a solution of compound 7 (1 g; 3.7 mmol) in 22 mL of MeOH, 1M NaOH (7 mL) was
solution was stirred at 40°C until the starting material was completely consumed (TLC). Then the 
solvent was removed under reduced pressure and the crude was dissolved in 1:1 (v:v) 1M NaOH (3.4 
mL):Acetone (3.4 mL) and kept at 0 °C. To this solution CbzCl (4.2 mmol; 1.3 mL) were added in tree 
portions and the pH was adjusted to 10-11 with 2M NaOH. The reaction was allowed to react over 
night at room temperature. Then the solvent is removed under vacuo and the residue dissolved with 
Et2O and washed with 2M NaOH to remove organic stuff. The aqueous layer is then acidified with iced 
6N HCl and extracted with EtOAc. Finally the organic layer is washed with brine, dried on Na2SO4 and 
removed under reduced pressure to give a crude, whose purification by FC (Silica gel, CH2Cl2: MeOH 
9:1) gave 0.86 g of product 10 as white solid (yield 62%). 1H-NMR (400 MHz): δ 1.36-1.45 (m, 2H, 
CH ), 1.54-1.63 (m, 2H, CH ), 1.91 (ddd, J=4.5, J=12.3, 2H, CH ), 2.30-2.50 (m, 2H, CH ), 3.20-3.30 
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MHz): δ 23.7, 32.7, 50.9, 63.2, 66.7, 128.0, 128.3, 128.6, 136.5, 154.2, 175.5. ESI-MS: 398.1 
[(M+Na) ], 376.1 [(M+H) ]. 
Coupling reaction between 10 and 7 
ethyl 5-azido-2-(5-azido-2-(3-azidopropyl)-2-(benzyloxycarbonylamino)pentanamido)-2-
+ +
(3-azidopropyl)pentanoate (16) 
To a solution of 10 (165 mg, 0.44 mmol) in DMF (1 mL) was added the amine 7 (118 mg, 0.44 mmol) 
and NMM (0.2 mL, 1.76 mmol). After 5 min, HATU (234 mg, 0.62 mmol) was added and the reaction 
was allowed to react for 7 d at 25 °C. The solvent was then removed, the residue was dissolved in 
noate (18) 
 
due was dissolved in EtOAc 
EtOAc and washed with 10% KHSO4, brine, 10% KHCO3, brine; then dried to recover 290 mg of crude. 
Purification by flash cromatography (Hexane:EtOAc / 8:2→7:3) afforded to coupling product (105 mg, 
yield 39%). 1H-NMR (300 MHz): δ 1.20-1.60 (m, 11H, 4xCH2 and CH3), 1.70-1.95 (m, 4H, 2xCH2), 
2.25-2.53 (m, 4H, 2xCH2), 3.12-3.39 (m, 8H, 4xCH2), 4.28 (q, 2H, OCH2CH3), 5.07 (s, 2H, OCH2Ph), 
5.83 (s, 1H, NHCbz), 6.97 (s, 1H, NH), 7.30-7.40 (m, 5H, H-Ar). 13C-NMR (100 MHz): δ 23.7, 32.7, 
50.9, 63.2, 66.7, 128.0, 128.3, 128.6, 136.5, 154.2, 175.5. Mass (HiResMALDI): 649.303 for 
(C26H38N14O5+Na+). 
Coupling reaction between 17 and 7 
ethyl 5-azido-2-(3-azidopropyl)-2-(2-(tert-
butoxycarbonylamino)propanamido)penta
To a solution of 17 (35 mg, 0.18 mmol) in DMF (2 mL) was added the amine 7 (50 mg, 0.18 mmol) and
DIPEA (0.15 mL, 0.9 mmol). After 5 min, HATU (138 mg, 0.36 mmol) was added and the reaction was 
allowed to react for 12h at 25 °C. The solvent was then removed, the resi
and washed with 10% KHSO4, brine, 10% KHCO3, brine; then dried to recover 84 mg of crude. 
Purification by flash cromatography (CH2Cl2:EtOAc / 8:2) afforded to coupling product (62 mg, yield 
78%). 1H-NMR (300 MHz): δ 1.15-1.35 (m, 8H, CH2, 2xCH3), 1.40-1.68 (m, 11H, Boc, CH2), 1.78-1.90 
(m, 2H, CH2), 2.42-2.61 (m, 2H, CH2), 3.08-3.35 (m, 4H, 2xCH2N3), 4.01-4.15 (m, 1H, CH), 4.23 (q, 
J=7.1, 2H, CH2O), 4.95 (m, 1H, NHBoc), 7.09 (s, 1H, NH). 
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Efficient synthesis of orthogonally protected
anti-2,3-diamino acids
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Abstract—An asymmetric synthesis of anti-2,3-diamino acids is reported. The enolates of N,N-dibenzylated b3-amino esters were treated
with di-tert-butyl azodicarboxylate (DBAD) to afford their N 0,N 00-di-Boc-2-hydrazino derivatives with excellent anti diastereoisomeric ratio.
Final Boc removal and reductive cleavage of the hydrazino bond led to the expected 2,3-diamino esters having only one free amino group. In
comparison with other asymmetric C-2 amination procedures, this method does not need the use of expensive chiral reagents and/or chiral
auxiliaries, while leads to products which can be orthogonally protected.
q 2005 Elsevier Ltd. All rights reserved.
1. Introduction
2,3-Diamino acids are important non-protein amino
acids, usually components of both natural and synthetic
bioactive compounds.1 In fact, they are currently well
recognized as key structural moieties in a variety of
biologically active molecules: (S)-2,3-diamino propanoic
acid (DAP, 1),2 2,3-diamino butanoic acids (DAB, 2 and 3)3
and (2S,3R)-2,3-diamino-4-phenylbutanoic acid (4)4 are
present in some antifungal dipeptides5 and in peptide
antibiotics, like aspartocin,3 glumamycin,6 lavendomycin7
and aminodeoxybestatin.8 Furthermore, (2R,3S)-2,3-di-
amino-3-phenylpropanoic acid (5) has been considered as
an alternative side chain in the anticancer drug Taxol.9
The elementary, polyfunctional 2,3-diamino acid unit has
been frequently used to probe several aspects of peptide and
protein structures. In addition, the usefulness of simple
chiral 1,2-diamines as auxiliaries and controller groups in
asymmetric synthesis (e.g., dihydroxylation,10 conjugate
addition,11 olefination,12 allylation,13 epoxidation,14 and
aldol reaction15) is also well documented. Their use to
resolve racemic mixtures of chiral allylic alcohols has been
reported as well.16
The development of simple and efficient methods to produce
enantiomerically pure 2,3-diamino acids from readily
available starting materials represent a fascinating goal
and several asymmetric syntheses have been reported so far.
The Mitsunobu reaction on serine,17 the Hofmann and
Curtius rearrangements of asparagine derivatives,18 and the
Schmidt reaction on aspartic acid19 were used to access
chiral 2,3-diaminopropanoic acid. A variety of other
syntheses have been also reported: the conjugate addition20
of homochiral lithium N-benzyl-N-a-methylbenzylamide to
a,b-unsaturated esters and in situ amination with trisyl
azide, the asymmetric Rh(I)-phosphine-catalyzed hydro-
genation of diastereoisomeric enamides,21 and the ring
opening of cis-3-alkylaziridine-2-carboxylates coming from
Sharpless asymmetric aminohydroxylation of a,b-unsatu-
rated esters.22
In this paper we report a new inexpensive, general and
highly stereoselective synthesis of anti-2,3-diamino acids
via amination of b3-amino esters.23
2. Results and discussion
N,N-Dibenzylated b3-amino esters (7a–c), in dry THF at
K78 8C and under dry nitrogen stream, were treated with
potassium bis(trimethylsilyl)amide (KHMDS) to get the
corresponding enolates. The use of more common bases,
such as LiHMDS and LDA, for the enolate generation was
0040–4020/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
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neglected since in our experience24 such bases lead to
significantly poorer results. After 1 h, solid di-tert-butyl
azodicarboxylate (DBAD) was added to the reaction
mixture that was kept at K78 8C for an additional hour.
Under such conditions, the Boc-diprotected hydrazino
derivatives of the starting 7a–c were obtained.
The double protection of the amino group is necessary to
avoid formation of by-products coming from the abstraction
of the N–H proton in the enolate production step.
Consequently, common protecting groups that are stable
under basic conditions, such as either Boc or Cbz, could not
be used under our reaction conditions. Therefore, in a first
attempt, the 4-methoxybenzyl group, we had already used
elsewhere,24 was chosen for its peculiar removal conditions
(CAN, CH3CN/H2O). Unfortunately, although the group
turned out to be stable under the reaction conditions, we
could not use it because the deprotection of the final 3-[di(4-
methoxybenzyl)amino]-2,3-diamino esters led to a plethora
of products coming from oxidative cleavage of the C2–C3
bond. Eventually, we used a double benzylic protection that
eliminated such deprotection problems and represented at
the same time a very bulky nitrogen substituent, suitable to
affect the stereochemical outcome25 of the enolate coupling
with the electrophile DBAD. As a matter of fact, the
coupling afforded a mixture of anti:syn Boc protected 2-
hydrazino derivatives of 7a–c with excellent diastereoiso-
meric ratio. Due to the complexity of the 1H NMR spectra of
the Boc containing hydrazino derivatives, they were
converted into the corresponding diastereoisomeric mix-
tures of diamino esters (e.g., 9) to determine accurately the
diastereoisomeric ratio.
The synthetic path is depicted in Scheme 1 and the results
obtained for selected b3-amino esters, namely the methyl
esters of b3-phenylglycine (6a), b3-phenylalanine (6b), and
b3-serine (6c), are reported in Table 1.
The more abundant anti diastereoisomers were submitted to
removal of the Boc protections (TFA in CH2Cl2) and
cleavage of the N–N bond by hydrogenolysis with Ni(Ra) at
low pressure and room temperature in an ultrasound bath.
The reduction of hydrazines to amines is reported to be
accomplished at high temperature, under high hydrogen
pressure.26 The use of ultrasound reduces significantly both
temperature and pressure.27 As a matter of fact, the
hydrogenolysis under such conditions was complete after
only 4 h and no traces of C-2 epimerization products could
be detected by 1H NMR spectroscopic analysis.
The anti configuration of the more abundant diastereo-
isomers coming from the couplings of 7a–c with DBAD
could be attributed, in the case of 8a, as follows: the final
product 9a was debenzylated and treated, without isolation,
with 1,1 0-carbonyldiimidazole to afford the imidazolidinone
10 (Scheme 2).
The 1H NMR spectroscopy coupling constant of 9.6 Hz
supported28 the cis-configuration of the H-4 and H-5 protons
and, thus, the anti-configuration of the starting diamino
compound.
In the light of this result and in agreement with our previous
work on the hydroxylation at C-2 of b3-amino esters, it
seems likely that the stereochemical outcome of the
functionalization at C-2 is independent of the nature of the
electrophile used, being only a function of the relative
stabilities of the enolate conformations.24
3. Conclusion
This amination procedure of b3-amino esters offers several
advantages, if compared with many other reported pro-
cedures. First of all, it does not require the use of either
chiral reagents or chiral auxiliaries: in fact, the observed
selection in the coupling step is merely due to the influence
of the existing chiral center of the starting b3-amino ester,
enhanced by the presence of two bulky substituents on the
nitrogen atom. Moreover, it is noteworthy that the amino
groups in the final 2,3-diamino esters have a different
protection status: this implies a broad flexibility of their use
in peptide synthesis. For instance, the free amino group can
be Boc protected and the benzyl groups then removed
hydrogenolitically to host an Fmoc protecting group, or vice
Scheme 1. Conversion of a-amino acids into monoprotected 2,3-diamino
esters.
Table 1. Functionalization at C-2 of the fully protected b3-amino esters
7a–c
Protected b3-
amino ester
R Boc protected 2-hydra-
zino derivatives of 7a–c
anti-2,3-Dia-
mino esters
(9a–c), yield
(%)a
Yield (%)b anti/syn
7a Ph 92 93:7 70
7b Bn 90 97:3 78
7c CH2OBn 90 94:6 65
a Overall yield after Boc removal and reductive cleavage of the hydrazine
moiety in the anti diastereoisomers 8a–c.
b Yield of both diastereoisomers.
Scheme 2. Synthesis of cis-imidazolidinone (10).
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versa should either Boc- or Fmoc-strategy be used.
Accordingly, in connection with our current interest in the
synthesis of glycosyl amino acids, we have prepared the
compound 13 as shown in Scheme 3.
4. Experimental
4.1. General
NMR spectra were recorded on Varian Inova 500 MHz,
Varian Gemini 200 MHz, Varian Gemini 300 MHz, Bruker
DRX 400 MHz spectrometers: chemical shifts are in ppm
(d) and J coupling constants in Hz; solvent CDCl3, unless
otherwise specified. GC/MS analyses were performed on
Hewlett–Packard 6890 GC/5973N MS. Optical rotations
were determined on Jasco P-1010 polarimeter (1.0 dm cell);
solvent CHCl3, unless otherwise specified. Infrared spectra
were recorded using JASCO FT/IR-430 Spectrometer.
Mps were taken on a Gallenkamp apparatus. Elemental
analyses were performed on a Perkin–Elmer Series II 2400,
CHNS analyzer. TLC were carried out on silica gel Merck
60 F254 plates (0.2 mm layer) and column chromatographies
on Merck Kieselgel 60 (70–230 mesh). Dry solvents were
distilled immediately before use.
4.1.1. N,N-Dibenzyl protections of 6a–c. Methyl (R)-3-
(dibenzylamino)-3-phenylpropanoate (7a): typical proce-
dure. A magnetically stirred suspension of b3-phenylglycine
methyl ester 6a (1.50 g; 8.38 mmol) and diisopropylethyl-
amine (DIPEA, 7.3 mL; 41.90 mmol) in toluene (18.0 mL)
was warmed gently until a clear solution was obtained.
Then, benzyl bromide (6.0 mL; 50.28 mmol) was added in
one portion and the resulting solution was refluxed for 4 h.
The reaction mixture was then cooled in an ice bath, diluted
with EtOAc (2!100 mL) and extracted with 10% aq
NH4Cl. The organic layer was washed with brine, dried
(Na2SO4), and evaporated under reduced pressure to afford
a crude reaction product whose chromatography on silica
gel (petroleum ether/EtOAc, 95:5) gave the pure crystalline
compound 7a, after recrystallization from hexane (2.56 g;
7.12 mmol; 85%). Mp 51.8–53.0 8C. [a]D
20 C71.6 (c 2.0).
1H NMR (500 MHz): d 2.73 (dd, JZ7.3, 14.6 Hz, 1H, H-
2a), 3.14 (dd, JZ8.8, 14.6 Hz, 1H, H-2b), 3.18 (d, JZ
13.7 Hz, 2H, NCHPh), 3.64 (s, 3H, OCH3), 3.78 (d, JZ
13.7 Hz, 2H, NCHPh), 4.33 (dd, JZ7.3, 8.8 Hz, 1H, H-3),
7.20–7.41 (m, 15H, H-Ar). 13C NMR (125 MHz): d 36.9,
51.8, 53.9, 59.1, 127.2, 127.7, 128.3, 128.4, 128.8, 129.1,
137.6, 139.8, 172.3. IR (KBr, cmK1): n 1714. Anal. Calcd
for C24H25NO2: C 80.19, H 7.01, N 3.90. Found: C 80.30, H
7.05, N 3.92.
Under the same conditions, the following N,N-diprotected
esters were also obtained.
Methyl (S)-3-(dibenzylamino)-4-phenylbutanoate (7b). Oil
(83%). [a]D
20K5.4 (c 1.0). 1H NMR (500 MHz): d 2.33 (dd,
JZ6.4, 14.2 Hz, 1H, H-2a), 2.56 (dd, JZ8.8, 13.2 Hz, 1H,
H-4a), 2.65 (dd, JZ8.3, 14.2 Hz, 1H, H-2b), 3.12 (dd, JZ
5.7, 13.2 Hz, 1H, H-4b), 3.40–3.50 (m, 1H, H-3), 3.56 (s,
3H, OCH3), 3.62 (d, JZ13.7 Hz, 2H, NCHPh), 3.76 (d, JZ
13.7 Hz, 2H, NCHPh), 7.20–7.70 (m, 15H, H-Ar). 13C NMR
(125 MHz): d 35.9, 36.3, 51.6, 53.7, 57.8, 126.4, 127.2,
128.4, 128.6, 129.1, 129.5, 139.7, 139.8, 172.9. IR (KBr,
cmK1): n 1712. Anal. Calcd for C25H27NO2: C 80.40, H
7.29, N 3.75. Found: C 80.25, H 7.32, N 3.77.
Methyl (R)-4-(benzyloxy)-3-(dibenzylamino)butanoate (7c).
Oil (86%). [a]D
20C31.6 (c 1.8). 1H NMR (500 MHz): d 2.55
(dd, JZ6.3, 14.6 Hz, 1H, H-2a), 2.68 (dd, JZ7.8, 14.6 Hz,
1H, H-2b), 3.47–3.54 (m, 1H, H-3), 3.56–3.62 (m, 4H, H-4a
and OCH3), 3.66 (d, JZ13.7 Hz, 2H, NCHPh), 3.71 (dd,
JZ9.8, 5.4 Hz, 1H, H-4b), 3.75 (d, JZ13.7 Hz, 2H,
NCHPh), 4.49 (d, JZ12.7 Hz, 1H, OCHPh), 4.52 (d, JZ
12.7 Hz, 1H, OCHPh), 7.20–7.45 (m, 15H, H-Ar). 13C NMR
(125 MHz): d 34.7, 51.7, 54.5, 55.2, 70.3, 73.3, 127.1,
127.8, 128.4, 128.6, 129.1, 138.6, 140.1, 173.0. IR (KBr,
cmK1): n 1715. Anal. Calcd for C26H29NO3: C 77.39, H
7.24, N 3.47. Found: C 77.25, H 7.27, N 3.48.
4.1.2. Reactions of 7a–c with DBAD. Methyl (2S,3S)-3-
(dibenzylamino)-2-[N 0,N 00-(di-tert-butoxycarbonyl)-hydra-
zino]-3-phenylpropanoate (8a): typical procedure. To a
magnetically stirred solution of 7a (2.56 g; 7.12 mmol) in
dry THF (75 mL), at K78 8C and under dry argon
atmosphere, 0.5 M KHMDS in toluene (28.5 mL;
14.24 mmol) was added dropwise. After 1 h solid di-tert-
butyl azodicarboxylate (2.85 g; 12.82 mmol) was added in
one portion to the reaction mixture kept at K78 8C under
stirring. Within 1 h the reaction was quenched by addition
of glacial AcOH (1.1 mL) and diluted with EtOAc. The
organic layer was washed with brine until neutral, dried
(Na2SO4), and the solvents evaporated in vacuo. The oily
residue, after chromatography on silica gel (hexane/EtOAc,
9:1), afforded the pure title compound 8a (foam; 3.86 g;
6.55 mmol; 92%). [a]D
20 C65.7 (c 1.6). The 1H NMR data
were not significant, apparently due to the occurrence of
mixtures of rotamers. IR (KBr, cmK1): n 3260, 1740, 1720.
Anal. Calcd for C34H43N3O6: C 69.25, H 7.35, N 7.13.
Found: C 69.17, H 7.31, N 7.15.
Under the same conditions, the following Boc diprotected 2-
hydrazino derivatives were also obtained.
Methyl (2S,3S)-3-(dibenzylamino)-2-[N 0,N00-(di-tert-butoxy-
carbonyl)-hydrazino]-4-phenylbutanoate (8b). Foam (90%).
[a]D
20 K2.3 (c 0.3). IR (KBr, cmK1): n 3250, 1730, 1712.
Anal. Calcd for C35H45N3O6: C 69.63, H 7.51, N 6.96.
Found: C 69.60, H 7.49, N 7.01.
Methyl (2S,3R)-4-(benzyloxy)-3-(dibenzylamino)-2-[N 0,N 00-
(di-tert-butoxycarbonyl)-hydrazino]butanoate (8c). Foam
Scheme 3. Preparation of the orthogonally protected 2,3-diamino acid 13.
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(90%). [a]D
20C45.0 (c 1.5). IR (KBr, cmK1): n 3270, 1728,
1715. Anal. Calcd for C36H47N3O7: C 68.22, H 7.47, N 6.63.
Found: C 68.19, H 7.40, N 6.68.
4.1.3. Reductive cleavages of the hydrazino bond in 8a–c.
Methyl (2S,3S)-2-amino-3-(dibenzylamino)-3-phenylpro-
panoate (9a): typical procedure. To a magnetically stirred
solution of 8a (3.86 g; 6.55 mmol) in dry CH2Cl2 (54 mL),
TFA (54 mL) was added in one portion. After 2 h, the
solvent was evaporated under reduced pressure. The crude
reaction product, redissolved in MeOH (26 mL), was trans-
ferred into a flask containing W-2 Raney nickel (3.86 g,
wet) and equipped with a hydrogen inflated balloon. The
flask was dipped into an ultrasound bath filled with water
and sonicated for 4 h at rt till the starting product was
completely consumed (TLC). The reaction mixture was then
filtered through Celitew washing with MeOH (100 mL).
Removal of the solvents under reduced pressure gave a
residue that was redissolved in EtOAc (200 mL), washed
with 10% aq Na2CO3 (2!100 mL), dried (Na2SO4), and
evaporated in vacuo, to afford an oil whose chromatography
on silica gel (hexane/EtOAc, 7:3) led to the pure title
compound 9a (oil; 1.71 g; 4.58 mmol; 70%). [a]D
20 C62.4
(c 1.1). 1H NMR (300 MHz): d 1.97 (bs, 2H, NH2), 3.05
(d, JZ13.5 Hz, 2H, NCHPh), 3.82 (s, 3H, OCH3), 3.83–
3.88 (m, 3H, H-2 and NCHPh), 4.26 (d, JZ10.3 Hz, 1H, H-
3), 7.20–7.60 (m, 15H, H-Ar). 13C NMR (50 MHz): d 51.7,
54.0, 56.3, 67.3, 126.9, 128.1, 128.3, 128.8, 129.7, 133.5,
139.0, 174.1. IR (KBr, cmK1): n 3500–3200, 1714. Anal.
Calcd for C24H26N2O2: C 76.98, H 7.00, N 7.48. Found: C
76.81, H 7.06, N 7.52.
Under the same conditions, the following 2-amino esters
were also obtained.
Methyl (2S,3S)-2-amino-3-(dibenzylamino)-4-phenyl-
butanoate (9b). Oil (78%). [a]D
20 C7.9 (c 0.4, MeOH). 1H
NMR (500 MHz): d 1.63 (bs, 2H, NH2), 2.93 (dd, JZ7.3,
13.7 Hz, 1H, H-4a), 3.09 (dd, JZ6.3, 13.7 Hz, 1H, H-4b),
3.23–3.29 (m, 1H, H-3), 3.60 (s, 3H, OCH3), 3.61–3.67 (m,
3H, H-2 and NCHPh), 3.70 (d, JZ13.7 Hz, 2H, NCHPh),
7.10–7.40 (m, 15H, H-Ar). 13C NMR (100 MHz): d 32.7,
52.2, 55.1, 55.6, 63.8, 126.5, 127.4, 128.5, 128.7, 129.4,
129.9, 139.9, 140.5, 175.9. IR (KBr, cmK1): n 3530–3210,
1712. Anal. Calcd for C25H28N2O2: C 77.29, H 7.26, N 7.21.
Found: C 77.19, H 7.25, N 7.23.
Methyl (2S,3R)-2-amino-4-(benzyloxy)-3-(dibenzylamino)-
butanoate (9c). Oil (65%). [a]D
20 C30.9 (c 1.0). 1H NMR
(500 MHz, C6D6): d 1.48 (bs, 2H, NH2), 3.22–3.28 (m, 1H,
H-3), 3.29 (s, 3H, OCH3), 3.58 (d, JZ6.8 Hz, 1H, H-2), 3.60
(dd, JZ5.8, 9.8 Hz, 1H, H-4a), 3.65 (d, 2H, JZ13.7 Hz,
NCHPh), 3.72 (dd, 1H, JZ4.9, 9.8 Hz, H-4b), 3.84 (d, 2H,
JZ13.7 Hz, NCHPh), 7.05–7.40 (m, 15H, H-Ar). 13C NMR
(100 MHz): d 52.1, 55.4, 55.6, 61.1, 67.2, 73.7, 127.3,
127.9, 128.0, 128.5, 128.8, 129.4, 138.7, 140.2, 175.7. IR
(KBr, cmK1): n 3510–3200, 1716. Anal. Calcd for
C26H30N2O3: C 74.61, H 7.22, N 6.69. Found: C 74.59, H
7.20, N 7.01.
4.1.4. Methyl (4S,5S)-4-methoxycarbonyl-5-phenyl-2-
imidazolidinone (10). A magnetically stirred solution of
9a (0.020 g; 0.053 mmol) in glacial AcOH (0.5 mL) was
hydrogenolysed over 30% Pd/C catalyst (0.006 g) for 2 h at
50 8C, under a slightly positive pressure given by an inflated
balloon (w3 bar). The mixture was then filtered through
Celitew washing with MeOH (10 mL). Removal of the
solvents under reduced pressure gave a residue that was
redissolved in dry THF (1.1 mL). The solution was cooled
to 0 8C. Et3N (0.063 mL, 0.053 mmol) and 1,1
0-carbonyl-
diimidazole (0.013 g; 0.079 mmol) were then added in
sequence. After 30 min at 0 8C and 2 h at rt the solvents
were evaporated under reduced pressure and the remaining
crude residue was dissolved in EtOAc and filtered on a short
silica gel plug (w3 cm3) with the same solvent (3!10 mL).
By partial evaporation of the solvent under reduced
pressure, a semicrystalline residue could be collected
whose recrystallization by the same solvent afforded the
pure 10 (0.010 g; 0.045 mmol; 88%) as a white solid. Mp
202–203 8C dec. (lit.27 203–205 8C). 1H, 13C NMR and IR
spectra were superimposable to those reported.
4.1.5. Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-
(dibenzylamino)-3-phenylpropanoate (11). To a solution
of compound 9a (0.67 g; 1.80 mmol) in dioxane (21 mL) at
0 8C, Et3N (0.42 mL; 2.70 mmol) and Boc2O (0.89 g;
3.60 mmol) were added in sequence. The reaction mixture,
warmed up to room temperature and stirred for 1 h, was then
diluted with EtOAc. The organic layer was washed with
brine until neutral, dried (Na2SO4), and the solvents
evaporated in vacuo to give an oil. Its chromatography on
silica gel (hexane/EtOAc, 9:1) afforded the pure title
compound 11 (oil; 0.78 g; 1.66 mmol; 92%). [a]D
20 C50.7
(c 1.5). 1H NMR (400 MHz): d 1.55 (s, 9H, Boc), 3.04 (d,
JZ13.5 Hz, 2H, NCHPh), 3.86 (s, 3H, OCH3), 3.97–4.02
(m, 3H, H-3, NCHPh), 4.58 (bd, JZ8.3 Hz, 1H, NHBoc),
5.14 (bt, JZ9.7 Hz, 1H, H-2), 7.24–7.44 (m, 15H, H-Ar).
13C NMR (125 MHz): d 28.3, 52.3, 54.1, 54.7, 65.0, 80.2,
127.3, 128.3, 128.5, 129.2, 130.1, 132.6, 139.1, 146.9,
154.9, 172.3. IR (KBr, cmK1): n 1718, 1705. Anal. Calcd for
C29H34N2O4: C 73.39, H 7.22, N 5.90. Found: C 73.25,
H 7.20, N 5.92.
4.1.6. Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-
amino-3-phenylpropanoate (12). A magnetically stirred
solution of 11 (0.78 g; 1.66 mmol) in glacial AcOH
(7.4 mL) was hydrogenolysed over 30% Pd/C catalyst
(0.23 g) for 2 h at 50 8C, under a slightly positive pressure
given by an inflated balloon (w3 bar). The mixture was then
filtered trough Celitew and washed with MeOH (100 mL).
The solvent was removed under reduced pressure and the
residue was dissolved in EtOAc (2!100 mL). The organic
layer was washed with 10% aq Na2CO3 (300 mL), dried
(Na2SO4), and the solvents evaporated in vacuo to give
compound 12 as a white crystalline solid, after recrystalli-
zation from hexane/acetone 9:1 (0.44 g; 1.49 mmol; 90%).
Mp 110.3–112.3 8C. [a]D
20 C29.0 (c 0.9). 1H NMR
(400 MHz, C5D5N): d 1.35 (s, 9H, Boc), 3.62 (s, 3H,
OCH3), 5.34 (d, JZ7.1 Hz, 1H, H-3), 5.77 (bt, JZ8.0 Hz,
1H, H-2), 7.21–7.35 (m, 3H, H-Ar), 7.89 (d, JZ7.3 Hz, 2H,
Ar-H), 8.80 (bd, JZ8.6 Hz, 1H, NHBoc). 13C NMR
(100 MHz, C5D5N): d 28.3, 52.4, 57.1, 59.4, 79.3, 128.6,
128.9, 138.0, 140.2, 156.8, 172.0. IR (KBr, cmK1): n 3350,
3200, 1765, 1715. Anal. Calcd for C15H22N2O4: C 61.21, H
7.53, N 9.52. Found: C 61.32, H 7.57, N 9.58.
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4.1.7. Methyl (2S,3S)-2-(tert-butoxycarbonylamino)-3-
(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenylpro-
panoate (13). To a stirred solution of 12 (0.44 g;
1.48 mmol) in dioxane (5.8 mL) and 10% aq Na2CO3
(0.31 g; 2.96 mmol) at 0 8C, Fmoc–OSu (0.41 g;
1.18 mmol) dissolved in DMF (1.5 mL) was added slowly.
The reaction mixture, after 30 min at 0 8C and 2 h at rt, was
extracted with CH2Cl2. The organic layer was washed with
brine until neutral, dried (Na2SO4), and the solvents
evaporated under reduced pressure to give an oil. The
chromatography on silica gel (CHCl3) afforded the pure
compound 13, white solid after recrystallization from
hexane/acetone 9:1 (0.50 g; 0.96 mmol; 65%). Mp 166.6–
168.1 8C. [a]D
20C38.7 (c 0.3). 1H NMR (500 MHz, C5D5N):
d 1.20 (s, 9H, Boc), 3.42 (s, 3H, OCH3), 4.14 (t, JZ6.8 Hz,
1H, Fmoc), 4.30 (dd, JZ6.8, 10.3 Hz, 1H, CHFmoc), 4.45
(dd, JZ6.8, 10.3 Hz, 1H, CHFmoc), 5.31 (t, JZ9.3 Hz, 1H,
H-2), 5.69 (t, JZ9.3 Hz, 1H, H-3), 7.05–7.70 (m, 14H, H-Ar
and NHBoc), 9.17 (d, JZ9.3 Hz, 1H, NHFmoc). 13C NMR
(125 MHz): d 28.5, 47.5, 52.9, 57.7, 58.0, 67.3, 120.2,
125.4, 126.8, 127.3, 128.4, 128.9, 141.5, 144.1, 155.9,
156.5, 170.4. IR (KBr, cmK1): n 3395 (br), 1705. Anal.
Calcd for C30H32N2O6: C 69.75, H 6.24, N 5.42. Found: C
69.82, H 6.27, N 5.43.
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